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The Progressive Aphasias
Stefano F. Cappa
Vita-Salute University and San Raffaele Scientiﬁc
Institute, Milan, Italy
Prevalent production disorders
Several clinical presentations are characterised by
the disproportionate impairment of language pro-
duction in comparison to other aspects of language
performance. These include a form with prevalent
articulation impairment, in the absence of an appar-
ent clinical language disorders. The typical motor
speech impairment is apraxia of speech, which in most
cases is accompanied by some degree of dysarthria.
The underlying site of prevalent cortical involvement
is the rolandic operculum, anterior insula and possibly
the opercular portion of Broca’s area [1]. Some patients
can show isolated speech impairments for years, but
the disorder most often evolves to a more classical
“aphasic” clinical picture when patients develop lan-
guage symptoms, typically a lexical retrieval deficit
and agrammatism. Patients then present with a mild
production deficit, dropping articles and proposition,
while they show clear syntactic comprehension prob-
lems in tasks such as sentence-to-picture matching.
When the grammatical impairment is prevalent, or
becomes apparent during the course of the disease
progression, the clinical picture is usually labelled
as “progressive non-fluent aphasia” (PNFA). Patients
with these kind of production deficits often also
develop more generalized motor impairments involv-
ing the trunk and limbs and some evolve to a clear
corticobasal or progressive supranuclear palsy syn-
drome. The most common pathological correlate in
patients with progressive production deficit is a tauopa-
thy, either corticobasal degeneration or progressive
sopranuclear palsy [2]. Less commonly patients can
have Pick’s disease, ubiquitin positive TDP43-related
inclusions (FTLD-U).
Prevalent semantic disorders
Other patients present with prevalent anomia,
single-word comprehension and non-verbal semantic
impairments. In the early stage, patients may present
with a prominent word-finding impairment in spon-
taneous speech and severe anomia in confrontation
naming tasks, with apparently preserved non-verbal
semantics. A non-verbal semantic deficit is almost
invariably present if tested with items that are suffi-
ciently low-familiarity. The non-verbal deficits include
object, people and environmental sound identifica-
tion deficits but word comprehension problems usually
prevail. This is the typical syndrome of “semantic
dementia” (SD), associated to left anterior temporal
lobe (ATL) atrophy [3, 4]. While prevalent left ATL
damage is clearly linked to the classical presentation
of SD, atypical clinical syndromes may arise when the
right ATL is the most affected. Patients with greater
right than left atrophy also show a more prominent
behavioural syndrome, with severe loss of empathy,
emotional processing deficits, personality changes and
compulsive behaviours (see above). Pathologically, SD
has been consistently associated with FTLD-U patho-
logical, although cases of Pick’s disease and AD are
less commonly identified [5].
Prevalent phonological/short-term memory
disorders
Another clinical presentation is characterised by
prominent anomia and repetititon impairment. Gorno
Tempini and colleagues [1] described ten patients
whose clinical presentation was characterized by slow
speech (without articulation deficits) and impaired sen-
tence comprehension and naming, but spared single
word comprehension and semantics. On voxel-based
morphometry analysis (VBM) this group was charac-
terized by a distinctive pattern of atrophy involving the
left posterior temporal cortex and inferior parietal lob-
ule. A further analysis of this clinical phenotype was
conducted in six new cases, based on an extensive neu-
ropsychological evaluation including an experimental
ISSN 1387-2877/11/$27.50 © 2011 – IOS Press and the authors. All rights reserved
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study of phonological loop functions (auditory and
visual span tasks with digits, letters, and words) [7].
The study indicated that speech rate was slow, with
long word-finding pauses. Grammar and articulation
were preserved, although phonological paraphasias
could be present. Repetition and comprehension were
impaired for sentences but preserved for single words,
and naming was moderately affected. Investigation
of phonological loop functions showed that patients
were severely impaired in digit, letter, and word span
tasks. Performance did not improve with pointing,
was influenced by word length, and did not show
the normal phonological similarity effect. For each
patient, a voxel-wise, automated analysis of MRI or
SPECT data were conducted. Atrophy or decreased
blood flow was consistently found in the posterior
portion of the left superior and middle temporal gyri
and inferior parietal lobule. These findings support
the idea that logopenic progressive aphasia (LPA) is
a distinctive variant of primary progressive aphasia.
Cognitive and neuroimaging data indicate that a deficit
in phonological loop functions may be the core mecha-
nism underlying the LPA clinical syndrome. The LPA
clinical picture is consistent and in most patients is
characterised by anomia, hesitations and slow lan-
guage production and severely defective repetition,
especially evident for low-probability sentences. How-
ever, some cases also show prominent phonological
errors in production and possibly greater white matter
involvement of the arcuate fasciculus. The differential
diagnosis with PNFA becomes problematic in these
cases because phonological paraphasias can easily be
mistaken for motor speech errors, especially in the
contest of decreased speech rate. A careful evaluation
of all domains of speech and language is mandatory
in these cases, since early correct diagnosis can have
important clinical and therapeutical implications. LPA
is most often caused by Alzheimer’s disease, and these
patients could therefore be candidates for experimental
AD therapies.
Conclusions
To summarise, in the case of progressive aphasias,
the phenotype is a predictor of the brain location
of pathology, which bears a probabilistic relation
with the type of pathology. Progressive production
impairments have been associated with tau pathol-
ogy, in particular if associated with apraxia of speech.
Prominent semantic disorders appear to be associated
with ubiquitin-positive pathology, compatible with a
TDP-43 proteinopathy. The phonological/short-term
memory forms, on the other hand, appear to be often
associated with evidence of cortical amyloid on PET
and Alzheimer pathology at autopsy. It is thus clinically
relevant to be able to identify the existence of consistent
associations between a set of relatively common clin-
ical presentations and the underlying neuropathology.
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Corticobasal Syndrome: Lumping Versus
Splitting
Barbara Borroni
Centre for Ageing Brain and Neurodegenerative Dis-
orders, University of Brescia, Brescia, Italy
Abstract
Current clinical criteria for Corticobasal Syndrome
(CBS) describe this disorder as an asymmetric,
akinetic-rigid syndrome, levodopa-resistant, associ-
ated with prominent apraxia, cortical sensory loss,
focal reflex myoclonus, dystonia, alien limb phenom-
ena, and without early dementia. Conversely, Corti-
cobasal Degeneration (CBD) defines autopsy findings
characterized by cortical degeneration with swollen
‘achromatic’ neurons, neuronal loss in the substan-
tia nigra and extensive neuronal and glial cytoplasmic
tau-positive inclusions. Patients with clinically clas-
sic CBS have a wide spectrum of pathologies, ranging
from CBD to Alzheimer’s disease (AD).
Recently, predictors of neuropathological features in
patients with CBS have been studied. By retrospective,
autopsy-confirmed studied, it has been demonstrated
that early episodic memory impairment versus early
behavioral abnormalities appear to best differentiate
AD and CBD, respectively. Moreover, temporoparietal
atrophy suggests AD, whilst, more focal atrophy pre-
dominantly involving the premotor and supplemental
motor areas suggests CBD or Progressive Supranuclear
Palsy pathology. As increased cerebrospinal (CSF)
fluid Tau and decreased CSF Abeta are reliable mark-
ers of AD, it has been suggested that these might be
used in clinical practice to identify AD pathology in
CBS patients.
In the present review, the overlap between CBD
and CBS will be reported, and the predictors of
neuropathological hallmarks in CBS discussed. Identi-
fying markers of pathology and the associated clinical
and biological features is of crucial importance for
therapeutic choices in CBS patients.
Text
Current clinical criteria for Corticobasal Syndrome
(CBS) describe this disorder as an asymmetric,
akinetic-rigid syndrome, levodopa-resistant, associ-
ated with prominent apraxia, cortical sensory loss,
focal reflex myoclonus, dystonia, alien limb phenom-
ena, and without early dementia [1]. As originally
conceived, neuropathology of the disease was con-
sidered as a specific disorder, namely Corticobasal
Degeneration (CBD), characterized by cortical degen-
eration with swollen ‘achromatic’ neurons, neuronal
loss in the substantia nigra and extensive neuronal and
glial cytoplasmic tau-positive inclusions [1]. Unfor-
tunately, the predictive value of this syndrome for
underlying pathology is poor [2], and there is grow-
ing evidence that patients with clinically classic CBS
have a wide spectrum of pathologies, ranging from
CBD to Alzheimer’s disease (AD). Moreover, in the
recent years, frontotemporal lobar degeneration with
tau-negative and TDP-43 immunoreactive inclusions
(FTLD-TDP) has been found at autopsy of sporadic
CBS cases [3].
Moreover, by a genetic point of view, patients
with classical CBS might bear pathogenetic mutations
within Microtuble Associated Protein Tau (MAPT)
[4, 5] and within Progranulin [6–8], thus leading
to either tau-positive or TDP-43 positive inclusions,
respectively.
These observations open a new chapter in the field
of CBS-CBD, in light of future therapeutic inter-
ventions aimed at targeting tau pathology or other
neuropathological abnormalities. The identification of
CBS patients who have really tau-positive inclusions,
and which type, and those with TDP43 inclusions or
other neuropathological features is mandatory.
A recent interesting workof autopsy cases at Queen
Square Brain Bank for Neurological Disorders [9]
has reviewed the cases with either clinical diagno-
sis of CBS or neuropathological diagnosis of CBD.
The authors reported that only almost 25% of CBS
cases had CBD pathology. These patients had unilat-
eral presentation, clumsy useless limb, limb apraxia
and myoclonus. However, the others CBS patients
had AD or Progressive Supranuclear Palsy pathol-
ogy. Conversely, CBD neuropathology can present
very commonly with clinical picture closely resem-
bling Progressive Supranuclear Palsy. These patients,
termed as CBD-Richardson’s syndrome, had delayed
onset of vertical supranuclear palsy (more than 3 years
after symptom onset) and predominantly downgaze
abnormalities [9].
Interestingly, the pathological prediction of primary
tauopathy is more accurate, and the clinical presen-
tation of CBS or Progressive Supranuclear Palsy-like
syndrome was 100% specific for a primary tauopathy,
as the neuropathological hallmarks will be those of
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CBD or Progressive Supranuclear Palsy (i.e. 4-repeat
tauopathies) or frontotemporal dementia/Pick’s dis-
ease (i.e. 3-repeat tauopathy) [9].
In clinical grounds, there is a urgent need of bio-
logical and neuroimaging markers able to identify
neuropathological correlates in CBS patients. Only
recently, predictors of neuropathological features in
patients with CBS have been considered. By retrospec-
tive, autopsy-confirmed studied, patients presenting as
CBS and having either CBD (CBS-CBD) or AD (CBS-
AD) pathology have been compared. One study did
not find any differences in regard to neuropsychologi-
cal profile, although CBS-AD were younger at onset,
more likely to have myoclonus and less likely to have
tremor [10]. Another work demonstrated that early
episodic memory impairment versus early behavioral
abnormalities appear to best differentiate CBS-AD and
CBS-CBD, respectively [11].
Moreover, imaging patterns of atrophy in CBS vary
according to pathologic diagnosis, and might be of
help in identifying AD and CBD during life. Using
automated and unbiased voxel-based morphometry
(VBM) techniques, Josephs and colleagues reported
that CBS-AD showed greater loss in both inferior and
parietal cortices than CBS-CBD [2]. These findings
suggest that in subjects presenting CBS prominent tem-
poroparietal atrophy may be a clue to the presence of
AD pathology. Conversely, more focal loss predomi-
nantly in the posterior frontal lobes is a signature of
CBS-CBD.
From the same group, it has been reported that
imaging patterns of atrophy in CBS vary according
to the presence of either tau or TDP43 pathology
[12]. Widespread atrophy pointed towards a patho-
logical diagnosis of AD or frontotemporal dementia
with TDP43 inclusions. On the contrary, more focal
atrophy predominantly involving the premotor and
supplemental motor area suggested CBD or Progres-
sive Supranuclear Palsy [12]. Moreover, among those
with TDP43 inclusions, CBS patients always pre-
sented type 3 according to MacKenzie criteria [13,
14].
Along with neuroimaging, biological markers hold
the premises to be of help in differentiating neu-
ropathologcal hallmarks in CBS. Up to now, the most
worldwide recognized biological markers are cere-
brospinal fluid (CSF) Tau and Abeta measurements.
A few studies on CSF markers in CBS are already avail-
able, reporting conflicting results. In two studies, CSF
Tau protein dosage was significantly higher in CBS
than healthy controls [15, 16], whereas other studies
showed no significant differences between CBS and
patients affected by neurodegenerative diseases with
distinct tau-related pathology [17, 18].
As increased cerebrospinal (CSF) fluid Tau and
decreased CSF Abeta are reliable markers of AD (i.e.
Tau/Abeta > 1) [19, 20], it might be suggested that
these biological markers might be used in clinical prac-
tice to identify AD pathology in CBS patients.
In a recent work [21], it has been reported that
patients with classical CBS have two distinct profiles
of CSF Tau/Abeta ratio, twenty percent present-
ing with an AD-like (increased CSF Tau, decreased
CSF Abeta, with CSF Tau/Abeta > 1) pattern and
the others presenting a non-AD pattern (nAD-like).
No differences in demographic characteristics were
detected between groups, and apraxia scores were
comparable. Compared to nAD-like CBS, AD-like
patients reported earlier memory impairment as well
as worse psychomotor speed and language dysfunc-
tions. Conversely, nAD-like patients had a more severe
akinetic extrapyramidal syndrome. Finally, in AD-like
CBS patients, CSF and neuropsychological profiles
were corroborated by greater hypoperfusion in those
areas typically affected by AD, namely hippocampus,
parahyppocampal region, precuneus and posterior cin-
gulate, bilaterally [21].
The findings described above represent the starting
point of future studies, prompted at identifying markers
of pathology and the associated clinical and biologi-
cal features in CBS patients. The identification of the
underlying pathological abnormalities is mandatory
for a correct therapeutic approach.
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Amyotrophic Lateral Sclerosis
and Dementia: The Borders
Lucio Tremolizzo, Emanuela Susani, Matteo De
Rosa, Michela Strozzi, Laura Marzorati, Ildebrando
Appollonio and Carlo Ferrarese
Department of Neurology, ALS clinic, S. Gerardo
Hospital, Monza and Department of Neuroscience
and Biomedical Technology, University of Milano-
Bicocca, Milan, Italy
Amyotrophic lateral sclerosis (ALS) is the most
frequent adult-onset motoneuron disease, defined by
the coexistent progressive degeneration of the first and
the second motoneuron. This disease is known since
the second half of 1800 and, over time, several concepts
related to its clinical phenotype, progression, etiology
and pathology have been repeatedly revised. In par-
ticular, the ideas that cognitive dysfunction might be
a consistent part of the clinical phenotype and that a
continuum between ALS and frontotemporal dementia
(FTD) might exist, are among the most revolutionary
changes observed in the field. Moreover, the evidence
of such an association leads necessarily to the need of
rethinking about the modalities by which support and
end-life procedures are proposed to these patients.
The concept of selective motoneuron involve-
ment had already been challenged some years ago,
especially by neuropathologists, who reported more
widespread degeneration with respect to the original
descriptions. However, the “classical” clinical picture
was still not encompassing cognitive impairment in
1994, with the first edition of the El Escorial diagnostic
criteria for ALS: in fact, cognitive dysfunction specif-
ically excluded a diagnosis of ALS at the moment [1].
Such limit was subsequently removed in 1998, with
the first revision of these diagnostic criteria, due to the
increasing evidence of an association between demen-
tia and ALS [2]. As a matter of fact, searching the
literature, this association has been reported since the
beginning of the last century [3], but these cases were
invariably regarded as anecdotal and atypical, hence
implicitly denying the possibility of a frequent rela-
tionship. Until about 2003, these accounts recurred
regularly during the years, enriching the picture by
adding new confirmatory findings due to the applica-
tion of novel techniques, such as, for example, imaging
[4–8]. After 2003, this phenomenon rapidly attenuates
and then disappears: indeed, FTD in ALS was not any
more regarded as a rarity worth of an ad hoc report,
but was felt as one possible expression of the clinical
phenotype generated by the disease.
Collecting data over the years, the researchers
arrived to hypothesize that ALS and FTD spectrum
might not only overlap but even share same of the
pathological mechanisms, belonging, therefore, to the
same nosological entity. A major advancement in
the field was obtained when Lomen-Hoerth and col-
leagues demonstrated that, if adequately tested, up to
half of ALS patients might fulfill the Neary criteria for
FTD diagnosis [9]. Nevertheless, there is still consid-
erable variability regarding the frequency of cognitive
impairment in patients affected by ALS, possibly due
to limited samples and power, difficulties in collecting
and interpreting data, limited follow-up due to the fast
progression of the underlying disease, and to the pres-
ence of confounding factors during test administration
(dysarthria, upper limb weakness). On the other hand,
investigating the phenomenon by inverting the fac-
tors, the demonstration that about 15% of FTD patients
might present clinical and/or EMG evidence compat-
ible with motoneuron disease appears [10]. Besides,
even basic research suggests that an ALS-FTD con-
tinuum might exist (see Fig. 1). For example, voxel
based morphometry MR data allowed to demonstrate
in vivo the presence of frontotemporal atrophy in ALS
patients, even when they express classical motoneu-
ron phenotypes in the absence of overt cognitive
deterioration [11]. SPECT and PET studies repeat-
edly demonstrated in the same brain areas metabolic
anomalies that were more pronounced in the presence
of cognitive dysfunction. Then, even when clinically
silent, frontotemporal dysfunction might be evidenced
in ALS patients early in the course of the disease:
preliminary longitudinal studies show that this phe-
nomenon might worsen over time, sometimes leading
to the surfacing of a full-blown dementia, although the
literature is not clear on this issue [12]. Neuropathol-
ogy also confirms this ALS-FTD overlap, arriving to
the definition of a disease, in which the recently recog-
ALS-FTD
FTD
ALS ALSbi
ALSci
FTDmi
Fig. 1. The existence of a phenotypic continuum might be hypoth-
esized between ALS and FTD. Motor (black) and cognitive (white)
symptoms might considerably overlap in the clinical phenotype
determining in few cases a real full-blown coexistence. Since
EMG and/or clinical motor impairment might be expressed in FTD
patients, we might suggest the term FTDmi (FTD with motor impair-
ment) for indicating them.
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nized TDP-43-based pathology often expresses itself
within the entire fronto-temporal lobes and beyond.
Again, FTD cases expressing spinal cord motoneuron
alterations typical of ALS might be observed in the
absence of motor dysfunction [13].
Approaching to a diagnosis
A recent workshop held in London, Canada, estab-
lished the consensus criteria for diagnosing FTD in
ALS [14]. Indeed, this intent goes beyond few noso-
logical minutiae, since cognitive dysfunction, besides
arising several important issues in the relationship with
the patient, might be also an indicator of a poor prog-
nosis. According to the consensus participants, axis
II evaluation focuses on cognitive and behavioural
characterization, essentially arriving to define five cat-
egories of ALS patients: “pure” ALS (no evidence of
cognitive impairment) – ALSci (ALS with cognitive
impairment) – ALSbi (ALS with behavioural impair-
ment) – ALS-FTD, with the possible presence of either
one of the three different FTD phenotypes (behavioural
FTD, non fluent progressive aphasia, semantic demen-
tia) – ALS in comorbidity with dementias other than
FTD. ALSbi can be diagnosed in presence of two
of the support characteristics among Neary criteria
[15], as evidenced from by at least two sources among
patient colloquium/observation, caregiver reports, and
structured interview. On the other hand, ALSci can be
diagnosed if a value lower than the fifth percentile is
scored by the patients in at least two different tests of
executive functions, taking into consideration the pre-
morbid level. In both cases, concomitant psychiatric
or other disorders must be excluded, as they might
act as confounders. Apathy and depression might lead
to overdiagnose cognitive dysfunction, although the
physician should be aware of the possibility that this
sometimes might appear later during the course of
the disease. Furthermore, pseudo-bulbar impairment,
respiratory insufficiency, sleep disturbances, delirium,
generalized asthenia, drug effects should be considered
as potential variables, and current recommendations
stress the necessity of minimizing the effects of these
disease-related confounders when preparing neuropsy-
chological test batteries.
Conclusions
In conclusion, although ALS is known since more
than 100 years the array of the possible nuances of the
clinical phenotype are only now surfacing in a struc-
tured manner to the attention of the clinician. It is
also important to note that, although the presence of
an ALS-FTD continuum can not be denied any more,
the wide spectrum of clinical phenotypes expressed
by ALS patients, in addition to common mechanisms,
might underlie a certain degree of diversity in the
involved pathological processes. A more deep compre-
hension of this complex relationship might therefore
be auspicated, since it might reveal, for example, to
play a critical role in the future attempts of optimizing
therapeutic trials for ALS.
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Diagnostic ﬂow chart for the atypical variants
of dementia
The differential diagnosis in dementia represents a
fundamental clinical step and it is essential to dispose
of effective screening tools for this process. Cogni-
tive, neuroimaging, genetic and bioumoral markers are
the main instruments used in the assessment of degen-
erative diseases, able to differentiate the variants of
dementia. Although this process is nowadays complex
and the evolution of dementia might follow a non linear
progress, the use of these instruments in clinical prac-
tice is of primary importance and their validity has
to be supported by experimental evidences. A num-
ber of information about diagnostic criteria for the
principal forms of dementia, such as Alzheimer’s and
Parkinson’s diseases are ready for use, while less pro-
cedural diagnostic information are available regarding
the atypical forms of dementia. The principal aim of
this paper is the to provide some practical guidelines
which might help in the differential diagnosis of atypi-
cal variants of degenerative diseases. A comprehensive
diagnostic flow chart for the atypical forms of dementia
is shown in Fig. 1.
Posterior Cortical Atrophy (PCA)
Diagnostic criteria indicated that PCA has an insidi-
ous onset and gradual progression, presents a cognitive
profile characterized by disabling visual deficits in the
absence of any ocular disease, preserved anterograde
memory, insight and awareness of illness in the absence
of tumor, stroke, parkinsonism or visual hallucinations
[1]. Other features that might be found are visuo-
constructive apraxia, topographical disorientation, and
Fig. 1. Diagnostic flow chart for the atypical variants of dementia.
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some elements of the Gerstmann’s and Balint’s syn-
dromes. PCA showed deficit of visual imagery, spatial
representation and episodic-autobiographical memory
[2]. Further features might be pre-senile onset, alexia,
ideomotor or dressing apraxia, and prosopoagnosia.
These clinical characteristics should be associated
with structural and/or functional brain dysfunction in
parieto-occipital regions (Brodmann areas 17 and 18)
involved in visual processing [1]. In these areas typical
AD neuropathological features, such as neurofibrillary
tangles and neuritic plaques, are usually found [3].
Genetic pathway showed similar findings to typical
Alzheimer’s Disease (AD), with homogeneous propor-
tion of APOE 4 and tau haplotypes.
Primary Progressive Aphasia (PPA)
Primary progressive aphasia presents with degenera-
tion of language process without generalized dementia,
usually associated with damage of the language dom-
inant network. Different variants of PPA have been
described [4, 5]. Agrammatic or nonfluent subtype is
characterized by abnormality in syntax or other aspects
of grammar, preserved single word comprehension
and poor fluency, corresponding to a deficit mainly in
left inferior frontal regions. Semantic dementia shows
abnormality in single word comprehension, impaired
naming, circumlocutions and paraphasia in the out-
put and relatively conserved grammar and fluency,
caused by atrophy of bilateral anterior and inferior
temporal regions, with a larger extensively in the left
hemisphere. Logopenic progressive aphasia featured
with word-finding difficulties, phonemic paraphasias,
slow speech, impaired naming, preserved grammar
and articulation, corresponding to left temporo-parietal
degeneration. Automated methods of analysis combin-
ing both neuroimaging and linguistic features could
help in the differential diagnosis of PPA variants [4].
APOE 4 allele frequency is different in the different
variants: 50–60% in the logopenic aphasia, and 20%
in the semantic dementia and non fluent aphasia [6].
Corticobasal Degeneration (CBD)
When CBD was described for the first time, it was
believed to be essentially a movement disorder. More
recently CBD has been considered as a neurodegener-
ative disease of late middle age, generally associated
with a clinical presentation known as corticobasal
syndrome (CBS), whose core clinical features are pro-
gressive asymmetric rigidity and apraxia, accompanied
by signs of cortical (alien limb phenomena, cortical
sensory loss, myoclonus) and extrapyramidal dysfunc-
tion (dystonia, bradykinesia and tremor) [7]. Recently
more attention has been given to speech deficits and
frontal symptoms as possible early clinical signs of
CBD [8]. The involvement of frontal structures is
supported by neuropsychological evaluation showing
deficits of attention, concentration, executive func-
tion, praxis, language and visuospatial domains [9].
Structural (CT, MRI) and functional (PET, SPECT)
neuroimaging also supports the clinical diagnosis, with
evidence of asymmetric fronto-parietal atrophy, as well
as a common involvement of basal ganglia, lateral ven-
tricles and cerebral peduncles [10]. CBD is generally
described as a tauopathy, pathologically characterized
by neuronal loss, gliosis and tau deposition in grey
and white neocortex, basal ganglia and brainstem [11].
Thus, the criteria for suspecting a clinical diagnosis
of CBD focuses on clinical and radiological typical
features.
Frontotemporal Dementia-Motor Neuron Disease
(MND-FTD)
Frontotemporal dementia (FTD) is one of the most
common early-onset dementia (average age at onset
around 50–60 years, although approximately 10% have
an age of over 70 years) and is clinically charac-
terised by progressive behavioural changes and frontal
executive deficits and/or selective language difficul-
ties, evolving into a severe dementia, accompanied by
progressive cerebral hypometabolism and atrophy of
frontal and temporal lobes [12]. The clinical spectrum
of FTD includes several syndromes: the behavioural
variant of FTD (bvFTD) and the language variants
semantic dementia (SD) and progressive non-fluent
aphasia (PNFA). In the last years more interest has
been attributed to the well documented overlap of FTD
with motor neuron disease (MND-FTD) [13]. Motor
neuron disease (MND) has long been defined a pure
motor system disease, but recent evidence has led to
consider it as a multisystemic disease, as up to 50% of
patients with MND have cognitive impairment that in
10–15% of cases fulfils the criteria for frontotemporal
dementia (FTD), thus designated as MND-FTD. Fur-
thermore, a similar proportion of patients with FTD
develop MND. Although all the subtypes of FTD can
occur with MND, this association is most commonly
seen with bvFTD, occasionally with PNFA and in
rare cases with SD. Pathological findings also sup-
port this overlap: MND patients and a subset of FTD
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cases have demonstrable TAR DNA binding protein
43 (TDP-43) inclusions, typically found in bvFTD.
As demonstrated by structural and functional neu-
roimaging techniques, the degree of neuronal loss
affects primarily the anterior cingulate gyrus, sub-
stantia nigra and amygdala, as well as middle and
inferior frontal gyri, more commonly in the right hemi-
sphere [14]. Less frequently neuronal cytoplasmic and
intra-nuclear inclusions immunoreactive for FUS/TLS
(fused in sarcoma/translated into liposarcoma) have
been found in pathological cases of FTLD-U without
TDP-43 inclusions [15]. Patients with FTD-MND have
the shortest survival, amongst all patients with a diag-
nosis of FTD, with a mean of 3 years. The pattern of
cognitive deficits is characterized by personality dis-
orders, mental rigidity, disinhibition, impulsivity, loss
of insight, lack of foresight and planning, distractibil-
ity, irritability and deficits on frontal-executive tests.
Apathy, which is reported in 50% of patients, can
alternate with irritability and sometimes aggression.
Psychotic features and bizarre behaviour may also be
present and can resolve within a few months leaving
the patients placid. When performed, the neuropsycho-
logical examination in non-demented individuals with
ALS, is characterized by deficits in a frontotemporal
pattern, with posterior association cortices relatively
spared. Language difficulties may also appear with iso-
lated anomia becoming more severe during the time
course of the disease. Severe progressive non-fluent
aphasia is a frequent feature and written language tends
to be involved later.
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Predictors of Successful Ageing:
Epidemiological Evidence
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It is the first time in the history of mankind that so
many people are surviving up to 85 years or longer. The
aging of the population is a relatively new phenomenon
that started in the industrialized countries and has now
also reached less developed areas of the world. We
are living longer on all the continents and this positive
phenomenon has focused attention on all the chronic
disorders that are strongly related to age, such as cog-
nitive impairment, dementia and multimorbidity. This
increasing focus on the negative aspects of aging has
already led to deleterious consequences for individuals
who are frightened, for example, at the appearance of
the first signs of memory decline which are immedi-
ately related to the development of a dramatic disease
such as Alzheimer’s disease. We need to implement a
more scientific attitude in our approach to health and
illness in old age. Aging covers a long period of our
lives, and is not necessarily linked to disease and dis-
ability, and most importantly aging is ongoing for the
whole of life.
During recent decades population-based studies on
health in aging have made tremendous progress. The
risk of disease and disability in late life is considered
to be a result of the complex interaction of genetic
susceptibility, biological factors, and environmental
exposure, experienced over the whole life span. Dif-
ferent factors associated with an increased risk of
mortality, morbidity and disability will be discussed
taking into account their different biological mecha-
nisms and grades of epidemiological evidence. Several
factors affect the health of elderly people, but current
evidence strongly supports the potential role of midlife
vascular risk factors, nutrition and psychosocial factors
in the pathogenetic process and clinical manifestation
of several age-related diseases such as dementia and
multimorbidity. It is expected that interventions lead-
ing towards the optimal control of vascular risk factors;
the maintenance of a socially-integrated lifestyle and
mentally-stimulating activities may lead to a healthier
life after the age of 70.
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In Alzheimer disease (AD) early deterioration in
memory is followed by progressive impairment of
other cognitive domains, and is accompanied by a
large spectrum of behavioral and psychological symp-
toms occurring during the entire course of the disease
[1, 2]. In individual patients, the time of appearance
of clinically relevant events such as severe cognitive
impairment or severe BPSD, loss of autonomy, institu-
tionalization and death are difficult to predict [2–6].
This heterogeneity might result from differences in
the localization and severity of brain damage, or vari-
ations in patients’ personalities, life history and risk
factors [7]. Studies suggest that presence of extrapyra-
midal signs and psychosis [8, 9], level of disease
severity [5, 10, 11] and education [12, 13]. However,
current knowledge is limited due to differences in
study populations, factors examined, instruments used
for evaluation, and definitions of outcomes. In AD
patients, memory impairment represents the prominent
and early disturbance and is caused, with any like-
lihood, by the early and preferential involvement of
temporal cerebral areas devoted to memory processes
(entorhinal cortex and hippocampus). In contrast, the
severity and timing of the involvement of other cogni-
tive domains is heterogeneous, varying from patient to
patient.
Authors used different instruments and methodolo-
gies to investigate the rate of AD progression but most
based the estimate on the general cognitive perfor-
mance of patients generally measured with the Mini
Mental Status Examination (MMSE). However no evi-
dence exists on the capacity of these measures of
catching the progression of the pathological process of
AD and it is possible that reductions at MMSE might
be largely determined by factors only indirectly related
to the progression of AD. The use of standardized and
agreed measures of progression remains one of the key
points for the study of prognostic predictors of AD.
The cohort study promoted by the Italian Associa-
tion for the Study of Dementias (SINDEM) is aimed at
evaluating the natural history of dementias. The idea
supporting the study is that a better knowledge of prog-
nostic predictors of AD and of other dementias might
give new insight into the pathogenic mechanisms of
these diseases besides to be useful for clinicians car-
ing for patients. As of November 2010, 20 neurological
centers enrolled 238 newly diagnosed patients with
AD. Diagnosis of AD was based on clinical diagnostic
criteria (NINCDS-ADRDA criteria). All the enrolled
patients were carefully investigated about presence of
comorbidities, and on life habits. The neuropsycholgi-
cal profile of each patient was characterized according
to an extensive battery of test that investigated differ-
ent cognitive domains. Of the enrolled patients with
AD 153 had at least one follow-up visit and could be
analyzed and investigated on prognostic predictors. A
decrease of 5 points or more in MMSE score in the first
24 months following enrolment was considered as an
indicator of disease progression. A 5-point decrease is
considered to be a clinically relevant worsening, and
is too large a change to be attributed to the intrinsic
limits of test reliability. The date of the visit when
the 5-point reduction was recorded marked the time
of occurrence of the progression. Data were analysed
with survival analysis considering the time of occur-
rence of 5 point decrease at MMSE as the end point.
The studied patients had a mean age of 74 year and
women represented the 64% of the entire cohort. The
mean disease duration since first symptoms was about
two years and at enrollment the mean score at MMSE
was 18. One fourth of the patients had a decrease of 5
points or more at MMSE during a follow-up period of
24 months.
Preliminary results suggest that more educated
patients had more rapid progressions, that more severe
involvement of cognitive functions and reduced social
and physical activities are negative prognostic fac-
tors and that diabetic patients had slower progression
rates as compared to non diabetic patients. Albeit pre-
liminary these results support the idea that relevant
knowledge on AD can be derived by the study of the
natural history of the disease.
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Cerebral white matter changes, also called leuko-
araiosis (LA) [1], are frequently observed on com-
puted tomography or magnetic resonance imaging
(MRI) in the brains of elderly subjects, particularly
in those with vascular risk factors [2]. Since age rep-
resents the strongest factor associated with LA, its
prevalence is expected to increase in the forthcoming
years as a consequence of the progressive aging of the
world population. From the clinical point of view, LA
has been found associated with motor and gait dis-
turbances, urinary dysfunctions, mood disorders, and
cognitive impairment [2]. All these factors notoriously
contribute to disability in the elderly.
During the last 10 years, clinical and functional
outcomes in 639 elderly patients with LA have been
investigated through the European multicenter collab-
oration called LADIS (Leukoaraiosis And DISability)
Study [3], which was started in 2001, supported by
the European Union, with the main aim of assessing
LA as independent predictor of the transition from an
independent functional status to disability in elderly
subjects. Final results have shown that the risk of tran-
sition or death was more than twofold higher in patients
with severe white matter changes compared to those
with mild degrees [4]. The LADIS study has also pro-
vided evidence that LA has an effect on cognitive
decline and dementia, independently of the presence of
other types of cerebral lesions, such as infarcts, mainly
of the lacunar type, atrophy and medial temporal lobe
atrophy (MTA).
The pathogenesis of LA is still a matter of inves-
tigation, althoughit is nowadays recognized as one of
the ischemic manifestation related to small vessel dis-
ease on the brain parenchyma [5]. The vessel lumen
restriction is thought to lead to a state of chronic hypop-
erfusion of the white matter, eventually resulting in
degeneration of myelinated fibres as a consequence
of repeated selective oligodendrocyte death. This kind
of white matter damage is thought to be a form of
incomplete infarct or selective necrosis. Alternatively,
acute occlusion of a small vessel is hypothesised to
occur, leading to focal and acute ischaemia and com-
plete tissue necrosis (pannecrosis): this is the putative
mechanism of lacunar infarcts. Other mechanisms
such as blood–brain barrier damage, local subclinical
inflammation, and oligodendrocytes apoptosis could
be involved in small vessel disease and contribute
to the final pathological picture [5]. In the neuro-
vascular unit, vessels and cells, including neurons,
closely interact, pointing to endothelial dysfunction as
a key element [6]. The strong epidemiological asso-
ciation that exists between white matter lesions and
vascular risk factors support ischemia as a main con-
tributing factor. Apart from ageing, the most common
risk factor for LA is arterial hypertension, followed by
diabetes mellitus [7]. All these conditions share a com-
mon substrate in the type of alterations induced on the
small penetrating arteries and arterioles of the white
matter. Moreover, recent findings provide evidence for
a remarkable susceptibility of the cerebral circulation
to the deleterious effects of Angiotensin-II, raising the
possibility that cerebrovascular dysfunction is an early
event also in human hypertension [8]. Cerebrovascu-
lar impairment can be present in patients who, based
on the magnitude of blood pressure elevation, do not
yet meet the criteria for hypertension, and although
the relevance of these experimental data to human
hypertension remains uncertain, they support early pre-
ventive interventions in patients with prehypertension,
especially in high-risk individuals with other cardio-
vascular risk factors [8].
Concerning the association of vascular risk factors
with LA, LADIS data have confirmed the trend in
the association between increasing age, increasing fre-
quency of hypertension, and increasing LA severity,
as well as the association of smoked cigarettes with
the most severe LA degree [9]. Considering vascu-
lar co-morbidities, only frequency of stroke increased
along with increasing LA severity. Combining risk fac-
tors and comorbidities in the same regression model,
history of stroke remained independently associated
with LA severity, while history of hypertension did
not. However, stratifying for stroke history, the trend
in the association between increasing prevalence of
hypertension and increasing LA severity was appar-
ent only among subjects without a history of stroke
and not among subjects with stroke history. In a
multinomial logistic regression model entering with
all the other risk factors and comorbidities the vari-
able stroke split into the 2 stroke types, lacunar and
non-lacunar stroke, increasing prevalence of lacunar
stroke proved the strongest independent factor asso-
ciated with LA severity. In this model the effect of
hypertension was weaker, although still showing an
incremental effect, while non-lacunar stroke remained
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associated with the most severe degree of LA only
[9].
The LADIS Study has also offered the opportunity
to study the natural course of LA and lacunes over the
3-year follow-up and to evaluate possible predictors,
among which vascular risk factors, for their devel-
opment [10]. LA progressed in 74% of the subjects,
mainly in the subcortical white matter, where LA was
also most prevalent at baseline. The majority of new
lacunes, which were found in 19% of the subjects, also
appeared in the subcortical white matter, mainly of
the frontal lobes, whereas most baseline lacunes were
located in the basal ganglia. Baseline LA and lacunes
predicted both LA progression and new lacunes. Fur-
thermore, previous stroke, diabetes, and blood glucose
were risk factors for LA progression. Male sex, hyper-
tension, systolic blood pressure, previous stroke, body
mass index, high-density lipoprotein, and triglyceride
levels were risk factors for new lacunes [10].
LADIS cross sectional analyses have shown that
severe LA was associated with worse cognitive per-
formances, and that among risk factors and co-
morbidities, diabetes, arterial hypertension and stroke
interfered with different cognitive domains [11]. The
effect of these vascular risk factors was independent
of LA severity, age and education, thus stressing the
need to control vascular risk factors in order to pre-
vent cognitive decline in the elderly. Finally, predictors
of cognitive decline and dementia have been inves-
tigated. LA severity was confirmed as one of the
main independent predictors of cognitive decline even
when controlling for medial temporal lobe atrophy. LA
severity and history of previous stroke were predic-
tors of vascular dementia [12]. Among all vascular risk
factors studied, diabetes was the only independent pre-
dictor of cognitive decline in the LADIS sample. This
effect was independent of LA severity and medial tem-
poral lobe atrophy, suggesting an effect mediated not
only by vascular damage or white matter disease, but
probably through direct neuronal metabolic damage
[12].
In conclusion, the LADIS study has documented a
specific role of LA in many aging-related processes,
confirming LA as a marker of poor prognosis in terms
of cognitive, mood and gait disturbances, and as a
predictor of fast transition to a disable status. The
understanding of the complex relationship between
LA and vascular risk factors is also essential for the
identification of potential preventive and therapeutic
targets, contributing to reduce the burden of disabil-
ity and cognitive decline. Preliminary studies indicate
that treating hypertension may slow the progression
of age-related white matter changes [13]. Now, future
research is needed to implement all possible measures
able to slow or halt progression of LA and the related
disability.
References
[1] Hachinski VC, Potter P, Merskey H (1987) Leukoaraiosis.
Arch Neurol 44, 21-23.
[2] Pantoni L, Garcia JH (1995) The significance of cerebral
white matter abnormalities 100 years after Binswanger’s
report: a review. Stroke 26, 1293-1301.
[3] Pantoni L, Basile AM, Pracucci G, Asplund K,
Bogousslavsky J, Chabriat H, Erkinjuntti T, Fazekas
F, Ferro JM, Hennerici M, O’Brien J, Scheltens P, Visser
MC, Wahlund LO, Waldemar G, Wallin A, Inzitari D (2005)
Impact of age-related cerebral white matter changes on the
transition to disability – the LADIS study: rationale, design
and methodology. Neuroepidemiology 24, 51-62.
[4] Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F,
Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M,
Langhorne P, O’Brien J, Scheltens P, Visser MC, Wahlund
LO, Waldemar G, Wallin A, Pantoni L; LADIS Study Group
(2009) Changes in white matter as determinant of global
functional decline in older independent outpatients: three
year follow-up of LADIS (leukoaraiosis and disability) study
cohort. BMJ 6, b2477.
[5] Pantoni L (2010) Cerebral small vessel disease: from patho-
genesis and clinical characteristics to therapeutic challenges.
Lancet Neurol 9, 689-701.
[6] Iadecola C (2010) The overlap between neurodegenerative
and vascular factors in the pathogenesis of dementia. Acta
Neuropathol 120, 287-296.
[7] Pantoni L, Garcia JH (1997) Pathogenesis of leukoaraiosis:
a review. Stroke 28, 652-659.
[8] Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola
C (2010) The cerebrovascular dysfunction induced by slow
pressor doses of angiotensin-II precedes the development of
hypertension. Am J Physiol Heart Circ Physiol, 2010 Oct.
22. [Epub ahead of print]
[9] Basile AM, Pantoni L, Pracucci G, Asplund K, Chabriat H,
Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, O’Brien J,
Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin
A, Inzitari D; LADIS Study Group (2006) Age, hyperten-
sion, and lacunar stroke are the major determinants of the
severity of age-related white matter changes. The LADIS
(Leukoaraiosis and Disability in the Elderly) Study. Cere-
brovasc Dis 21, 315-322.
[10] Gouw AA, van der Flier WM, Fazekas F, van Straaten EC,
Pantoni L, Poggesi A, Inzitari D, Erkinjuntti T, Wahlund LO,
Waldemar G, Schmidt R, Scheltens P, Barkhof F; LADIS
Study Group (2008) Progression of white matter hyperin-
tensities and incidence of new lacunes over a 3-year period:
the Leukoaraiosis and Disability study. Stroke 39, 1414-
1420.
[11] Verdelho A, Madureira S, Ferro JM, Basile AM, Chabriat
H, Erkinjuntti T, Fazekas F, Hennerici M, O’Brien J,
Pantoni L, Salvadori E, Scheltens P, Visser MC, Wahlund
LO, Waldemar G, Wallin A, Inzitari D; LADIS Study (2007)
Differential impact of cerebral white matter changes, dia-
betes, hypertension and stroke on cognitive performance
among non-disabled elderly. The LADIS study. J Neurol
Neurosurg Psychiatry 78, 1325-1330.
Invited Speakers S21
[12] Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO,
Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar
G, Wallin A, Hennerici M, Inzitari D; LADIS Study (2010)
White matter changes and diabetes predict cognitive decline
in the elderly: the LADIS study. Neurology 13, 160-167.
[13] Dufouil C, Chalmers J, Coskun O, Besanc¸on V, Bousser MG,
Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M,
Tzourio-Mazoyer N, Tzourio C; PROGRESS MRI Substudy
Investigators (2005) Effects of blood pressure lowering on
cerebral white matter hyperintensities in patients with stroke:
the PROGRESS (Perindopril Protection Against Recurrent
Stroke Study) Magnetic Resonance Imaging Substudy. Cir-
culation 13, 1644-1650.
S22 Invited Speakers
Dual Tasking and Memory Binding
in Alzheimer’s Disease
Sergio Della Sala, Jennifer A. Foley, Mario A. Parra
and Robert H. Logie
Human Cognitive Neuroscience and Centre for Cog-
nitive Ageing and Cognitive Epidemiology, University
of Edinburgh, Edinburgh, UK
The ideal assessment of AD
Early and accurate diagnosis of Alzheimer’s disease
(AD) has important prognostic and therapeutic impli-
cations. It is also crucial that the patients involved in
treatment trials have the correct initial diagnosis and
can be followed up over time [1].
Physiological biomarkers are available. However,
they are often invasive (e.g. lumbar punctures), expen-
sive, not widely available and require specialist
facilities and staff. Even the promising morphomet-
ric analysis of hippocampal volume based on MRI
requires a great deal of specialised expertise, and
automatized versions have yet to be validated [2].
Therefore, cognitive tests that could reliably discrim-
inate between AD, normal ageing, chronic depression
and non-AD dementias would represent the ideal
assessment.
They should also be theoretically and psychometri-
cally sound, ensuring that the results are reliable and
valid, and are both sensitive and specific to AD.
Limitation of current cognitive assessment
Memory disorder is the cognitive hallmark of AD.
However, memory problems also occur in many other
disorders, including depression and even healthy nor-
mal aging, leading to diagnostic uncertainty. So,
memory tests are sensitive but not specific to the dis-
ease. Moreover, performance on such tests reaches
floor very early in the disease making them a poor
marker of disease severity and progression.
Dementia severity scales are useful to assess overall
severity, but like episodic memory tests, they are not
specific to AD and have poor sensitivity for testing
cognitive impairment in well educated individuals.
The available test batteries involve several tests that
require extended testing times, and extensive training
to administer and score. They also tend to be cons-
tructed from tests chosen to assess a wide range of dif-
ferent cognitive abilities. This maximises the chances
that one or more tests will show an impairment. How-
ever, a major disadvantage is that this kind of broad test
battery may detect cognitive impairments that could
reflect any of a range of underlying neuropathologies.
This is of very limited help in diagnosing the spe-
cific underlying pathology in a particular patient. In
recent years, there has been significant advancement
in published scientific evidence for specific cogni-
tive impairments that can identify the early stages of
AD, but do not appear in other conditions that can be
mistaken for AD such as chronic depression or even
healthy ageing. This has led to the possibility of using
short, objective cognitive assessments that are targeted
as diagnostic aids for AD. Here, we describe the evi-
dence for this form of targeted cognitive assessment.
Dual tasking
Our previous work over two decades [e.g. 3–7] has
shown that in addition to the well-established mem-
ory disorder, people with AD demonstrate impairment
in the ability to do two things at once, or ‘dual task-
ing’. These findings have been replicated by other
researchers [8]. Importantly, when individual perfor-
mance levels on single tasks are equated across groups,
dual task is not affected by age [4, 6, 9].
In contrast, people with AD always show a strik-
ing impairment in dual tasking ability, in computer
based laboratory tasks [4, 5, 7, 10], in paper and pen-
cil versions [6, 10] and in everyday tasks [e.g., 11,
12]. This impairment appears to be specific to AD and
not present in people with other disorders that can be
confused with AD, such as chronic depression, even
when severity of episodic memory disorder is equated
between groups [13]. Crucially, unlike memory mea-
sures, the dual task did not discriminate between the
group with depression and the healthy controls.
Unlike many other cognitive tests, the dual task mea-
sure does not show practice-based improvements with
repeated testing. It is also an objective performance
measure, so is not prone to biases in response that
can affect questionnaire based measures. It has high
internal consistency, as evidenced by the large number
of studies reporting the same findings with different
task combinations [6]. Moreover, it has been shown
that it is the ability to perform two tasks at the same
time that is a problem for AD, not an effect of overall
demand of a difficult task on their damaged cognitive
system [5]. Unlike many memory tests, it has no ceiling
and, as the assessment is adjusted to individual level
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of ability, it can be used to assess patients with AD
for longer. Moreover, the dual task measure is brief,
non-invasive, inexpensive, easily portable and usable
by primary health care staff with a minimal amount of
training.
Dual tasking proves to be a very specific measure of
the cognitive deficits associated with AD. However, in
the clinical versions of the tasks its sensitivity was not
ideal [6], and this led to a refinement of the procedure.
Short-term memory binding
To increase the sensitivity, while maintaining high
specificity for AD we have developed a version of dual
task performance based on short-term feature binding
in memory, which has the further advantage of not
being dependent on language.
Short-term memory (STM) binding is the memory
function that enables the integration and temporary
retention of the multiple features of objects, such
as their shape and colour [14]. Our version of this
paradigm assesses memory for single features (e.g.,
shape or colour only) and for the binding of these
features (coloured shapes) (Fig. 1A) and there is no
learning involved.
STM binding of colour and shape does not decline as
people age [15] and is not affected by chronic depres-
sion [16], but it shows a clear and specific effect in
sporadic AD [17]. Moreover, a selective deficit of
bindings held in visual STM was also observed in car-
riers of the mutation E280A of the Presenilin-1 gene
who will subsequently develop familial AD in 100%
of cases [18]. Of note, these carriers were otherwise
completely asymptomatic based on standard neuropsy-
chological measures (Fig. 1B). Finally, the impairment
was not found in fronto-temporal dementia, Parkin-
son’s disease, vascular dementia, or dementia with
Lewy bodies, all of which showed equivalent per-
formance in memory for binding and memory for
individual features, demonstrating that the STM bind-
ing impairment is specific to AD. Hence, STM binding
appears to be a promising candidate as a preclinical as
well as a clinical marker that is specific to AD and
could be used to aid diagnosis as well as to assess
disease progression.
Conclusion
Both the classic dual tasking and the STM binding
paradigm specifically differentiate between the cog-
nitive deficits associated with AD, and those deficits
associated with both healthy aging and a variety of
other dementias. These specifically refined tests take
into account ‘floor-effects’ as the disease progresses
and age-related and intergroup differences in cognitive
impairments. They also provide for an internal control
in the testing protocol, and do not show evidence of
learning or improvement with practice, giving them
high reliability.
Fig. 1. (A) STM binding paradigm: two conditions assessed STM for single features (C1 and C2) and one assessed STM for bound features (C3).
The participants detected changes between the Study and Test display. Changes were in the Test display and consisted of new features replacing
studied features (C1 and C2) or features swapping between objects (C3). (B) Data collected from asymptomatic carriers of the E280A-PS1
mutation. The condition assessing STM binding was the only task that showed impaired performance in carriers.
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Cognitive Neuroscience of Decision
Making: Clinical Implications
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The neuropsychology of reasoning and decision-
making is an interdisciplinary sector of research
devoted to build a neurobiological model of inferential
and decisional-processes, by means of the integra-
tion of methods from several disciplines (psychology,
economics and neuroscience). The interest of this sec-
tor has initially focused on the neural correlates of
reasoning. A new interdisciplinary field has recently
developed, which specifically aims at investigating
how inferences and decisions are made by the brain
in several domains.
The implications of this area of research for clin-
ical neurology are multiple, and involve several
diseases, such as Parkinson’s disease, motor neuron
disease and fronto-temporal dementia. In particular,
the behavioural variant of frontotemporal dementia is
characterized by a clinical picture, in which the main
components of social cognition and decision mak-
ing are involved. The presentation is dominated by
changes in personality and social conduct, reflecting
in its early stages by the involvement of ventrome-
dial limbic structures, responsible for social-emotional
intelligence. The patients can be euphoric, highly dis-
tractible, logorrhoic and restless. In contrast, they can
also be apathetic and lacking initiative. They may show
dishinibition in alimentary and sexual behaviour. They
tend to be inflexible, and not to adapt to environmental
requests. They show defective empathy, as manifested
by shallow, tactless and rude behaviours. The socially
inadequate actions and verbal responses may lead to
violation of moral norms and legal infringements.
Overall, these clinical features can be interpreted theo-
retically within the framework of contemporary social
cognitive neuroscience [1].
In the early stages, social cognition impairment can
be observed in the absence of other cognitive dysfunc-
tion. This is important to note clinically, because it
means that the profile of neuropsychological perfor-
mance on cognitive tests, including “frontal lobe” and
“executive function” can be totally unremarkable. This
is due to the fact that these tests typically evaluate dor-
solateral, rather than ventromedial frontal functions.
The following aspects needs to be carefully consid-
ered, on the basis of detailed history taking as well as
of experimental tests.
Empathy
Loss of empathy is frequently reported by relatives
and friends as a “personality change”. The Inter-
personal Reactivity Index can be used for a formal
assessment [2]. The questionnaire evaluated both cog-
nitive (perspective taking and fantasy) and emotional
(personal distress and emotional concern) aspects of
empathy. Bv-FTD patients show a selective impair-
ment in perspective taking, while a more global
dysfunction was present in patients with a diagnosis
of semantic dementia (SD, see below). The patients
are totally unaware of these personality changes.
Emotion recognition
The ability to recognize emotional facial expression
can be considered as a pre-requisite for understand-
ing and sharing emotional states. Many studies have
shown defective recognition, in particular of negative
emotions, by FTD patients [3]. It is noteworthy, how-
ever, that when the task involves more ecologically
valid stimuli (short videoclips), and evaluates subjec-
tive ratings, behavioural and autonomic responses to
basic emotional situations, the FTD patients do not
appear to be impaired in comparison to controls [4]. In
contrast, in a more complex context, using The Aware-
ness of Social Inference Test (TASIT), bvFTD showed
a defective comprehension of sarcasm [5].
Theory of mind
The ability to attribute mental states to others,
and to understand them, has been linked to fronto-
medial cortex function, and has been found to be
defective in FTD [6]. This impairment has been con-
nected to defective comprehension of social situations
[7].
Moral reasoning
The violation of social norms is a frequent rea-
son for the early suspicion of a diagnosis of FTD.
These include violation of traffic norms, theft, sexual
aggression, etc. It has been suggested that these man-
ifestations reflect the acquired loss of moral sense, as
a sort of “moral agnosia”. This does not seem to be
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the case, as Bv-FTD patients are usually fully aware of
the norms if questioned directly. They appear to solve
moral dilemmas in a deliberate, purely cognitive way,
without emotional colouring. This may lead to “util-
itarian” responses, which reflect the lack of empathy
and appropriate emotional responses [8].
A recent challenge in the field has been the identi-
fication of a subgroup of patients fulfilling the clinical
criteria for Bv-FTD, who fail to show disease progres-
sion [9]. Long-term follow-up studies are needed to
clarify the status of what has been called the “pheno-
copy” of Bv-FTD.
Similar disorders can be found in other disease con-
ditions, which are characterised by the pathological
involvement of the decision-making-social cognition
networks. This is of course not limited to neurological
disorders, but also to many psychiatric conditions, in
which the same structures can be involved by differ-
ent mechanisms, such as anatomical disconnection or
neurochemical dysfunction.
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When we think about emotions we often refer to
our conscious experience of them, the internal state
of mind that is associated with complex physiological
activities in our brain and in our body.
However, within an evolutionary perspective, those
physiological activities that are connected with what
we call emotions are nothing more than shortcuts to
provide living organisms with adaptive reactions to
complex challenges of the environment.
Within this framework, emotions can be seen as
tools that humans share with animals to provide fast
decisions. Sometimes we tend to oppose emotional to
“logical” decision, the latter being based on rationale
methods of contrasting choices using the principle of
utility, whereby assigning weighted criteria assesses
the value of each option. However, emotions can
be hardly excluded by decision-making processes.
Indeed, it can be argued than when this happens deci-
sional ability is seriously impaired.
This is the case of patients with acquired brain dam-
age to brain areas involved in emotional processing
(i.e., prefrontal cortex) and that appear to fail in every-
day life social relationship due to their difficulty in
making decisions. In recent decades, neuroscience is
providing a robust evidence of the role of the pre-
frontal cortex in cognition, emotion regulation, control
of impulsive behavior, and moral reasoning. These
findings converge in demonstrating that there are indi-
viduals that, due to their brain pathology, are capable of
differentiating right from wrong but are, nonetheless,
incapable of appropriately regulating their behavior.
Demonstrating the strong link between brain pathol-
ogy, emotion regulation, and decision-making poses
completely new perspectives to the criminal justice
system as long as individuals might not always be
considered fully responsible of their acts based on the
rationale knowledge of the legal rules.
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Deﬁnition of capacity
Capacity is has been defined as “something that
distinguishes between a person who is capable of mak-
ing a decision and whose choice must therefore be
respected [irrespective of the ‘reasonableness’ of that
decision] from one who requires others to make deci-
sions for him/her” [1].
Conversely, lack of capacity constitutes a status that
is defined by functional deficits (due to mental or cog-
nitive impairment) judged to be sufficiently severe as to
make the person currently unable to meet the demands
of a specific decision-making situation weighed in the
light of its potential consequences [2, 3].
The term capacity – capacity to act in Italy, compe-
tence or mental capacity elsewhere [2–6] – is common
in legal arenas, and should be distinguished from
the terms “decision-making capacity” and “clinical
competence”, often adopted in health-related litera-
ture. Capacity mainly refers to a legal concept, which
implies the capacity to decide or undertake actions that
may have legal implications. Only a judge can declare
the lack of capacity, whereas a physician assesses
whether someone has sufficient capacity to make a
decision – decision-making capacity. This assessment
is based on a broad spectrum of individual abili-
ties related to cognitive, functional, emotional and
social competences, which allow a person to perform
different actions ranging from simple daily activi-
ties to complex choices like voting, making medical
decisions, testifying, managing financial resources,
marrying, living alone, etc., based both on the patients’
decisional autonomy and ad hoc cognitive skills.
Assessment of these ‘capacities’ is the concern of the
clinician and is the basis of relevant information which
will permit a legal decision. The distinction between
legal capacity and clinical capacity lies in the role
of the person making the judgment. Judges have sole
jurisdiction to declare a person as having lost legal
capacity, therefore meaning the person needs someone
else to make decisions for him/her. Physicians do the
same in their daily practice, e.g., stating that a patient is
not competent to decide whether to undergo surgery. In
short, the terms capacity and decision-making capac-
ity distinguish between legal and medical judgments,
but their outcomes are similar: a person can no longer
choose for himself.
This gives rise to the question of whether capacity
is a monolithic attribute or whether it can be divided
into specific subtypes?
Viewing incapacity as a global rather than a sit-
uation-specific deficit has long been a given for clin-
icians, but this is now questionable [3–5, 7, 8]. There
are many clear-cut cognitive processes supporting
capacity as a whole, such as the ability to process
information, reason, make a decision, and articulate
that decision. However there is emerging evidence that
specific competencies are governed by distinct rules
and that the type and level of ability needed to be
competent to make one type of decision may be differ-
ent from those needed to make another. For example,
the criteria for determining financial or testamentary
capacities are reasonably different from those used in
medical decisions. This new approach has implications
for assessments in this area. From a legal point of view,
capacity is now mostly defined in terms of specific
competencies. Current theories of decision-making
capacity recognize this specificity when determining
whether a patient still has the capacity to make that
decision and courts have begun to accept that compe-
tency is situation-specific and that the determination
that a person lacks the capacity to do something – e.g.,
economic management – does not mean that the patient
lacks capacity for any other purpose.
Clinicians involved in capacity assessment thus have
a duty to identify the specific capacity at issue and to
tailor the assessment using methods and procedures
designed to assess that particular capacity.
Assessment of capacity
There is widespread agreement that a capacity
assessment is a clinical assessment, but issues such as
who should do it, how the assessment should be per-
formed, and what level of mental/cognitive impairment
defines lack of capacity remain largely unresolved and
there are no gold-standard measuring instruments. In
any case, clinicians must have a clear understanding of
the complex concept of decision-making capacity and
awareness that capacity may be fluctuating, intermit-
tent and situation-specific.
Different models of decision-making capacity has
been proposed, all identifying four key conditions [8,
9]: the ability to state and express a decision (express-
ing), the ability to comprehend the meaning of in-
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formation relevant to choice (understanding), the abil-
ity to recognize how information applies to a person,
such as risks and benefits of the choice (appreciation),
and the ability to compare options and logically infer
the consequences of choices (reasoning). These key
conditions concern how the choice is made, not its
nature: capacity does not depend on the fact that the
subject makes a decision which seems “reasonable” to
most people, and conversely a bizarre choice must not
be considered an index of incapacity per se [9, 10].
However, this does not imply that the quality of the
decision should be neglected in capacity judgement,
since the consequences of the choice have to be con-
sidered. Contextually, the examiner must be sure that
the subject is absolutely autonomous and aware in his
decision-making.
Clinical capacity assessment should reasonably
follow a multistep and multidimensional process,
incorporating clinical and neuropsychological exam-
inations designed to test both general cognitive status
and those cognitive domains underlying the decision-
making key conditions, as well as assessment of
knowledge specific to the type of capacity being
investigated. The ideal assessment of capacity should
include:
a) detailed history-taking with the patient and other
informants (relatives, caregivers, friends, general
practitioner, etc.) and a neuropsychiatric exami-
nation;
b) a battery of neuropsychological tests explor-
ing both general cognition and specific domains
involved in abilities for which the assessment of
capacity is requested. The decision-making neu-
rocognitive substrate is mainly represented by
supramodal functions – attention, esecutive func-
tions, memory – and these must constitute the
core of capacity assessment [5, 7];
c) assessment of abilities related to single capaci-
ties needs ecological evaluations and functional
ability measuring tools including “purpose-built”
tests, scales, questionnaires and vignettes. Many
ad hoc scales have been proposed [5, 11] but
may prove unreliable in the absence of a careful
and competent clinical and neuropsychological
assessment;
d) interpretation of test results on the basis of the
patient’s disease (clinical features, course of ill-
ness) and the complexity of the choice, grading
them in relation to known legal standards;
e) identification and recommendation of adapt-
ing strategies and environment supports aimed
to improve subjects’ decisional capacities, and
cognitive training of domains involved in
decision-making capacity.
Ethical issues
Determination of incompetence is one of the most
extreme infringements of a citizen’s rights [3], because
legal revocation of capacity may result in loss of basic
individual freedoms. For this reason, capacity must be
presumed until one has proof to the contrary.
Clinicians involved in the assessment of capacity
must be aware of the professional controversies and
ethical challenges inherent in the assessment of capac-
ity, including the current lack of methodological and
procedural guidelines.
Ethical challenges include balancing the need to
respect an individual’s freedom of choice and self-
determination (ethical principle of autonomy) with the
need to promote the individual’s safety and protection
(principles of beneﬁcence and nonmaleﬁcence), attain-
ing professional competence and selecting, using and
interpreting assessment methods appropriately [7, 11,
12].
Conclusions
Capacity assessment requires the utmost responsi-
bility. It also requires a high degree of professional
competence as well as adherence to biomedical ethics,
balancing respect for patients’ self-determination and
the need to protect them. Continuing medical educa-
tion and improvement of the assessment tools in this
field are essential for a more appropriate approach to
the human rights of cognitively impaired patients.
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Alzheimer’s disease (AD) is marked by a multitude
of structural and biochemical changes that played a
major role in the definition of the disease more than
a century ago by Alois Alzheimer [1]. Intraneuronal
neurofibrillary tangles composed of highly phosphory-
lated cytoskeletal proteins and extracellular amyloid-
surrounded by neuronal and glial responses define the
complex senile plaques [2] (Fig. 1). With a vast array
of changes, sorting out the initial changes from subse-
quent changes has been like untying a Gordian knot.
Every pathway examined is fundamentally altered to
establish what appear to be de novo relationships
between systems. The past 30 years of pulling apart
pleotrophic changes has only advanced a better under-
Fig. 1. In Alzheimer’s disease, the brain develops numerous abnor-
mal pathological structures that contribute to the loss of cognitive
function. Extracellular senile plaques composed of amyloid-
(arrows) and intraneuronal formation of neurofibrillary tangles
(arrowheads) result in a Gorgian knot of tissue disruption.
standing of the pathways, not the system. As Alexander
did for the knot, cutting complexity is required. Biol-
ogy is the sword, the elegant simplicity of evolution,
natural selection and biological self organization is as
much a guide for the properties of chronic pathology
as they are for normal physiology. Biological prop-
erties are based on selective advantage for offspring
survival. Biology confers emergent properties based on
selective advantage, not self-destruction. We argue that
the emergent properties of AD are based on responses
of the brain to injury, amyloid- is upregulated with
injury [3], and it is not a surprise that it is upregulated
during the greatest insult that we all face, aging [4].
The apparent pathology of AD may play a protective
role [5] responsible for the survival of neurons for years
following onset of AD [6]. That amyloid-, tau, oxida-
tive stress, and altered signal transduction are also seen
in brain injury supports the view of these changes as
responses to the disease that are essential to maintain
normal function, and their removal can be detrimen-
tal [7]. This view moves the argument from pathology,
end stage or incipient, molecular biology or genetic, to
the biology driving disease years prior to any apparent
abnormality. Biology is driven by responses that favor
survival not self-destruction. In contrast, the amyloid
cascade fundamentally favors the brain that destroys
itself, for no apparent selective advantage.
Understanding the biology of normal as well as
pathological aging (AD) opens the field to new ther-
apeutic avenues that focus on promoting successful
responses of the brain to maintain normal function.
And while that might be to remove amyloid- from
some compartments, it might also be to promote its
accumulation in others. Instead of focusing on cures,
which so far have been ineffective for age-related
chronic conditions, the interest should be on therapeu-
tics to increase the number of high-quality years. This
change in focus in AD research is already happening
and offers the hope of a greater understanding of what
we can do to patients in our lifetime.
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Abstract
In this review, we detail the genetics of those dis-
eases which have tangle pathology. These include
Alzheimer’s disease (AD), frontotemporal dementia
with tau pathology (FTD-T), progressive supranuclear
palsy (PSP), corticobasal degeneration (CBD), Parkin-
son’s dementia complex of Guam (and related diseases:
PDC) and myotonic dystrophy. Our intention is not to
reiterate the well established, but rather, in the case of
mendelian disease, to discuss new findings and also to
discuss the new findings from genome wide association
studies.
Introduction
Genetic analysis has led to enormous progress in
our understanding of the tangle diseases. With respect
to mendelian forms of the tangle diseases we now
know that all cases of autosomal dominant Alzheimer’s
disease have mutations in the APP or presenilin 1
and 2 genes (reviewed in [1]) and that most, if not
all autosomal dominant tangle disease have mutations
in the MAPT gene (reviewed in [2]). In this review,
with respect to mendelian forms of the disease, we
highlight unusual mutations and discuss their general
mechanisms and then discuss genetic analysis of the
non-mendelian forms of the illnesses.
Mendelian disease
Autosomal Alzheimer’s disease
Dominant disease. All cases of autosomal dominant
Alzheimer cases are caused by mutations in APP and
presenilin 1 and 2 [1]. All mutations are missense muta-
tions with a couple of exceptions: duplications of the
APP gene can cause Alzheimer’s disease [3] and some
mutations in the presenilin 1 gene result from in frame
deletions which do not disrupt the overall structure of
the protein, most notably the exon9 mutation [4].
While there have been reports of presenilin 1 mutations
causing frontotemporal dementia (and thus implying
that there was a route PSEN1 – >MAPT which did not
involve APP), most of these reports were misleading
and involved (probably harmless) polymorphisms in
the presenilin 1 gene in patients with dementia who had
pathogenic mutations in other genes (see refs [5–8]).
The presenilins are the major component of -
secretase, together with nicastrin, APH-1 and PEN2
[9]. Recently, loss of function mutations (nonsense,
frameshift etc.) in presenilin and the other -secretase
components has been shown to cause acne inversawith
no hint of a dementing illness [10]. This phenotype
appears to be due to a problem with the cleavage of
Notch by -secretase. Indirectly this observation of the
phenotypic effects of clear loss of function mutations,
together with the fact that clear simple loss of func-
tion mutations do not occur in Alzheimer’s disease
strongly suggests that Alzheimer causing mutations
are not simple loss of function changes. However, it
remains possible, even probable, that loss of func-
tion of -secretase is part of the mechanism. Clearly,
Alzheimer causing mutations have in common that
they increase A42 [11]. Several lines of evidence sug-
gest that this is mediated though a dominant negative
loss of function of greater than 50% with respect to
APP as a substrate. First, knockdown of presenilin 1
to <20% residual level leads to increases in A42 of
the same order as pathogenic mutations [12]. Second,
the known loss of function mutation, which causes the
notch phenotype in C. elegans, sel12, is an Alzheimer
causing mutation [13, 14], and third, some Alzheimer
pathogenic mutations have been directly shown to be
loss of function changes (e.g. [15]). Thus the most
parsimonious current view is that Alzheimer causing
mutations lead to a greater than 50% decrease in -
secretase activity with regards to APP as a substrate,
leading to an increase in A42 and a decrease in A40
production. Quite why these mutations do not appear
to lead to acne inversa is not clear, but presumably
relates to differences in the specificity of the complex
to different substrates.
The major hypothesis concerning Alzheimer’s
pathogenesis, especially as it relates to the autosomal
dominant forms has been that it is the increase in the
process of A deposition that is key to pathogenesis
[16]. An alternative is that it is the loss of activity in
-secretase activity towards its multiple substrates that
is in fact the key (with mutant APP acting as a com-
petitive inhibitor in APP mutation families) [17, 18].
This hypothesis is a logical formal possibility, although
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the findings with acne inversa and the analogy with
Worster Drought syndrome (another plaque and tangle
disease) [19], both point towards the A hypothesis
being the more plausible.
Recessive Alzheimer’s disease?
All the above comments relate to autosomal dom-
inant disease. No loci for autosomal recessive disease
have been identified, although two homozygous patho-
genic mutations in the APP gene have been reported
[20, 21]. Technically, this would have been very
difficult because recessive early onset disease would
usually appear merely as sporadic and the challenges
of identifying recessive disease loci, if they exist, was
extremely challenging. Whole genome genotyping
arrays now make this challenge tractable and there
have been two reports of potentially recessive disease
in inbred populations. If there are such loci, they
should be identified in the near future [22, 23].
Frontotemporal dementia with tau pathology
Mutations in the MAPT mutations are either the
major or the only cause of autosomal dominant fron-
totemporal dementia with tangles. Mutations are of
three types: point mutations in exons 1, 9, 10, 11, 12 and
13 [23, 24], mutations which alter the splicing of exon
10 such that more of this exon is incorporated in to the
final protein [25, 26] and thirdly, structural mutations
at the locus [28, 29]. A recent review has discussed the
former two groups of mutations and so these will not
be further discussed [30]. PGRN, VCP and CHMP2B
mutations are other causes of FTD, but these cause the
clinical phenotype but without the occurrence of tan-
gles and so are outside the scope of this review (see
[31]).
The report of a duplication of the MAPT locus in
a case of FTD with parkinsonism is of great interest,
although not definitive [28]. It is of interest because it
fits with the general pattern in the protein deposition
diseases, of gene duplications being pathogenic, like
SNCA and APP duplications [32, 33]. This seems to
be a general phenomenon in neurodegenerative protein
deposition disorders [34]. It is not definitive how-
ever, because it was not possible to assess segregation
in the kindred meaning that it remains possible that
this was just a chance finding: assessment of other
FTD cases should eventually resolve this uncertainty.
The duplication, which has also been reported in two
young children with developmental delay [35, 36] is
the inverse of the deletion of the locus which causes
a mental retardation syndrome. The deletion is caused
by the fact that the locus is inverted on ∼20% of Euro-
pean chromosomes [37, 38].
The internal MAPT deletion is also interesting [29].
The deletion takes out exons 7 and 9 from the full length
protein (the deletion encompasses exons 6–9 but 6 and
8 are not brain expressed). As with the duplication,
there was not the possibility of assessing segregation
though there was a clear family history of disease. The
resultant protein, like many of those with point muta-
tions, is less effective at stabilising microtubules [39].
Unfortunately, there was no autopsy available from the
patient and so we do not know whether only the mutant
protein was deposited.
Genetic analysis of complex tangle diseases:
association studies, including genome wide
association studies
Genetic analysis of diseases with complex modes
of transmission has not had great success until 2008
with the advent of genome wide association studies.
Before that time, candidate gene association studies
were the only approach that was possible, and these had
limited success. For Alzheimer’s disease, the identifi-
cation of apolipoprotein E as a risk locus was an early
success [40] (see the Alzgene website for summary
statistics for all association studies in Alzheimer’s dis-
ease [41]) and for progressive supranuclear palsy and
corticobasal degeneration, the MAPT locus was a clear
candidate gene which showed a strong association [42–
44].
Late onset Alzheimer’s disease
Beyond apolipoprotein E, no other reported asso-
ciations with Alzheimer’s disease had been identified
[39]. However, in whole genome analysis, a number
of loci have been identified including CLU [45, 46],
CR1 [46], PICALM [45], BIN1 [47], ABCA7, CD2AP,
CD33, EPHA1 and MS4A4/MS4A6E [48, 49]. The
number of loci identified simply reflect the numbers
of samples analysed, and it is likely that the number
of established loci will increase considerably over the
next year. The loci identified so far fit into three broad
pathways: the complement cascade (which had been
previously proposed to be important in Alzheimer’s
disease based on pathologic studies [50, 51], endo-
somal vesicle recycling and cholesterol metabolism
(which, of course, is the classical role of apolipopro-
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tein E) [52]. Thus, the genes involved in late onset
Alzheimer’s disease are involved in a defined num-
ber of pathways. It is not yet clear how the pathways
identified by this analysis relate to APP metabolism or
function.
Progressive supranuclear palsy
and corticobasal degeneration
PSP and CBD are the most common sporadic
tauopathies. MAPT associations for both diseases have
been established for many years [42–44]. The asso-
ciated MAPT haplotype is also related to increased
expression of the 4-repeat isoform of the tau protein
[53]. A whole genome association has additionally
identified associations with STX6, a protein thought
to be involved in vesicle fusion and in MOBP,
a myelin protein. Additionally other genes involved
in both the innate immune system and the endoplas-
mic stress response also seemed to have a role in PSP
[54]. The association study for CBD was underpow-
ered but proffered evidence for the same loci as for
PSP. This study was, because of the comparative rarity
of the diseases, of necessity, rather small and again, as
for Alzheimer’s disease, undoubtedly more loci will be
found as additional samples are assessed.
Other disease with tangles
Tangles are found in many other diseases. These
include some autosomal prion diseases [55] and
Worster Drought syndrome (British Dementia) [19].
These, like Alzheimer’s disease are diseases in which
there is an extracellular amyloid and intracellular
tangles. The occurrence of tangles in these diseases
suggests by analogy that tangle formation is somehow
a general response to the amyloid deposition process.
Tangle formation also occurs in the CNS in myotonic
dystrophy [56]. The reason for this occurrence is not
clear and deserves further study, but may relate to dis-
regulation of tau splicing indirectly induced by the
CUG expansions in DMPK mRNA that define DM1.
The CUG expansions sequester the RNA binding pro-
tein MBNL1, leading to a reduction in cellular levels of
the protein and widespread pre-mRNA splicing defects
(reviewed in [57]). The splicing of MBNL1 is also
affected, although it is thought that changes to MAPT
splicing are a result of reduced levels of functional
MBNL1 rather than changes in MBNL1 expression
[59]. DM1 seems to be distinct from other tangle dis-
orders with aberrant splicing of tau in that it is altered
splicing of exons 2 and 3 of MAPT that is observed,
rather than altered exon 10 splicing as seen in FTD, PSP
and CBD [60]. The functional significance of this is not
known and warrants further investigation. Finally, it is
worth noting that splicing of exons 2 and 3 can also
differ between the two major tau haplotypes, with H1
showing reduced exon 2 and 3 inclusion [61].
Tangles have been a feature of three epidemic dis-
eases: Von Economo’s disease (the sleepy sickness)
[62], Subacute Sclerosing Panencephalitic Encephali-
tis [63] and Parkinson Dementia/Motor Neuron
Disease complex of Guam (lytico-bodig) [62–64]. The
first of these was a prevalent parkinsonian disorder pos-
sibly related to the∼1920 influenza pandemic [63] and
the second is a rare complication of measles infection
[64] and the last was the prevalent and phenotypically
varied, idiopathic disease found on Guam after the Sec-
ond World War [65]. While the cause of the latter has
never been determined, it seems that it, like PSP and
CBD shows a MAPT association [66].
A note about Parkinson’s disease
Parkinson’s disease is defined pathologically by the
presence of Lewy Bodies composed of alpha-synuclein
rather than the presence of tau tangles. However, there
are several reports of tangle pathology in PD, and the
association of mutations in MAPT with the clinical
syndrome of parkinsonism prompted several candi-
date gene studies reporting an association of the H1
haplotype with PD (see [67]). This association was
confirmed by a recent GWAS that variation at the
MAPT locus is a major factor influencing PD risk [68].
The disease associated H1 haplotype can be further
dissected into several sub-haplotypes, and, interest-
ingly, the haplotype associated with PD is distinct from
the haplotype associated with PSP and CBD [67, 69].
Increased 4R tau levels are found in PD brain with
the disease haplotype, suggesting some common func-
tional mechanisms [70].
General principles
It is clear from the above discussion that tangle
formation and cell death can be initiated by very dis-
parate events: from APP mutations, to measles virus
exposure. Our aim to draw commonalities between
these initiating events and this is clearly still a dif-
ficult challenge. A conventional separation has been
between primary tauopathies, where tau is the only
deposited protein, and secondary tauopathies, where
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there is some deposition of extracellular amyloids. This
separation seems to have merit in that in all the cases
where it has been possible to assess, the occurrence
of the primary tauopathy diseases is influenced by the
splicing and expression of the tau protein. This is not
true of the secondary tauopathies where the autoso-
mal dominant genes simply relate to the production
of the amyloid deposits. So far, none of the same risk
genes, or indeed none of the same pathways have been
implicated both in Alzheimer’s disease and in PSP.
As more genes are identified for both diseases, this
may, of course, change, but currently, the most par-
simonious explanation is that the aetiologies of the
different diseases are not related to each other and
that factors which influence the production of tangles,
have little influence on the occurrence of Alzheimer’s
disease.
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Immune responses are the major active defense
mechanisms of the body. Antigens are the molecules
against which an immune response can be directed;
antigens are foreign or self-component. Any immune
response is accompanied by inflammation. Inflamma-
tion is a complex process which commences with a
primary reaction and is followed by a secondary reac-
tion which involves supplementation by blood borne
elements. Both primary and secondary reactions may
be either successful or have lethal consequences; fac-
tors determining the responses of the nervous system
are the route of entry of the antigens, the type of antigen
(proteins, organisms, type of organisms), the compe-
tence of the host to mount an immune response, and
the unique features of the human central nervous tissue,
namely the blood–brain barrier.
The immune system operates by means of the secre-
tion of single antigen-specific antibodies (humoral arm
of immunity); this implies the recognition of the anti-
gen (epitope) by B lymphocytes containing specific
surface-bound immunoglobulins. After binding an epi-
tope to their surface IgM, B cells proliferate and mature
within the lymph nodes, become plasma cells and
secrete antibodies (IgG); IgG antibodies to a specific
epitope have higher affinity than their IgM progenitors.
Antigen-antibody binding permits either activa-
tion of complement, or binding of the complex to
phagocytes, or to other effectors of the inflammatory
responses. Most sustained antibody responses necessi-
tate collaboration between B cells and T cells (helper
T cells, CD4+).
T cells of lymph nodes operate by themselves (cel-
lular arm of immunity) or as helpers of B cells. By
means of the T cell receptor (TCR), T cells recognize
the epitopes presented to them by the antigen present-
ing cells (APC). Monocytes, macrophages, dendritic
cells, as well as B cells, may function as APC.
A major role in foreign antigen presentation, as well
as in self-recognition, is played by mayor histocom-
patibility complex (MHC) proteins expressed on the
surface.
Activated T cells secrete interferon gamma, which
favours antigen presentation, while APC and CD4 cells
release IL-1 and -2 respectively, providing mitogenic
signals. As a consequence, activated CD4 cells expand,
leave the lymph nodes and home to target tissue, in
which antigen presentation is amplified.
The effector phases of the cell-mediated immune
response is represented by delayed-type hypersensitiv-
ity response and cytotoxycity. An example of the first is
experimental allergic encephalitis (EAE) in Lewis rats.
EAE is produced by immunizing with a peptide that
cross-reacts with aminoacid sequences within myelin
constituents. In EAE, activated CD4 cells release lym-
photoxin, and macrophages, driven by lymphokines,
release IL-1 and TNF. TNF is toxic to oligodendro-
cytes, causing them to retract their processes and to
close their K+ channels. TNF can cause demyelina-
tion and possibly oligodendrocyte killing; IL-1 and
lymphotoxin may potentiate the TNF effects. Antigen
presentation is effected by astrocytes and microglia;
the oliogodendrocytes provide the antigen, i.e. myelin
basic protein (MBP), but do not present it. A similar
pathogenic sequence of events may occur in multiple
sclerosis, Guillain-Barre` syndrome and postinfectius
or post-immunization encephalitis.
Cell-mediated cytotoxicity involves CD8 cell pro-
liferation, and is facilitated by IL-2 produced by CD4
cells within the lymph nodes. Expanded T cell clones
enter the target organ; target cells present antigen via
their class I MHC molecules, and cytotoxic cells adhere
to their target, release perforin and other cytolitic prod-
ucts. Brain cells do not express class I MHC alleles,
but IFN-gamma secreted by CD4 and CD8 cells may
induce the expression on astrocytes and oligodendro-
cytes.
The setting in motion of humoral and cellular
immune response requires the existence of lymph
nodes and free access to the target organ; the recog-
nition of self requires the expression of class I
MHC alleles. Class I MHC alleles are expressed on
the surface of cells in most body tissue, with the
notable exception of healthy brain, which is thought
to be a major reason why grafts of brain tissue to brain
are rejected indolently.
However, the concept of immunologic privilege of
the brain needs to be revisited, taking into account
that lymphocytes re-circulate in the normal brain,
intrathecal production of immunoglobulin is reported
in pathological conditions (multiple sclerosis, viral
encephalitis), and antibodies and peptides, amyloid
beta included, are transported between the brain and
the blood [1].
In addition, dendritic cells (DC) are normally
present in the CSF compartment, including lep-
tomeninges and choroid plexus, and additional DCs
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are recruited from blood and, possibly, from brain
microglia in case of brain or CSF inflammation.
A connection between central nervous system
(CNS) and deep cervical lymph nodes exists, poten-
tially allowing mature DCs to migrate out of the CNS
and induce a T cell response against foreign anti-
gens present in the intratecal compartment. In chronic
inflammation, some DCs may interact with T cells
directly in the meninges; in chronic EAE, T cells of
the meningeal infiltrates express TCRVbeta8.2, i.e. are
directed against MBP, and proliferate in situ, contribut-
ing to and maintaining lesion activity with features of
chronicity and autoimmunity [2]. A key questions is
why chronic inflammation and autoimmunity do not
develop in the neurological diseases associated with
tissue damage and release of myelin antigens, such as
stroke.
A typical feature of the CNS, and an additional
issue of confusion when analyzing the effects of sys-
temic modifiers of immunity and inflammation in
Alzheimer patients, is microglia. Microglia are res-
ident macrophages in the CNS; they derive from
myeloid precursor cells and enter the developing CNS
during embryogenesis. The resting microglia, iden-
tified by ramified morphology, change phenotype to
an activated morphology characterized by hypertrophy
and extensive branching as a consequence of disease
or injury. Activated microglia upregulate receptors and
cytoplasmic molecules, but the active status does not
clarify the role of microglia in disease pathogenesis
and whether it acerbates pathology or aids in tis-
sue repair. After an acute brain injury, activation of
microglia is accompanied by the synthesis of proin-
flammatory cytokines and inflammatory mediators and
results in additional detrimental tissue damage. In slow
degeneration, such as Wallerian degeneration within
the CNS, activated microglia is associated with an
anti-inflammatory phenotype [3].
Microglia was originally considered as the major
player of not specific innate immune defense in CNS,
which respond immediately to all provocations to
the host; nevertheless, microglia do not phagocyte
amyloid beta in normal conditions. In neurodegener-
ative diseases, activated microglia is present; its role
as contributor or consequence of the pathology is
not fully understood. Apparently, neither extracellu-
lar misfolded proteins nor chronic neuronal loss are
able to induce a strong proinflammatory response.
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Resting State Network Abnormalities in Alzhei-
mer’s disease: Beyond the Default Mode Network
Federica Agostaa, Michela Pievania, Cristina Geroldib,
Massimiliano Copettic, Giancarlo Comia, Giovanni
Frisonib and Massimo Filippia
aScientiﬁc Institute and University Hospital San Raf-
faele, Milan, Italy
bIRCCS Centro San Giovanni di Dio – Fatebene-
fratelli, Brescia, Italy
cIRCCS-Ospedale Casa Sollievo della Sofferenza, San
Giovanni Rotondo, Italy
Aims and methods: Using resting state (RS) func-
tional MRI (fMRI), the connectivity patterns of the
default mode network (DMN), as well as the fronto-
parietal, executive, and salience networks were explo-
red in 13 patients with Alzheimer’s disease (AD) and
12 patients with amnestic mild cognitive impairment
(aMCI) relative to 13 healthy controls.
Results: Compared with healthy controls and
aMCI, AD was associated with opposing connectivity
effects in the DMN (decreased) and frontal networks
(enhanced). The only RS abnormality found in aMCI
patients compared with controls was a precuneus con-
nectivity reduction in the DMN. RS fMRI group
differences were only partly related to grey matter atro-
phy. Cognitive impairment correlated with enhanced
executive network connectivity in aMCI, and with a
reduced connectivity of the same network in AD.
Conclusions: This study shows that AD is associ-
ated with an alteration of large-scale functional brain
networks, which extends well beyond the DMN. The
limited resources of the parieto-temporal cortex of AD
patients may be paralleled, in an attempt to maintain
cognitive efficiency, by an increased prefrontal connec-
tivity. A medial parietal RS fMRI signal change seems
to be present since the early phase of AD.
Brain Leptin Signature of Hyperphagia
in Frontotemporal Lobar Degeneration
Antonella Albericia, Barbara Borronia, Carmelo
Iacobellob, Silvana Archettib, Enrico Premia, Carlo
Cerinia, Alessandra Valerioa, Luigi Caimia and
Alessandro Padovania
aUniversity of Brescia, Brescia, Italy
bSpedali Civili, Brescia, Italy
Background: Frontotemporal lobar degeneration
(FTLD) is characterized by abnormal eating behaviour.
We demonstrated a selective gender differences in lep-
tin levels between females in FTLD, as compared to
Alzheimer disease (AD) patients, providing a evidence
of an involvement of leptin in the regulation of hyper-
phagia of FTLD.
Aims: To understand the brain frameworks associ-
ated with leptin in FTLD.
Methods: FTLD patiens were recruited, and exten-
sively assessed for their cognitive and behavioral
profiles. Serum leptin levels were measured using a
human leptin enzyme linked immunoasorbent assay
(ELISA) kit according to manufacturer’s instructions
(Diagnostic Biochem Canada Inc. Version 6). Mag-
netic resonance imaging (MRI) was performed, and
Voxel Based Morphometry (VBM) analyses were
implemented in the SPM8 software package (Well-
come Department of Imaging Neuroscience, London;
http://www.fil.ion.ucl.ac.uk/spm) running on Matlab
6.5.1 (MathWorks, Natick, MA).
Results: Leptin levels correlated with gender, BMI,
and hyperphagia. Higher leptin levels were specifically
associated with greater atrophy in Brodmann area 6.
Conclusions: We provided a novel biochemical and
structural framework to FTLD, and its relationship
with the control of body weight and energy homeo-
stasis.
Gait Assesment and Cognition in Parkinson’s
Disease
Marianna Ambonia, Paolo Baroneb, Alfonso Fasanoc,
Luigi Iuppariellob, Ilaria Listaa, Riccardo Tranfagliab,
Simona Nicolosid and Giuseppe Sorrentinoa
ISSN 1387-2877/11/$27.50 © 2011 – IOS Press and the authors. All rights reserved
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aUniversity of Naples Parthenope, Naples, Italy
bUniversity of Naples Federico II, Naples, Italy
cCatholic University of Sacred Heart, Rome, Italy
dUniversity of Enna Kore, Enna, Italy
Background: Increasing evidences support a strong
association between gait and cognition. Originally the
construct of Mild Cognitive Impairment (MCI) was
conceptualized as the transitional state between nor-
mal aging and Alzheimer’s disease (AD), recently, this
concept has been applied to cognition in patients with
Parkinson’s disease (PD).
Aims: To perform a quantitative gait assessment in
PD patients with or without MCI.
Methods: Forty-three PD patients were investigated.
All patients were assessed both clinically and cogni-
tively. Quantitative gait analysis was performed in the
following conditions both at off and on state: 1) nor-
mal gait (Gait-off an, Gait-on); 2) motor dual task
(Mot-off, Mot-on); 3) cognitive dual task (Cog-off,
Cog-on).
Results: Based on neuropsychological testing, nine-
teen subjects were classified as patients with MCI
(MCI+) and twenty-four subjects without (MCI−).
The two groups didn’t differ on clinical features.
MCI+ vs MCI− showed: 1) reduced single/double
support time ratio in Mot-off (p = 0.044), Cog-off
(p = 0.011); 2) increased step length variability in
Gait-off (p = 0.030); 3) reduced gait stride in Cog-on
(p = 0.046).
Conclusions: MCI+ vs MCI− PD patients displayed
specific gait features: impairment of dynamic stability,
increased variability and reduced gait stride.
A Methodological Approach for an Early
Identiﬁcation and Diagnose of Cognitive
Disorders of Patients Seen in the UVA n°1
of the Neurologic Clinic of the AOU of Sassari
Caterina F. Bagella, Rossella Cherchi, Dario Zanetti,
Raimonda Piu and Maria R. Piras
Azienda Ospedaliero-Universitaria, Sassari, Italy
Background: During the last ten years, the Alzhei-
mer’s Evaluation Units (UVA) have obtained an impor-
tant role in the diagnosis, follow-up and management
of patients with cognitive disorders and are an impor-
tant support for family and care-givers.
Aims: Based on our clinical experience and on the
state of art, we elaborated a data survey form (SRD)
for each patient seen for the first time in our unit. The
SRD contains patient-specific information; informa-
tion regarding risk factors (environmental and non);
age and modality of outbreak of the cognitive disorder;
neuropsychological information; and the pharmaco-
logical therapy.
Results: The observation time was of one year.
We’ve diagnosed 68 new cases: 29 with Alzheimer
(AD), 5 with Frontotemporal, 1 with Lewy Body,
9 with Vascular Dementia (VaD), 1 with Multisis-
temic Atrophy (MSA), 1 with dementia caused from
hydrocephalus, 23 with Mild Cognitive Impairment
(MCI) (15 EOMCI and 8 LOMCI). From our study
emerged that there isn’t a significant numerical differ-
ence between familial and sporadic AD form (14 FAD
and 15 SAD), women are noticeably more predisposed
for AD (EOAD 6 : 1, LOAD 14 : 8) and school atten-
dance is generally very low (5.6 ± 1.2). Within MCI
we’ve 15 EO (13 women on 15) and 8 LO (6 women
on 8) and school attendance is higher (8.15 ± 4.7).
From a first analysis of the more significant risk factors
(hypertension, hypercholesteremia, diabetes) emerged
that of 22 ADLO 13 are hypertensive, 3 hypercholes-
terolemic and 5 diabetic; and of 7 ADEO patients 4
are hypertensive, 2 hypercholesterolemic and 1 dia-
betic. Things change when we analyse VaD patients,
i.e. 7 are hypertensive, 3 hypercholesterolemic and
2 diabetic. Particular attention has to be given to
MCI, i.e. of 23 new cases, 9 are hypertensive, 6 are
hypercholesterolemic, none has diabetes, and 8 have a
familiarity for dementia.
Conclusions: The SRD has not only allowed us to
elaborate a more accurate method to diagnose patients
affected by a cognitive deficit, but also to notice how
risk factors, co-morbidity, age, school attendance and
gender are modified in accordance with the variation of
the clinical phenotype. In the future management of our
unit the SRD will not only have the function to create
an accurate and specific database in order to lay the
foundations for a systematic epidemiological study of
the patients seen in our unit, but also to give a dynamic
overview of a considerable part of the North Sardinian
cognitive impaired population.
fMRI, Tractography and EEG Analysis
Integrated into Neurological Diagnosis
of Corticobasal Degeneration. A Case Study
Francesca Baglioa, Maria G. Pretib, Ludovica
Griffantib, Luigi Pugnettia, Elisabetta Farinaa,
Massimo Garegnania, Maria M. Laganàa, Pietro
Cecconia, Giuseppe Basellib and Raffaello Nemnia,c
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aFondazione Don Gnocchi, Milan, Italy
bPolitecnico, Milan, Italy
cUniversity of Milan, Milan, Italy
Background: The phenotypes of Corticobasal De-
generation (CBD) and Progressive Supranuclear
Palsy(PSP) are closely related and frequently overlap
at the onset.
Aims: We report a case of early atypical Parkinson-
ism prevalent on the left side, introducing the use of
advanced neurophisiological and neuroimaging tech-
niques in order to further support the clinical diagnosis
of CBD.
Methods: A single patient was examined with ad-
vanced MRI techniques-fMRI with passive motor task
and DTI- and EEG source mapping. Tractography
of the cortico-spinal tract (CST) was performed and
fMRI-based tractography was also applied.
Results: Although conventional MRI does not reveal
asymmetric brain damage, fMRI and EEG during hand
motor passive task confirmed that the left hand move-
ment was less effective than the right, and displayed
asymmetric activation patterns in pre- and postcen-
tral gyri (right > left). fMRI-guided tractography also
found asymmetric recruitment of CST, whereas the
conventional CST tractography showed a consider-
able difference between the number of right and left
reconstructed tracts.
Conclusions: The combination of tractography,
fMRI and EEG confirms the clinical asymmetric
parkinsonism by mapping the specific bundles in-
volved in the functional activation consequent to the
hands passive motion. Taking together, these findings
supports the clinical diagnosis of CBD excluding other
closely related diseases, such as PSP.
The Efﬁcacy of Multidimensional Stimulation
Therapy in Mild to Moderate Alzheimer’s
Disease Patients: a Randomized Controlled
Trial with fMRI
Francesca Baglioa, Ludovica Griffantib, Maria G.
Pretib, Maria M. Laganàa, Margherita Alberonia, Fabi-
ana Villanellia, Laura Carellia, Francesca Saibenea,
Raffaella Critellia, Pietro Cecconia, Giuseppe Basellib,
Raffaello Nemnia,c and Elisabetta Farinaa
aFondazione Don Gnocchi, Milan, Italy
bPolitecnico, Milan, Italy
cUniversity of Milan, Milan, Italy
Background: There is good evidence that group
Multidimensional Stimulation Therapy (MST) leads to
generalised cognitive benefits in Alzheimer’s disease
(AD). However, few literature illustrates whether some
aspects of cognition might change more than others.
Aims and methods: Thirty-six AD patients were ran-
domized in treated (tMST) and non-treated (ntMST)
groups. MST sessions involved reality orientation,
physical, recreational, and occupational activities. In
all groups before and after rehabilitation – tMST
groups- or observation period-ntMST groups – we
evaluated neuropsychological and neurobehavioral
assessments and collected functional MRI (fMRI) data
with a paced-overt verbal fluency paradigm.
Results: The tMST and ntMST groups were compa-
rable at the baseline regarding MMSE values and fMRI
activations pattern. Direct comparison (paired t-test;
p < 0.005) of fMRI results before and after rehabilita-
tion or observation period showed: 1. in tMST groups
greater activation after MST in bilateral temporal cor-
tex, basal ganglia and right hippocampus; 2. in ntMST
groups no significant changes in brain activation pat-
terns after the observation period.
Conclusions: Increased fMRI activations only in
tMST groups support that MST appears to have partic-
ular effects in promoting cognitive functions (language
function, response inhibition, motor preparation and
sustained attention). Particularly, the efficacy on lan-
guage may be explained through generating opinions
and creating new semantic links.
Cognitive Training in Outpatients Affected
by Mild Cognitive Impairment:
a Longitudinal Study with fMRI
Francesca Baglioa, Ludovica Griffantib, Maria G.
Pretib, Maria M. Laganàa, Margherita Alberonia, Raf-
faella Critellia, Alessandra D’Amicoa, Alessandra
Pinia, Pietro Cecconia, Giuseppe Basellib, Raffaello
Nemnia,c and Elisabetta Farinaa
aFondazione Don Gnocchi, Milan, Italy
bPolitecnico, Milan, Italy
cUniversity of Milan, Milan, Italy
Aims: The aim of this study was to evaluate the
impact of a 3 months cognitive training (CT) on
the clinical, neuropsychological, neurobehavioral and
neuroimaging evolution of Mild Cognitive Impairment
(MCI) patients.
Methods: Thirty MCI patients were evaluated with
neuropsychological and neurobehavioral assessments
at the study inclusion and after 6 and 12 months. Fifty
percent were randomized to a 12 weeks CT consisting
of 2 individual sessions/week. fMRI with verbal flu-
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ency paradigm was performed in CT group before and
after rehabilitation.
Results: The CT group did not differ from the group
without CT in MMSE value at the baseline (p = 0.36)
and after six months (p = 0.61). Despite a statistical
comparable performance on correct responses during
the task (92% before versus 93% after CT; p = 0.7),
direct comparison of fMRI results before and after
rehabilitation showed: before CT, greater activation
in bilateral frontal areas and anterior cingulate cor-
tex (p < 0.005); after CT, in right temporal cortex and
parahippocampal gyri (p < 0.005).
Conclusions: Increased fMRI activations on frontal
areas before CT could be related to a higher cog-
nitive load required to complete the verbal fluency
task. Our fMRI results showed that CT is a useful
non-pharmacological treatment to improve response
inhibition, motor preparation and sustained atten-
tion.
Multidisciplinary study in FTD Italian patients
Silvia Bagnoli, Irene Piaceri, Andrea Tedde, Benedetta
Nacmias, Laura Bracco, Alberto Pupi and Sandro Sorbi
University of Florence, Florence, Italy
Background: The frontotemporal dementia (FTD)
is an heterogeneous disease both in terms of clinical,
genetics and neuropathology.
Aims: In this study, a group of 171 Italian patients
with FTD was analyzed with a multidisciplinary
approach including a thorough clinical evaluation, an
extensive genetic analysis and functional neuroimag-
ing with FDG-PET. The aim was to define markers of
disease to improve diagnostic protocols.
Methods: Genetic analysis was performed in all
the patients in the genes associated in FTD (PGRN,
MAPT, TDP-43) and in Presenilin1 gene (PS1)
recently involved in FTD.
Results: We identified the presence of five muta-
tions: one mutation (V363I) in the MAPT gene,
three mutations (T272fsX10, R493X, C139R) in the
PGRN gene and 1 mutation (L171P) in the PS1
gene. The FDG-PET showed hypometabolism pattern
compatible with a diagnosis of FTD and differential
characteristics with respect to the forms of Alzhimer’s
disease.
Conclusions: The extension on a larger scale of this
multidisciplinary study will provide a powerful route
to understanding the mechanisms underlying the dis-
ease and could provide evidence to future therapeutic
treatments.
Early-onset Dementia with Presenilin-1
Mutation and Motor Abnormalities
in an Italian Patient: a Case Report
Pierluigi Bertoraa, Elisa Capiluppia, Carlo Lovatib,
Giuliana Cislaghib, Raffaele Malettac, Daniela
Galimbertia,d and Claudio Mariania
aUniversity of Milan, Milan, Italy
bAzienda Ospedaliera L. Sacco, Milan, Italy
cA.S.P. Catanzaro, Lamezia Terme, Italy
dFondazione Cà Granda, IRCSS Ospedale Policlinico,
Milan, Italy
Case report: A 37-yr old, previously healthy woman
developed progressive impairment of memory, orien-
tation, and speech over a period of 2 years. No family
history of dementing illnesses was present. Neu-
rological examination showed temporal and spatial
disorientation, nonfluent aphasia, defects in sustained
attention and order comprehension. Mild limb ataxia,
myoclonic jerks of upper limbs with a consistent EMG
pattern, and psychomotor apraxia were also present.
Brain magnetic resonance imaging showed diffuse
cortical and deep atrophy and nonspecific minute T2-
hyperintense lesions in supratentorial white matter.
Routine cerebrospinal fluid (CSF) examination was
normal. Low levels of CSF A1-42 (184 pg/ml, nor-
mal > 600), elevated total Tau protein (1030 pg/ml,
normal <300) and phosphorylated Tau (1030 pg/ml,
normal <40) were found. 14-3-3 protein was slightly
elevated. No mutations of prion protein gene were
found. Brain SPECT showed mild left parieto-
temporal hypoperfusion. An EEG evidenced moderate
and diffuse slowing of cerebral rhythms. Mutation of
the presenilin-1 gene (exon 7, met233Thr) was found.
Conclusions: The clinical presentation and the
results of instrumental and laboratory tests make a
diagnosis of early-onset Alzheimer disease likely.
The peculiar clinical presentation, which adds motor
signs (myoclonus) to the cognitive impairment warrant
further investigation about the clinico-pathological
features of neurodegeneration in this patient.
EEG and Mild Cognitive Impairment (MCI):
Possible Predictive Value for Progression
to Lewy Body Dementia
Stefania Bifolchetti, Laura Bonanni, Elisa Mancino,
Leopoldo Ricciardi, Francesca Anzellotti, Fausta Cic-
cocioppo, Daniela Monaco, Maria C. D’Amico, Iole
Borrelli, Holta Zhuzhuni, Astrid Thomas and Marco
Onofrj
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G. D’Annunzio Chieti-Pescara University, Chieti,
Italy
Aims: The aim of this study is to investigate whether
q-EEG can identify specific patterns that have predic-
tive value for progression from MCI to dementia.
Methods: In the study were enrolled non-demented
subjects (n = 21) who meet Petersen’s criteria for
MCI – called isolated MCI (i-MCI) – and 28 Parkin-
son’s disease patients with MCI (p-MCI) matched
on age and years of education. All patient under-
went to quantitative EEGs (QEEG) from 21 scalp
derivations: power spectra measurements or CSA,
including the four variables, Dominant Frequency-DF,
DF Variability-DFV, Frequency Prevalence-FP and
Band Inscription-BI, and the resulting categorization
in 5 patterns observed in anterior (F3, F4, Fz) and
posterior (P3, P4, O1, O2) pooled derivations were
analysed for the purpose of the present study. The neu-
ropsychological battery includes: executive functions,
memory, language, attention, visuospatial/constructive
skills and evaluation of anxiety and depression.
Results: In the i-MCI group 80.9% of the patients
showed pattern CSA-1, whereas the most part of PD
patients (92.8%) with MCI showed patterns CSA > 1.
Conclusions: qEEG could be used as a reliable and
sensitive biomarker(s) of different subtypes of MCI.
Joint Analysis of Structural and Quantitative
Magnetization Transfer MRI for Classiﬁcation
of Alzheimer’s Disease and normal aging
Marco Bozzalia, Giovanni Giuliettia, Viviana Figuraa,
Roberta Perria, Camillo Marrab, Franco Giubileic and
Mara Cercignania
aSanta Lucia Foundation, Rome, Italy
bCattolica University, Rome, Italy
cSapienza University, Rome, Italy
Background: Quantitative magnetization transfer
(qMT) is an MRI able to detect biological changes
of brain tissues due to modifications of sub-cellular
components.
Aims: To determine the joint contribution of gray
matter (GM) atrophy and qMT parameters for the clas-
sification of AD patients.
Methods: We recruited overall 30 subjects (19 AD;
11 healthy controls [HC]), who underwent neuropsy-
chological examination and MRI at 3.0T : T1-weighted
volumes were used for GM volumetrics, while qMT
sequences were used to assess RM0B, F, and T2B
parameters. A logistic regression analysis was car-
ried out to assess the contribution of GM atrophy and
qMT parameters to the classification in AD or HS
categories.
Results: GM atrophy in putamen, pallidus and tha-
lamus, and reduced RM0B in areas belonging to the
so-called default-mode network (i.e., posterior cingu-
late, parietal cortex) and in hippocampus/parahippo-
campus were found to be predictive of AD. RM0B
resulted as the qMT parameter most sensitive to AD
pathology.
Conclusions: QMT seems promising for the diag-
nosis of AD. The anatomical distribution of RM0B
changes (which overlap the typical pattern observed by
PET scans), indicate qMT as a technique able to reflect
both, structural and metabolic information in vivo
and non-invasively.
Profound Semantic Impairment in Corticobasal
Degeneration: a New Phenotypic Variant
of Tauopathies
Viviana Cafazzo, S. Baldinelli, L. Vella, L. Provinciali
and S. Luzzi
Polytechnic University of Marche, Ancona, Italy
Background: It is generally assumed that semantic
knowledge is relatively preserved in CBD; however,
no longitudinal studies have deeply investigated this
cognitive domain.
Case report: Mrs MG, a right-handed 69-year-old
woman with 5 years of education, came to our atten-
tion complaining a 3-year history of involuntary
movements of her left upper limb. The neurological
examination revealed a left akinetic-rigid extrapyra-
midal syndrome and dystonia of left upper limb.
Background neuropsychological evaluation revealed
ideomotor apraxia of MG’s left upper limb, a dysex-
ecutive syndrome and anomias. A deep assessment
of language confirmed moderate naming impairment
with semantic paraphasias, errors in semantic matching
tests, difficulty in single word comprehension with ten-
dency to choice semantic distractors. Indeed the patient
showed problems in recognition of famous faces and in
detecting silhouettes. Brain MRI scan showed an asym-
metrical atrophy (>left) of the right parietal lobe and
bilateral atrophy of the temporal pole lobes. The 123-I-
FP-DAT SCAN was abnormal. A 18 month-follow-up
confirmed the clinical and neuropsychological picture
revealing a worse performance mainly in the domains
of praxis and semantics.
Conclusions: The present case provides evidence
that semantic knowledge can be damaged in CBD
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and reinforces the view that tauopathies do have an
high phenotypic variability.
Cognitive Rehabilitation in Patients with Mild
Cognitive Impairment
Sergio Cammarata, Cristina Novello, Valeria Pollero
and Monica Colucci
E.O. Galliera, Genoa, Italy
Background: Mild cognitive impairment (MCI)
patients are at increase risk of developing dementia.
To date it remains controversial if cognitive training
intervention can improve cognitive and functional per-
formances and delay the development of dementia.
Aims: To explore the benefits of a computer-based
cognitive training (CT) in patients affected by MCI
of the amnestic type (a-MCI) according to Petersen
criteria, compared with not treated a-MCI patients in
a longitudinal follow-up study.
Methods: Eighteen a-MCI patients were random-
ised to receive CT programme consisted in 20 indi-
vidual sessions of 45 minutes two days a week for
ten weeks and sixteen a-MCI received no intervention.
All the a-MCI patients underwent a multidimen-
sional assessment concerning neuropsychological and
functional characteristics, at baseline and after 9
months follow-up. The neuropsychological perfor-
mances were compared.
Results: a-MCI patients treated with CT showed
significant improvements (pre- and post-intervention
difference) on verbal and nonverbal episodic mem-
ory and attention. In contrast a-MCI patients without
treatment, showed no significant difference between
baseline and follow-up cognitive performances.
Conclusions: These results suggest that computer-
based cognitive training can improve a-MCI patients
cognitive performances.
Cognitive Decline and Extrapyramidal Features
in a Sporadic case of Frontotemporal
Dementia-Parkinsonism caused by a Novel
Progranulin Mutation
Miryam Carecchioa, Daniela Galimbertib, Francesca
Cortinib, Claudia Cantonib, Elio Scarpinib, Francesco
Monacoa and Emanuela Terazzia
aUniversity of Eastern Piedmont, Novara, Italy
bUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
Background: Mutations in Progranulin (GRN) have
been reported in autosomal dominant and sporadic
FTLD cases.
Case report: We report on a 54 years old male pre-
senting at age 51 with an asymmetric rest tremor in his
right hand; one year later, he started complaining of
short-term memory deficits, poor concentration, word
finding difficulty with apathy and echolalia. There was
no significant family history and he had a major depres-
sive episode at age 18. On examination, he showed
camptocormia; on the right side, he had reduced arm
swings and a rest, postural and intention tremor with
mild bradykinesia on finger tapping and cogwheel
rigidity in the elbow. His MMSE score was 24/30.
A brain MRI scan showed marked, slightly asym-
metric (L > R) frontotemporal cortical atrophy with
periventricular hyperintensity on FLAIR sequences.
CSF biomarkers were normal (A1-42 637 pg/ml, Tau
264 pg/ml, P181-Tau 16 pg/ml) and GRN plasma lev-
els were markedly decreased (13 pg/ml; ref > 70). GRN
sequencing revealed a novel mutation in exon 10
[Gly387fs25X (g.11654delG)] resulting in a premature
stop codon.
Conclusions: Our case underlines the importance of
assessing GRN plasma levels also in sporadic patients
with cognitive decline and extrapyramidal features
and confirms a normal CSF profile in these subjects
as previously observed.
Neuropsychological Evaluation and CSF Markers
of Neurodegeneration in Amyotrophic Lateral
Sclerosis Patients
Cecilia Carlesi, Cristina Pagni, Leda Volpi, Elena Cal-
darazzo Ienco, Livia Pasquali, Lucia Petrozzi, Gabriele
Siciliano and Gloria Tognoni
University of Pisa, Pisa, Italy
Background: Amyotrophic Lateral Sclerosis (ALS)
should be regarded as a multisystem disorder with cor-
tical involvement beyond the confines of the primary
motor areas.
Aims: To evaluate neuropsychological profile in
ALS patients as compared to healthy controls matched
for age, sex, education and to correlate neuropsycho-
logical measures to cerebrospinal fluid value of t-TAU,
p-TAU and -amiloid.
Methods: Ten patients with sporadic ALS and 6
controls, were studied. The neuropsychological assess-
ment consisted of standardized tests for executive and
memory functions. We evaluated also cerebrospinal
fluid value of t-TAU, p-TAU and -amiloid.
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Results: The data analysis showed in ALS patients
as compared to healthy controls a poorer performance
in a test of verbal memory (RAVLT immediate recall).
Moreover data obtained showed in ALS patients the
presence of positive correlation between t-TAU and
p-TAU value and number of errors in Stoop test and a
negative correlation between p-TAU value and MMSE.
Conclusions: These results support the presence
of extra-motor neuronal involvement, in particularly
of executive functions in ALS patients. Even for the
t-TAU and p-TAU data are in some way conflicting,
they could be markers related to frontal cortex degen-
eration also in sporadic ALS patients with normal
cognition.
FractalAnalysis ofRetinalVesselsRevealsReduced
Complexity in CADASIL
Michele Cavallaria, Teresa Falcoa, Marina Frontalib,
Silvia Romanoa, Francesca Bagnatoc and Francesco
Orzia
aSapienza University, Rome, Italy
bCNR, Rome, Italy
c3NIH, Bethesda, USA
Background: The cerebral autosomal dominant
arteriopathy with subcortical infarcts and leucoen-
cephalopathy (CADASIL) affects middle-aged adults
and leads to disability and dementia. Animal models
provide compelling evidence for the crucial patho-
genetic role of a specific arteriopathy affecting mainly
the small cerebral arteries, through an early dysfunc-
tion of the neurovascular unit. It is uncertain, however,
whether, and at which stage, the small vessels undergo
morphological changes in humans. In vivo, direct
imaging of small vessels in the brain is still lacking.
Ophtalmoscopic examination is a simple and accessi-
ble technique that is thought to represent a window into
cerebral microcirculation.
Aims: We sought to test the hypothesis that subjects
with CADASIL present changes in the retinal vessels,
as compared to a group of control persons. In order to
test the hypothesis we carried out a fractal analysis of
the vascular tree in digital retinal photographs.
Subjects: Ten subjects with genetically confirmed
diagnosis of CADASIL and ten gender and age-
matched control subjects.
Methods: Fractal analysis of retinal digital images
was performed using the computer-based program
ImageJ and the FracLac plugin. Brain MRI lesional
load assessment in FLAIR and T1-weighted DICOM
images was perormed using MIPAV software. The
analysis was carried out on a single parameter, the
mean fractal dimension (mean-D). We used Student’s
t-test in order to detect differences in fractal dimension
between CADASIL and control group. Linear regres-
sion was performed to test for a correlation between
mean D and lesional load in the CADASIL group.
Results: Both the mean age and the prevalence of
cerebrovascular risk factors did not differ between the
groups. There was a marked difference in the mean-D,
the value being significantly lower in the subjects with
CADASIL (1.42 ± 0.05) than in control (1.50 ± 0.04;
p < 0.001; figure). Linear regression analysis revealed
no correlation between mean-D and MRI lesional load.
Conclusions: Fractal dimension is an index of the
complexity or density of the retinal vessel branch-
ing. The reduced fractal dimension likely reflects early
abnormalities of the brain microvessels, associated
with the chronic progression and poor vessel remod-
elling of the disease.
Sociocultural Construction of Dementia in Two
Eastern Societies
Gabriele Cipriani and Gemma Borin
University of Pisa, Pisa, Italy
Background: Western and non-Western cultures dif-
fer significantly in disease construction.
Aims: To report the perception of disease in two
eastern communities.
Results: In China dementia is seen as a normal part
of aging. There the family, rather than the individ-
ual, is the most important unit of social organization.
Furthermore, cognitive domain is not taken to be the
total sum of the person: greater emphasis is placed on
the affective dimension. Traditional Confucian ethical
values specifically mandate that the eldest son cares
for his parents in their old age. So, Chinese elderly
with dementia are not particularly vulnerable to stigma.
Boke is a very important folk concept that describes
early stages of dementia in Japan. Traditionally, it is
very important for Japanese to be socially involved
and boke is viewed as a preventable of frailty arising
from inactivity and insufficient involvement in social
settings. Boke suggests some degrees of moral lack-
ing: this is related to the problem of Japanese people
to be unable to carry out reciprocal obligations in daily
social networks. To become boke is considered a kind
of anti-social behavior.
Conclusions: Anthropological perspective shows
the need to extend dementia models beyond the
biomedical for providing care in a contextualized way.
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Reversible Dementia and Corticosteroid Therapy
Gabriele Cipriania, Lucia Picchib, Angelo Nutib and
Ubaldo Bonuccellib
aUniversity of Pisa, Pisa, Italy
bASL12, Viareggio, Italy
Background: Excessive circulating corticosteroids’
levels are associated with cognitive impairment. We
report the case of a patient who developed a reversible
dementia-like syndrome receiving a long-term corti-
costeroid therapy.
Case report: EC, a 75-year-old woman, suffering
from giant cell arteritis, was treated with prednisone
60 mg per day. After seven months of treatment she
developed insomnia and impaired memory. The month
later she presented defective temporal orientation and
was unable to care for herself. Neurologic examination
was normal. Neuropsychological testing confirmed
grossly cognitive deficits. Brain gadolinium-enhanced
NMR showed mild temporal atrophy. SPECT demon-
strated a non-diagnostic pattern of mild diffuse
hypoperfusion. The diagnosis of neurodegenerative
disease (AD, LBD, FTD) was improbable consider-
ing that cognitive deficits were rapidly progressive; in
the absence of cancer and of any concurrent inflamma-
tory, infectious, ischemic, toxic-metabolic cause the
working diagnosis was “steroid induced organic brain
syndrome”. Prednisone dosage was discontinued. Cog-
nitive deficits improved in 15 days. Two months after
withdrawal of the corticosteroid therapy the patient
was asymptomatic. Neuro-psychological tests showed
great improvement in all functions.
Conclusions: Neuro-psychiatric adverse effects dur-
ing systemic corticosteroid therapy occur frequently.
Cognitive deficits, have been documented during both
long and short term therapy.
Two Cases of Sporadic Creutzfeldt-Jakob Disease
(sCJD): Clinical, Molecular and MRI Findings
Monica Colucci, Andrea Assini, Daniela Audenino,
Daria Bianchini, Giovanni Ajmar, Sandro Ratto, Maria
P. Fondelli, Nunzio P. Nuzzi, Maria C. Novello, Valeria
Pollero and Sergio Cammarata
E.O. Ospedali Galliera, Genoa, Italy
Aims and methods: We describe two cases of sCJD
admitted to our Neurological Unit that underwent to
serial EEG recordings, quantification of tau protein
in CSF and 14-3-3 analysis; the prion protein gene
(PRNP) codon 129 genotype was determined and for
each patient two MRI study were performed.
Results: One patient was homozygous for methio-
nine at codon 129; he died after 6 months and post-
mortem examination was conducted. The MRI showed
in diffusion-weighted imaging (DWI) a cortical and
basal ganglia involvment. The other patient was het-
erozygous (MV) at codon 129 and is still alive after
one year from the disease onset. Initially, DWI demon-
strated an isolated cortical involvment, but during the
follow-up the MRI pattern was modified, showing
basal ganglia lesions in addition to the cortical hyper-
intensities.
Conclusions: Some authors postulated that an iso-
lated cortical pattern is seen more often in patients
with slow disease progression. Our findings suggest
that MRI lesion profile can change during the course
of the disease. In particular, we hypothesize that an
isolated cortical hyperintensity in DWI could repre-
sent an early sign of CJD and might be found in the
earlier stage of the disease; therefore, it will be easier
to see in sCJD with slow disease progression.
Cerebrospinal Fluid Levels of Tissue Inhibitor
of Metalloproteinase 1 are Increased in Subjects
with Mild Cognitive Impairment
Cristoforo Comia, E. Boggioa, Miryam Carecchioa,
Daniela Galimbertib, Annalisa Chiocchettia, Sara
Buttinia, Elio Scarpinib, Francesco Monacoa and
Umberto Dianzania
aUniversity of Eastern Piedmont, Novara, Italy
bUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
Background: Tissue inhibitors of metalloproteinases
(TIMPs) have been shown to be increased in post-
mortem brain tissue from AD patients and have been
localized to neuritic senile plaques. TIMPs have been
investigated in both plasma and CSF of patients with
AD compared to controls, but no statistically signifi-
cant difference was found. Moreover, TIMP-1 plasma
levels have been studied in MCI subjects compared to
controls and again no difference was found.
Aims and methods: In the present study we aimed
at assessing TIMP-1 levels in the CSF of MCI sub-
jects compared to AD patients and healthy controls.
We enrolled 20 patients with AD, 15 patients with MCI
and a CSF biomarker profile suggestive for AD, and
35 controls.
Results: We found that TIMP-1 levels were sig-
nificantly increased in MCI subjects (median value
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65 ng/ml) compared to both AD patients (22 ng/ml)
and controls (25 ng/ml). On the contrary, no difference
was found between AD patients and controls.
Conclusions: Our data support in vivo the hypothesis
that TIMP-1 up-regulation represents a self-defensive
attempt to eliminate amyloid deposition from AD
brains.
Sleep Disorders in Different Subgroups of Mild
Cognitive Impaired Patients
Marta Z. Conti, Salvatore Caratozzolo, Barbara Vicini
Chilovi, Marina Zanetti, Maddalena Riva, Luca
Rozzini and Alessandro Padovani
Spedali Civili, University of Brescia, Brescia, Italy
Background: Despite literature suggests that sleep
disturbance is an important psycobehavioral symptom
in neurodegenerative disease, few studies have exam-
ined this disorder in subjects affected by mild cognitive
impairment (MCI).
Aims: To investigate the sleep disturbances in differ-
ent subtypes of MCI.
Methods: Thirty one subjects affected by amnestic
MCI (aMCI), 16 subjects affected by non amnes-
tic MCI (naMCI) and 58 healthy control subjects
underwent a comprehensive neuropsychological eval-
uation. We compared the proportion of patients with
MCI between groups using standard diagnostic crite-
ria. Sleep disorders were evaluated using two different
scale: Pittsburgh Quality Index-PSQI measuring the
quality of sleep and Epwort Sleepiness Scale measur-
ing the sleepiness.
Results: Data show that naMCI patients have more
behavioral disturbances when compared with aMCI
(mean score PSQI 8.3 ± 5.8 vs 5.3 + 3.4: p = 0.004)
and compared with controls (mean score PSQI 8.3 +
5.8 vs 4.5 ± 2.9; p = 0.02). No difference was found in
the scores measuring sleepiness between groups.
Conclusions: The preliminary analysis of the data
suggests that the sleep disturbances are more present
in naMCI patients and that this disorders could
be (associated with non memory neuropsychological
disturbances) a clinical non biological predictor of
dementia, non Alzheimer type.
Oligodendrocyte Lineage Transcription Factor
2 Role in Alzheimer’s Disease: Association
and Expression Analysis
Francesca Cortinia, Chiara Fenoglioa, Francesca
Clericib, Luisa Benussic, Roberta Ghidonic, Salvatore
Galloned, Alessandra Marconee, Chiara Villaa, Maria
Serpentea, Claudia Cantonia, Elisa Ridolfia, Massimo
Franceschif , Giuliano Binettic, Innocenzo Rainerod,
Stefano Cappae, Claudio Marianib, Nereo Bresolina,
Elio Scarpinia and Daniela Galimbertia
aUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
bUniversity of Milan, Ospedale Sacco, Milan, Italy
cIRCCS Centro S. Giovanni di Dio-FBF, Brescia, Italy
dUniversity of Turin, Turin, Italy
eOspedale San Raffaele Turro, San Raffaele Scientiﬁc
Institute, Milan, Italy
fClinica Neurologica, Casa di cura Santa Maria di
Castellanza, Varese, Italy
Background: Oligodendrocyte Lineage Transcrip-
tion Factor 2 (OLIG2) is a helix-loop-helix transcrip-
tional factor. It is expressed both in the developing
and in the mature vertebrate central nervous system.
Recently studies identified OLIG2 as a candidate gene
for schizophrenia and psychotic symptoms, which can
occur also in patients with Alzheimer’s disease (AD).
Aims and methods: To carry out an association study
of OLIG2 rs1005573 (T/C) and rs2834072 (A/G) by
allelic discrimination in a population of 348 patients
with AD and 326 age-matched controls. To perform
an expression study of OLIG2 in Peripheral Blood
Mononuclear Cells (PBMC).
Results: The frequency of the rs1005573 C allele
was significantly increased in patients as compared
with controls (40% versus 31%; p = 0.015; OR: 1.48;
CI 95%: 1.09–2.02). Stratifying according to gen-
der, a statistically significant difference was observed
in female patients as compared with female controls
(42% versus 33%: p = 0.007; OR: 1.76; CI 95%: 1.19–
2.62), but not in males (p > 0.05). Conversely, we didn’t
observe any differences stratifying according to age
at onset (early/late). No differences in the distribu-
tion of rs2834072 between cases and controls were
found. Significantly decreased relative expression lev-
els of OLIG2 in PBMC was observed in patients versus
controls. Patients carrying the rs1005573 C allele dis-
played an even lower expression rate than non-carriers
(0.101 ± 0.067 vs 0.911 ± 0.203; p = 0.001).
Conclusions: rs1005573 variant is a risk factor for
Alzheimer, and acts by regulating OLIG2 mRNA
levels.
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Free and Cued Selective Recall Reminding Test
(FCSRT): from Subjective Memory Complaints
to Alzheimer Disease
Valentina Cucumoa, Paola Frassonb, Roberta Ghirettia,
Laura Parisic, Simone Pomatia, Alessandra Marconeb,
Francesca Clericia, Stefano Cappab and Claudio
Mariania
aUniversity of Milan, Ospedale Sacco, Milan, Italy
bVita-Salute San Raffaele University, Milan, Italy
cCampus Biomedico University, Rome, Italy
Background: The Free and Cued Selective Recall
Reminding Test (FCSRT) is an episodic verbal mem-
ory test with semantic cueing that permits to isolate
the patient’s storage capacities.
Aims: To analyze the performance of subjects
with subjective memory complaint (SMC) at FCSRT,
assuming a continuum from SMC to MCI to AD.
Methods: One hundred sixty seven healthy controls,
31 SMC, 36 amnestic MCI and 25 mild AD subjects
underwent the FCSRT. The following FCSRT sub-
items were analyzed: index of cueing (IC), delayed free
recall (DR-F), delayed total recall (DR-T), number of
intrusions. A complete neuropsychological assessment
and an evaluation of functional impairment completed
the study protocol.
Results: A statistically significant difference was
observed among the performances of the four groups
for all the variables studied. A logistic regression
analysis with group (SMC and Ctrls) as a dependent
variable and a stepwise approach identified a final
model with DR-F differentiating the two groups. No
differences in IC and number of intrusions were found.
Conclusions: These preliminary results suggest that
the FCSRT could be useful in detecting early memory
difficulties in SMC.
Reduced Striatal Dopamine Transporter Binding
in Posterior Cortical Atrophy
Chiara Cupidi, Valentina Arnao, Sabrina Realmuto,
Antonio Cinturino, Renato Costa and Tommaso Piccoli
University of Palermo, Palermo, Italy
Background: Posterior cortical atrophy (PCA) is
a rare neurodegenerative syndrome characterized by
cognitive decline with visuospatial and visuopercep-
tive dysfunction, but relatively preserved memory,
insight and judgement. The neuropathologic correlates
of PCA remain poorly defined. Pathological findings
have been often revealed Alzheimer’s Disease (AD),
even if Lewy Bodies Disease (LBD) has also reported.
The evaluation of striatal dopamine transporter (DAT)
using functional imaging with dopaminergic presynap-
tic ligand (ioflupane or DAT-scan) has been recently
demonstrated to enhance the accuracy of diagnosis of
DLB in vivo.
Aims: The study was aimed at evaluating the pres-
ence of nigrostriatal dopaminergic dysfunction in
patients affected by PCA, using single photon emission
computed tomography (SPECT) with a dopaminergic
presynaptic ligand.
Methods: Five patients (4 male and 1 female, mean
age 64.2 ± 5.54 years, mean age at onset of 59 ± 5.6
years) fulfilling clinical criteria for PCA were selected.
Standardized diagnostic protocol with extensive neu-
ropsychological assessment and brain MRI or CT was
conducted. A SPECT scan with ioflupane was carried
out for each patients. Quantitative analyses of SPECTs
were performed using ROIs placed in the caudate,
putamen and occipital cortex. An abnormal scan was
defined by a posterior putamen binding value lower
than 2 SD respect to mean in normal subjects.
Results: The patients presented with progressive
visual agnosia and constructional apraxia, which were
associated to transcortical sensorial aphasia with alexia
and agraphia in two patients. Other cognitive domains
such as verbal memory and executive functions were
normal. Neurological examination did not reveal
parkinsonian signs. Brain imaging ruled out basal gan-
glia lesions. Probable or possible LBD diagnosis was
not supported by clinical features, in accord to inter-
national standardized criteria. Three patients showed
abnormal DaT-scan in both posterior putamens, while
in 2 patients the DaT uptake was decreased in putamen
and/or in caudatum.
Conclusions: We observed a reduced DaT uptake
in striatum of PCA patients, suggestive for a dys-
function of nigrostiatal dopaminergic system. These
findings could suggest PCA as a possible cognitive
variant of LBD. In this perspective, neuroimaging with
presynaptic dopaminergic ligand could be proposed as
biological marker in vivo for this rare condition.
A 3 years follow-up of a MCI cohort
Sabrina Curcio, Nicoletta Smirne, Rosanna Colao,
Francesca Frangipane, Gianfranco Puccio, Maria
Mirabelli, Raffaele Maletta, Alessandra Clodomiro,
Raffaele Di Lorenzo and Amalia C. Bruni
Centro Regionale di Neurogenetica, Azienda Sanitaria
Provinciale di Catanzaro, Lamezia Terme, Italy
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Introduction: Predictive role of neuropsychological
tests in dementia is of interest for clinicians. Aims of
this work were to calcolate MCI progression rate in
dementia and to assess the possible predictive value
of neuropsychological tests.
Aims and methods: Two hundred and eighty seven
subjects, 126M; 161F, average age 71.9 ± 7.8 years.
Mental Deterioration Battery was used to assess cog-
nitive functions; correlation test, t-Student, logistic
regression for statistical analysis.
Results: The patients had a MMSE of 24.4 ± 3.4
and an onset of 69.1 ± 8.5 yrs. After a 3 years follow-
up period the progression rate was 12.3% per year.
75.5% of converters was diagnosed as Alzheimer’s
disease. Converters had a lower score in neurocogni-
tive tests and later age of onset than non-converters.
Patients with highest conversion rate had at base-
line a multidomain cognitive impairment with amnesia
(48%). Predictive tests were: Rey’s words recall test
(p-value = 0.000); categorical verbal fluency (p-value =
0.032); drawings copy with allmarks (p-value = 0.005);
attentive matrices (p-value = 0.002).
Conclusions: Our study confirms that progression
rate of MCI in dementia is nearly 12% per year.
Subjects with multidomain cognitive impairment with
amnesia, deficits in delayed recall, in visual-spatial
and attention, with a later onset have a greatest risk
to convert in dementia.
Neuropsychological and Behavioral Features
of Elderly with Cancer After Rehabilitation
Interventions
Fulvia Di Iulio, Silvia Zabberoni, Mirella Multari,
Giovanni Morone, Jacob Shofany, Stefano Paolucci,
Massimo Musicco and Carlo Caltagirone e Luca
Cravello
Tor Vergata University, Foundation Santa Lucia,
Rome, Italy
Background: Elderly patients with cancer often need
rehabilitation but frequently suffer from cognitive dis-
turbances and depression that might reduce the efficacy
of interventions.
Aims: To assess, in patients with a history of cancer
admitted to a rehabilitation hospital, the prevalence of
cognitive disturbances and of depression and to evalu-
ate the efficacy, on functional recovery, of an intensive
cognitive and anti-depression intervention.
Methods: We studied 148 patients with a history of
cancer that were randomly assigned to receive an inten-
sive or a standard treatment. At inclusion patients were
evaluated with an extensive neuropsychogical battery
and were investigated on the presence and severity of
depression.
Results: Almost all showed abnormal scores at one
or more neuropsychological tests and half of them had
symptoms of depression. Patients randomized for the
intensive cognitive treatment performed a cognitive
rehabilitation, while those randomized to the intensive
antidepressive treatment were treated with serotonin
reuptake inhibitor drugs according to a standardized
protocol. The standard intervention consisted in a
treatment according to caring physiscian preferences.
A follow-up visit including all the neuropsychologi-
cal and behavioural evaluations of the baseline was
performed at hospital discharge. Patients assigned to
intensive treatment showed better functional recovery
than those assigned standard treatment.
Lifestyle and Rate of Progression of Cognitive
Decline: Results of the SINDEM Cohort Study
Simona Di Santo and Massimo Musicco for the SIN-
DEM Cohort Study Group
Consiglio Nazionale delle Ricerche, Istituto di
Tecnologie Biomediche, Segrate (Milano), IRCCSFon-
dazione Santa Lucia, Rome, Italy
Background: In Alzheimer disease (AD) early deter-
ioration in memory is followed by progressive impair-
ment of other cognitive domains, and is accompanied
by a large spectrum of behavioral and psychological
symptoms occurring during the entire course of the
disease. In individual patients, the time of appearance
of clinically relevant events such as severe cogni-
tive impairment or severe BPSD, loss of autonomy,
institutionalization and death are difficult to predict.
This heterogeneity might result from differences in
the localization and severity of brain damage, or vari-
ations in patients’ personalities, life history and risk
factors. Studies suggest that presence of extrapyrami-
dal signs and psychosis, level of disease severity and
education. However, current knowledge is limited due
to differences in study populations, factors examined,
instruments used for evaluation, and definitions of out-
comes. In AD patients, memory impairment represents
the prominent and early disturbance and is caused, with
any likelihood, by the early and preferential involve-
ment of temporal cerebral areas devoted to memory
processes (entorhinal cortex and hippocampus). In
contrast, the severity and timing of the involvement
of other cognitive domainsis heterogeneous, varying
from patient to patient. Authors used different instru-
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ments and methodologies to investigate the rate of AD
progression but most based the estimate on the general
cognitive performance of patients generally measured
with the Mini Mental Status Examination (MMSE).
However no evidence exists on the capacity of these
measures of catching the progression of the patholog-
ical process of AD and it is possible that reductions
at MMSE might be largely determined by factors only
indirectly related to the progression of AD. The use
of standardized and agreed measures of progression
remains one of the key points for the study of prognos-
tic predictors of AD.
Aims and methods: The cohort study promoted by
the Italian Association for the Study of Dementias
(SINDEM) is aimed at evaluating the natural history of
dementias. The idea supporting the study is that a better
knowledge of prognostic predictors of AD and of other
dementias might give new insight into the pathogenic
mechanisms of these diseases besides to be useful for
clinicians caring for patients. As of November 2010,
20 neurological centers enrolled 238 newly diagnosed
patients with AD. Diagnosis of AD was based on clin-
ical diagnostic criteria (NINCDS-ADRDA criteria).
All the enrolled patients were carefully investigated
about presence of comorbidities, and on life habits. The
neuropsycholgical profile of each patient was charac-
terized according to an extensive battery of test that
investigated different cognitive domains.
Results: Of the enrolled patients with AD 153 had
at least one follow-up visit and could be analyzed and
investigated on prognostic predictors. A decrease of 5
points or more in MMSE score in the first 24 months
following enrolment was considered as an indicator of
disease progression. A 5-point decrease is considered
to be a clinically relevant worsening, and is too large
a change to be attributed to the intrinsic limits of test
reliability. The date of the visit when the 5-point reduc-
tion was recorded marked the time of occurrence of the
progression. Data were analysed with survival analysis
considering the time of occurrence of 5 point decrease
at MMSE as the end point. The studied patients had a
mean age of 74 year and women represented the 64%
of the entire cohort. The mean disease duration since
first symptoms was about two years and at enrollment
the mean score at MMSE was 18. One fourth of the
patients had a decrease of 5 points or more at MMSE
during a follow-up period of 24 months.
Conclusions: Preliminary results suggest that more
educated patients had more rapid progressions, that
more severe involvement of cognitive functions and
reduced social and physical activities are negative
prognostic factors and that diabetic patients had slower
progression rates as compared to non diabetic patients.
Albeit preliminary these results support the idea that
relevant knowledge on AD can be derived by the study
of the natural history of the disease.
Applause Sign in Alzheimer’s Disease
Katia Fabi, Martina Pesallaccia, Mauro Silvestrini,
Leandro Provinciali and Simona Luzzi
Università Politecnica delle Marche, Ancona, Italy
Introduction: Originally, the applause sign has been
considered highly specific for Parkinsonian disorders.
Recently, we were able to provides evidence for pres-
ence of the applause sign in cortical dementias such as
AD and FTD.
Aims: The present study aims to analyse if the
severity of cognitive impairment can play a role in the
generation of the applause sign.
Methods: Eighty one patients with AD were enrolled
and stratified on the basis of the severity of disease: 32
patients with mild AD (MMSE 21–30); 35 patients
with moderate AD (MMSE 11–20) and 14 patients
with severe AD (MMSE 0–10). The applause sign was
detected using the three clap test: the subjects was
asked “to clap three times as quickly as possible after
demonstration of the examiner”. The subject’s perfor-
mance was considered normal when he/she clapped
three times (score = 3), abnormal when the subject
clapped more than three times (2 = four times, 1 = five
to ten times, 0 = more than ten times).
Results: The Kruskal-Wallis test and the Mann-
Whitney test did not show a significant difference in the
presence of the applause sign in the three subgroups.
Conclusions: The present study excludes any po-
tential influence of the severity of disease with the
generation of the applause sign.
MRI Multimodal Investigation on a Small Cohort
of Patients Affected by Amnetsic Mild Cognitive
Impairment
Fabrizio Fasano, Chiara Ganazzoli, Simona Gardini,
Fabio Sambataro, Letizia Concari and Paolo Caffarra
University of Parma, Parma, Italy
Aims: In the present study we push the envelope
of the MRI multimodal methodology to investigate
a small cohort of patients affected by amnestic mild
cognitive impairment.
Methods: The intra-subject inter-modality variabil-
ity, and the inter-subject variability are challenged
Abstracts S57
by the use of the novel Symmetric Normalization
(SyN) method. Abnormal iron content, as revealed by
transverse relaxometry, and gray matter atrophy were
assessed in a group of 10 patients in comparison to a
group of 10 healthy subjects. The acquisition protocol
was performed on a GE MR750 3T scanner equipped
with an 8 channel Head Coil, and consisted in a T1
weighted high resolution image, and in a couple of
EPI acquisitions (SE and GRE) both acquired 6 times
with different TE. Statistical analysis was implemented
through non-parametric permutation statistics.
Results: The morphometric investigation revealed
differences between groups in the right hippocampus
and medial parahippocampal gyrus, and in the ante-
rior part of the parahippocampal and fusiform gyrus
bilaterally. Iron content analysis didn’t reveal any dif-
ference between the two groups, neither in a voxel
based approach nor in the analysis performed on 90
labeled areas.
Clinical and Neurophysiological Correlates
of Visual Hallucinations in LBD
Silvia Favaretto, Francesca Gnoato, Nela Jelcic,
Viviana Lunardelli, Sara Pompanin, Marina Saladini,
Mario Ermani and Annachiara Cagnin
Ospedale Universitario di Padova, Padova, Italy
Aims: To study clinical, neuropsychological and
neuropsysiological correlates of visual hallucination
(VH) in DLB.
Methods: LBD patients were assessed with NPI,
UPDRS, and questionnaires for fluctuations and RBD.
A broad neuropsychological battery was administered,
including VOSP test for visuo-spatial abilities. Stan-
dard EEG was analyzed with the software sLoreta
to detect mapping of distributed sources of electrical
activity.
Results: Among 61 LBD patients, 33 (54%) had
VH. DLB VH+ were older respect to VH- (mean
age VH+: 77 ± 6, VH−: 71 ± 6, p < 0.001). There
were no differences on UPDRS score, RBD or fluc-
tuations frequency. VH+ had a lower MMSE score
(VH+: 20.9/30, VH−: 24/30, p = 0.01) and performed
worse on attention (p < 0.001) and VOSP. In VH+
EEG analysis showed a source of delta activity in the
parieto-occipital area (BA 30) and of theta activity in
the frontal region (BA 24).
Conclusions: In LBD, VH are associated with older
age, greater cognitive impairment with worse atten-
tion and visuo-spatial abilities. We hypothesized that
the source of theta activity in frontal regions could be
the correlate of attentional deficits, while the indepen-
dent delta source in the parieto-occipital regions could
be the correlate of a “functional lesion” in regions
processing visuo-spatial information.
Sociocognitive Functions Decline During Normal
Aging: Facial Expression Recognition
Francesca Federicoa, Nicola Polizzottob, Valentina
Bianchettia and Fiorenzo Laghia
aSapienza University, Rome, Italy
bUniversity of Siena, Siena, Italy
Background: Sociocognitive functions involved the
processing of emotions and the regulation of social
behavior. Some neuropsychological evidence showed
that sociocognitive function are related to frontal lobes
and in particular ventromedial frontal areas. It is well
known that frontal areas activity declines with normal
aging.
Aims: We investigate the facial expression recogni-
tion in three groups of subjects: young adults, adults
and old adults.
Methods: We used a self-reported test battery that
comprises Roman Alexithimia Scale; Self-efficacy in
managing negative affect; Self-efficacy in express-
ing positive emotions, and a computerized task. The
task use a software that enables images of faces to
be modified quantitatively so as to gradually change
their expression (morphing). The subject was invited
to report when he/she recognizes a new expression.
Transitions between all six basic emotions are shown
in a continuous, random manner. By analyzing the
accuracy of emotion recognition and factors from
behavioral scales we founded a decline on facial
expression recognition not accompanied by difficulty
in sympathizing with others.
Conclusions: This pattern could reflect a disso-
ciation between the neuropsychological decline of
frontal functions that support the explicit facial expres-
sion recognition and the behavioral preserved social
function.
Study of Amnesia in Three Variants of Alzheimer’s
Disease
Laura Ferigo, Valeria Valbusa, Francesca Sala, Elis-
abetta Broggio, Giuseppe Moretto and Giuseppe
Gambina
Azienda Ospedaliera Universitaria Integrata Verona,
Verona, Italy
S58 Abstracts
Background: The heterogeneity of Alzheimer’s dis-
ease (AD) is demonstrated in many of its aspects:
clinical manifestations, types and patterns of neurolog-
ical and neuropsychological symptoms; the memory
impairment may presents heterogeneity too.
Aims: To describe the heterogeneities of memory
impairment in atypical presentation of AD.
Methods: We describe and analyze the performance
at the Rey Auditory Verbal Learning Test of 7 patients
with diagnosis of three variants (v.) of AD: 1 case
(posterior v.) with progressive visual-spatial dysfunc-
tion, 2 cases (aphasic v.) with progressive aphasia,
4 cases (frontal v.) with predominant behavioural dis-
orders. All patients were submitted to neurological
and neuropsychological examination, morphology and
functional neuroimaging.
Results: Our data show different patterns of mem-
ory impairment in AD. The Rey Auditory Verbal
Learning Test highlights the following patterns: frontal
with false recognitions and verbal intrusions; aphasic
with low learning and phonemic and semantic para-
phasias; posterior with good learning and few missed
recognitions.
White Matter Damage in Frontotemporal Lobar
Degeneration Spectrum
Massimo Filippi, Federica Agosta, Elisa Scola, Elisa
Canu, Alessandra Marcone, Giuseppe Magnani, Lidia
Sarro, Giancarlo Comi, Stefano F. Cappa and Andrea
Falini
Scientiﬁc Institute and University Ospedale San Raf-
faele, Milan, Italy
Aims and methods: We used diffusion tensor (DT)
MRI to assess white matter (WM) damage in behav-
ioral variant frontotemporal dementia (bvFTD) and
primary progressive aphasia (PPA) variants. Thirteen
bvFTD and 20 PPA (9 nonfluent, 7 semantic, and 4
logopenic) patients were studied. Grey matter (GM)
and WM atrophy was assessed using voxel-based mor-
phometry.
Results: bvFTD patients showed widespread pat-
terns of DT MRI abnormalities affecting the most of
the WM, bilaterally. In PPA patients, WM damage was
more focal and varied by variant, with predominant
left fronto-temporo-parietal abnormalities in nonflu-
ent, left frontotemporal in semantic, and the least
extensive WM damage involving the left frontoparietal
network in logopenic. Although WM abnormalities
mirrored the patterns of GM atrophy, DT MRI changes
extended beyond the topography of GM loss. Left unci-
nate was the best predictor of patient diagnosis in each
group, followed by anterior corpus callosum in bvFTD,
left superior longitudinal fasciculus in nonfluent, and
left inferior longitudinal fasciculus in semantic.
Conclusions: DT MRI metrics may be early markers
of WM integrity loss in bvFTD and PPA variants that
only at a later stage will be detectable by volumetric
measures. DT MRI may be an additional tool in the
diagnostic workup of these patients.
The Topographical Distribution of White Matter
Damage in Progressive Supranuclear Palsy
Syndromes
Massimo Filippia, Federica Agostaa, Michela
Pievania, Sebastiano Galantuccia, Tanja Stojkovicb,
Giancarlo Comia and Vladimir S. Kosticb
aScientiﬁc Institute and University Ospedale San Raf-
faele, Milan, Italy
bUniversity of Belgrade, Belgrade, Serbia
Aims and methods: We investigated the pattern of
microstructural changes of white matter (WM) in
patients with different progressive supranuclear palsy
(PSP) syndromes using diffusion tensor (DT) MRI and
tract-based spatial statistics approach. Thirty-seven
PSP patients and 34 age- and sex-matched healthy
subjects were studied. PSP patients were classified as
Richardson’s syndrome (PSP-RS, 21 patients) or PSP-
Parkinsonism (PSP-P, 16 patients) based on clinical
criteria.
Results: Compared with controls, PSP-RS patients
showed areas of WM damage in the superior
cerebellar peduncle (SCP), cerebral peduncles, and
multiple supratentorial areas including corpus callo-
sum, cingulum, corona radiata, internal capsulae, and
fronto-parietal WM. On the contrary, in PSP-P patients
relative to controls the pattern of WM damage was
restricted to the corpus callosum, with a relative spar-
ing of the SCP. When patient groups were contrasted
directly, PSP-RS patients showed a more marked dam-
age to the SCP, bilaterally than those with PSP-P. No
difference was found when comparing PSP-P vs. PSP-
RS patients.
Conclusions: This study suggests an impaired struc-
tural integrity of WM tracts in PSP patients. In keeping
with pathological data, WM damage was more pro-
nounced in PSP-RS vs. PSP-P patients. The less
prominent involvement of WM in PSP-P patients
might be associated to their favorable clinical status.
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Closing-in behaviour in Mild Cognitive
Impairment
Sara Finottoa, Elisabetta Ambronb,c, Robert D.
McIntoshb, Francesca Clericia, Claudio Mariania and
Sergio Della Salab
aOspedale Luigi Sacco, University of Milan, Milan,
Italy
bUniversity of Edinburgh, Edinburgh, UK
cSuor Orsola Benincasa University, Naples, Italy
Background: “Closing-in behaviour” (CIB) is the
tendency in figure copying to draw very close to or
on top of the model. CIB has never been explored in
people with Mild Cognitive Impairment (MCI).
Aims and methods: The files of 313 people diag-
nosed with MCI were reviewed and CIB was found in
74 people. Then, two approaches were used to explore
CIB. First, we assessed the cognitive correlates of CIB,
by selecting two groups of MCI – with (n = 35) and
without CIB (n = 133) – who underwent executive,
visuo-constructional and memory tasks. Second, we
capitalised on the cognitive profiles of the MCI, sub-
dividing the overall sample into MCI with and without
memory deficits.
Results: MCI people with CIB showed lower per-
formance in visuo-constructional (z = −2.54, p < 0.05)
and executive tasks (z = −3.64, p < 0.001) than those
without CIB, but the two subgroups did not differ
in severity or memory performance. Moreover, the
frequency of CIB was higher in Multidomains non-
Amnestic MCI (33%) than in Amnestic MCI (9%).
Conclusions: The findings suggest a stronger asso-
ciation of CIB with impairment of executive functions
rather than memory. This is consistent with the hypoth-
esis that CIB is a primitive default behaviour, released
under conditions of reduced executive resources.
Effects of Linguistic Training in Primary
Progressive Aphasia
C. Fontia, I. Cristoforib, L. Cretellaa and A. Stracciaria
aS.Orsola-Malpighi University Hospital, Bologna,
Italy
bUniversity of Lyon, Lyon, France
Background: Primary progressive aphasia (PPA)
is a degenerative syndrome characterized in its early
stage by deterioration of language without dementia.
At present, there are no effective drugs for PPA. A treat-
ment option may be language therapy, which is used to
explore and improve alternative communication strate-
gies; however, literature on this topic is very poor.
Aims and methods: In our study, two PPA patients
underwent linguistic training three times a week for
six months. Training consisted of one-hour sessions
which included exercises involving language, exec-
utive functions and memory (i.e. reading, writing,
and summarizing stories). Patients were evaluated via
Aachener Aphasie Test (AAT) before and after the
treatment.
Results: Patient 1 exhibited an improvement in
understanding and repetition subtests of the AAT.
Patient 2 showed a decreased score on the denomina-
tion subtest, while performances on the other subtests
remained stable. Qualitatively, both patients showed
improved capabilities in communication behavior,
syntactic structure, and (only in patient 1) semantic
structure. At functional imaging patient 1 had a nor-
mal cerebral PET, whereas patient 2 presented a left
frontoparietal hypoperfusion on SPECT.
Conclusions: Notwithstanding these differences,
these data suggest that language rehabilitation in PPA
may produce beneficial effects on general linguistic
competence.
CSF Markers in the Differential Diagnosis
of Alzheimer’s Disease from Frontal Variant
of Frontotemporal Dementia
Massimo Franceschia, Giuseppe Magnanib, Francesca
de Rinoa, Francesca Casob, Elisabetta Coppib, Gabri-
ella Passerinib, Matteo Zabeoa and Filippo Martinelli
Boneschib
aIRCCS Multimedica, Castellanza (Varese), Italy
bIRCCS S. Raffaele Scientiﬁc Institute, Milan, Italy
Background: The early differentiation between
Alzheimer’s disease (AD) and frontal variant of fron-
totemporal dementia (fvFTD) is often difficult.
Aims and methods: We evaluated the usefulness
of baseline CSF beta-amyloid 1-42 (bA), tau (t) and
Th131-phosphorilated tau (Pt) in the early differentia-
tion of AD from fvFTD, following up the patients for
one to five years to confirm the initial diagnoses.
Results: Seventy-two patients with AD and 42
patients with fvFTD showed baseline different CSF
levels of Pt (increased in AD, p = 0.001), bA (reduced
in AD, p = 0.012), and ratio Pt/bA (p = 0.003).
A multivariate logistic regression model has been
implemented with the diagnosis as dependent variable
and gender, education, age at onset, basal MMSE and
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levels of CSF metabolites as independent variables.
Only bA and Pt were predictors of the model, and a
higher index of the ratio Pt/bA was associated with a
higher risk of AD versus fvFTD (p = 0.005; OR: 58.7).
ROC analyses suggest that the ratio Pt/bA is able to
predict diagnosis with an AUC of 0.73 (optimal level
being 0.156 = sensitivity 79.7% and specificity 68.3%).
Conclusions: Our findings suggest that CSF meta-
bolites may be only further tools in the early differen-
tiation of AD from vfFTD.
Pharmacogenomics of Response to
Acetylcholinesterase Inhibitors in Alzheimer
Disease Patients: Preliminary Data of a
Genome-Wide Association Study
Massimo Franceschia, Giacomo Giacaloneb, Sara Lu-
polib, Paola Brambilllab, Federica Espositob, Giuseppe
Magnanib, Elisabetta Coppib, Francesca Casob, Chiara
Vismarab, Daniela Galimbertic, Elio Scarpinic, Gian-
luigi Forlonid, Diego Albanid, Giancarlo Comib and
Filippo Martinelli Boneschib
aIRCCS Multimedica, Castellanza (Varese), Italy
bIRCCS S. Raffaele Scientiﬁc Institute, Milan, Italy
cUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
dPharmacological Institute Mario Negri, Milan, Italy
Background: The positive effect of Acetylcho-
linesterase Inhibitors (AChI) in Alzheimer’s disease
(AD) is restricted to a minority of AD patients.
Aims: We looked for genetic markers predictive of
response to AChI treatment in AD patients.
Methods: As preliminary data of a genome-wide
pharmacogenomic case-control association study
(GWAS), we focused on 267 candidate genes be-
longing to ADME (Absorption, Distribution, Metab-
olization, Excretion) panel (www.pharmaadme.org).
The study enrolled 183 AD patients treated with AChI,
mean age at onset was 72 years, 68% of patients
were female, follow-up ranged from 6 to 18 months.
Annualized difference between Mini Mental State
Examination (MMSE) performed at baseline and at
the end of the follow-up (delta MMSE) was measured.
Responders were defined for a worsening of no more
than 1 point in delta MMSE, non-responders for a
worsening of more than 3 points. Genotyping was per-
formed using the Illumina® Human660 K BeadChip:
8037 SNPs belonging to ADME genes were tested for
association after quality controls.
Results: Among the top 10 SNPs for allelic associ-
ation p-value, one belonged to TAP1 gene and two to
CYP7B1 gene (non significant after Bonferroni correc-
tion). A replication study, on an independent cohort, of
these SNPs together with the top SNPs of the GWAS
is ongoing.
FTDClinical Characterization of PGRNMutations
in a Large Calabrian Kindred
Francesca Frangipane, Nicoletta Smirne, Rosanna
Colao, Livia Bernardi, Gianfranco Puccio, Sabrina
A.M. Curcio, Maria Mirabelli, Raffaele Maletta, Maria
Anfossi, Maura Gallo, Silvana Geracitano, Maria
G. Muraca, Alessandra Clodomiro, Annelisa Borelli,
Raffaele Di Lorenzo, Francesco Comito, Vincenzo
Valenti, Sandra Marzano, Rosa A. Leone and Amalia
C. Bruni
Azienda Sanitaria Provinciale Catanzaro, Lamezia
Terme, Italy
Introduction: Mutations in the progranulin gene
(PGRN) are responsible for familial forms of FTD.
Aims: To describe clinical phenotype of FTD asso-
ciated to different PGRN mutations in an isolated
calabrian population.
Methods: Sixteen FTD patients performed a
complete neurological/neuropsychological evaluation.
PGRN gene was sequenced in all subjects. Plasma
levels of PGRN were measured.
Results: One known frameshift (1145insA in 12
related patients) and two novel missense (A266P and
C126W, in 3 related patients and in 1 sporadic subject,
respectively) PGRN mutations were identified. Re-
duced levels of PGRN protein in plasma were de-
termined in the PGRN 1145insA and A266P mutated
patients. All mutated patients presented at onset with
behavioural FTD; the 1145insA carriers showed a
dysexecutive profile: distractibility, deficit of planning,
disinhibition, neurological examination evidenced
extrapyramidal signs and primitive reflexes; the
A266P carriers manifested apathy, reduction of ver-
bal initiative (apathetic profile) and normal neurologic
examination. The C126W carrier presented with para-
noid delusions and irritability, normal neurologic
examination. Mean of age at onset was statistically dif-
ferent among 1145insA carriers (64.2 + 12.5 yrs) and
A266P carriers (75.7 + 2.9 yrs).
Conclusions: Our findings, related to different FTD
phenotypes, seem to corroborate a genotype-phe-
notype relationship in PGRN mutations.
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Neuropsychological Features of Creutzfeld-Jakob
Disease
Daniela Frosini, Cristina Pagni, Chiara Pizzanelli,
Mirco Cosottini, Irene Ghicopulos and Gloria Tognoni
Univeristy of Pisa, Pisa, Italy
Aims: To investigate cognitive profile in a group
of 9 patients with sporadic Creutzfeld-Jakob disease
(sCJD).
Methods: A retrospective study was conducted on
data derived from neuropsychological evaluation of 9
patients with sCJD. All patients performed EEG, DWI
MRI, tau and 14.3.3 protein level. Post mortem patho-
logical findings were available in all but one patients
and were consistent with the diagnosis.
Results: Cognitive symptoms were the reason for
medical consulting in 5 patients, All patients who per-
formed an extensive neuropsychological battery (n = 6)
showed an impairment in at least one cognitive domain
that, in 5 patients, concerned the executive functions.
MMSE was impaired in all patients who performed it,
while digit span was usually preserved. Furthermore,
in all patients, DWI MRI was consistent with clini-
cal diagnosis, 14.3.3 protein was present in and TAU
protein was abnormally elevated.
Conclusions: Cognitive impairment may represent
one of the earliest features of CJD that may precede,
in some cases, the onset of psychiatric or neurological
symptoms. Executive functions, specifically attention,
seems to be particularly involved even though there is a
variability in neuropsychological profiles probably due
to different disease duration at the time of evaluation.
Depression in Subjects with Mild Cognitive
Impairment does not Increase the Risk
of Developing Alzheimer’s Disease
S. Fusari Imperatoria, B. Caracciolob, S. Pomatia, L.
Maggiorea, I. Covaa, D. Galimbertic, E. Scarpinic, F.
Clericia, C. Mariania and L. Fratiglionib
aUniversity of Milan, Ospedale Sacco, Milan, Italy
bKarolinska Institutet, Stockholm, Sweden
cUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
Aims: To examine the relationship between depres-
sion and the risk of progression of mild cognitive
impairment (MCI) to Alzheimer’s disease (AD)
(NINCDS-ADRDA criteria) 169 MCI consecutive
patients from the “Luigi Sacco” Hospital were
followed-up for an average of 2.6 years.
Results: At baseline, depression was diagnosed
according to DSM-IV criteria and depressive symp-
toms were assessed using the Geriatric Depression
Scale (GDS). Eighty-two (48.5%) out of 169 MCI
subjects progressed to AD. These subjects were
older (76.1 ± 56.3 vs. 73.2 ± 7.8 years; p = 0.01) and
had lower MMSE score (24.8 ± 2.8 vs. 26.0 ± 2.5;
p < 0.05) as compared to non-converters. Minor
depression occurred more frequently among non-
converters (48.2% vs. 35.3%; p < 0.05). The multivari-
ate analysis, adjusted for socio-demographic variables,
MMSE score, MCI subtypes, and APOE-e4 allelic sta-
tus showed that the risk of progression to AD in MCI
patients was not associated to GDS scores (HR 0.96;
95% CI 0.92–1.00), major depression (HR 0.82; 95%
CI 0.50–1.35) or minor depression (HR 0.79; 95% CI
0.49–1.27).
Conclusions: Depression co-occurring with MCI
does not predict progression to AD. On the contrary,
depressive symptoms occur more frequently in MCI
that do not progress to AD. These data confirm that
depression present at the time when MCI is detectable
may be independent from AD-related neuropathology.
Binding of Lipid-Based Nanoparticles to Plasma
Abeta: Relevance for new Therapeutic Strategies
in Alzheimer’s Disease
Gloria Galimberti, Elisa Conti, Fulvio Da Re, Marco
Tironi, Massimo Masserini and Carlo Ferrarese
University of Milano-Bicocca, Monza, Italy
Background: Depletion of Abeta represents the
most efficacious perspective to prevent beta-amyloid
toxicity and Alzheimer’s disease (AD) development.
Nanoparticles (NPs) constitute an innovative vehicle
potentially able to localize and interact with Abeta,
in vitro and ex vivo. Studies performed in plasma
from human subjects may represents an interesting
opportunity to analyze the capability of NPs to bind
the Abeta peptide present in periphery. However, it
is noteworthy that Abeta and plasma proteins are in
a state of dynamic equilibrium between bound and
unbound forms depending on respective concentra-
tions. So Abeta levels could be very high but only the
free molecules can be measured by ELISA.
Aims and methods: For this reason a method to dis-
sociate Abeta-plasma proteins complexes was set up
to evaluate real Abeta content.
Results: Preliminary findings, performed in human
plasma samples, confirmed an increase in detectable
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plasma Abeta 1-42 after dissociation procedure with
respects to non dissociated samples. Following incu-
bation with lipid-based NPs at different time and
concentrations, a slight decrease in Abeta levels was
shown. Further studies on a larger group of controls
and AD patients may support the capacity of lipo-
somes to sequester Abeta from plasma suggesting new
therapeutic opportunities.
Semantic Memory Impairment and
Neurofunctional Alterations in Mild Cognitive
Impairment
Chiara Ganazzolia, Simona Gardinia, Fabrizio Fas-
anoa, Letizia Concaria, Fabio Sambataroa, Francesca
Ferrari Pellegrinib, Massimo Marchia, Annalena
Venneric, Fernando Cuetosd and Paolo Caffarraa
aUniversity of Parma, Parma, Italy
bAUSL, Parma, Italy
cUniversity of Hull, Hull, UK
dUniversity of Oviedo, Oviedo, Spain
Aims: The present preliminary study is aimed to
investigate the semantic memory performance and the
brain structural and functional patterns of MCI.
Methods: Ten MCI patients and ten healthy con-
trols underwent semantic memory assessment and
MRI investigation on a 3T GE Scanner. Semantic bat-
tery included naming and word-definition matching of
objects, actions and famous people and semantic flu-
ency for different categories. MRI protocol consisted
in high resolution structural imaging and functional
MRI during rest (eyes open). Connectivity Default
Mode Network (DMN) was measured using indepen-
dent component analysis.
Results: MCI scored significantly lower in total nam-
ing, naming of famous people and semantic fluency for
fruits, politicians and singers, and showed less imme-
diate recalls, compared to controls. The voxel-based
morphometry analysis revealed higher atrophy in the
right hippocampus and medial parahippocampal gyrus,
and in the anterior part of the parahippocampal and
fusiform gyrus bilaterally in MCI. DMN connectiv-
ity was significantly lower in posterior cingulate and
precuneus in MCI compared to healthy controls.
Conclusions: Visual naming, especially for famous
people, and semantic fluency for specific categories are
damaged in MCI. Structural and functional alterations
were detected in brain regions critical for memory pro-
cesses, such as medio-temporal and precuneus regions,
in MCI.
Multiple Features Targets Cancellation Test:
Normative Data and Equivalent Scores
Roberta Ghiretti, Simone Pomati, Valentina Cucumo,
Francesca Clerici and Claudio Mariani
University of Milan, Ospedale Sacco, Milan, Italy
Background: Multiple features targets cancellation
test (MFTCT), a non-verbal cancellation task, has been
shown to be sensitive to cognitive decline in patients
with Alzheimer’s disease (AD) and multi-infarct
dementia (MID).
Aims and methods: To collect normative values in
an Italian population sample. One hundred and twelve
normal subjects were assessed with MFTCT. Time to
complete the test (TIME) provided a measure of psy-
chomotor speed and divided attention; hits and false
alarms (FALSE) provided a measure of accuracy and
selective attention.
Results: A direct relation was observed between
age and TIME, and between education and hits and
an inverse relation between education and FALSE.
Adjusted scores were obtained by adding/subtracting
the correction factors provided by the regression
equations. Cutoffs were established as a result of non-
parametric lower tolerance limits. Equivalent scores
(ES) were obtained with the method described by Cap-
itani and Laiacona. The mean values obtained by the
subjects in our sample were similar to those of the
control subjects of the original study.
Conclusions: By providing normative data for
MFTCT our work broadens the number of tests that can
be employed in the work-up of patients with dementia,
particularly in the assessment of selective and divided
attention.
Benton’s Judgement of Line Orientation-Short
form: Normative Data and Equivalent Scores
Roberta Ghiretti, Simone Pomati, Valentina Cucumo,
Francesca Clerici and Claudio Mariani
University of Milan, Ospedale Sacco, Milan, Italy
Background: Benton’s Judgement of Line Orien-
tation (BJLO) is a widely used instrument to assess
spatial perception and orientation. Shorter versions of
the test (15-items) have been employed in the assess-
ment of patients with dementia.
Aims and methods: To collect normative values in
an Italian population sample (104 normal subjects) for
the short version.
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Results: A direct relation was observed between
total score, age and education. Adjusted scores were
obtained by adding/subtracting the correction factors
provided by the regression equations. Cutoffs were
established as a result of non-parametric lower toler-
ance limits. Equivalent scores (ES) were obtained with
the method described by Capitani and Laiacona.
Conclusions: By providing normative data for BJLO
our work broadens the number of tests that can be
employed in the work-up of patients with dementia,
particularly in the assessment of visuo-spatial func-
tions.
Neurological, Cognitive and Imaging Features of
Progressive Apraxia and Visuo-spatial dysfunction
Valeria Isella, Cristina Mapelli, Francesco Rucci,
Francesca Ferri, Debora Traficante, Carlo Ferrarese
and Ildebrando M. Appollonio
Clinica Neurologica, S. Gerardo, Università di Milano
Bicocca, Monza, Italy
Aims and methods: In the present case series we
describe the neurological, cognitive and neuroimaging
features of 15 patients with mild cognitive impair-
ment presenting with progressive visuospatial deficits
and apraxia that were prominent with respect to
memory impairment. Study participants underwent
UPDRS part III, neuropsychological assessment, brain
CT/MRI scan, SPECT/FDG-PET scan, and 123I-FP-
CIT SPECT.
Results: Eight out of 15 patients (53%) showed clin-
ical or imaging evidence of parkinsonism. With respect
to cases with no extrapyramidal involvement, they
presented with less severe visuo-spatial impairment,
more severe limb apraxia and more frequent memory
and language deficits. They were also older at disease
onset, and showed more widesperad atrophy and major
frontal plus minor occipital involvement at neuroimag-
ing. No difference was detected in disease duration,
MMSE score and executive function impairment.
Conclusions: Our findings suggest that progressive
parietal dysfunction may actually be split into at least
two distinct profiles: a visuospatial syndrome due to
more posterior (parieto-occipital) degeneration, and a
limb apraxia syndrome due to more anterior (parieto-
frontal) degeneration, also showing parkinsonism and
language and memory deficits. The first picture basi-
cally meets criteria for Posterior Cortical Atrophy,
while the latter shows most, though not all, features
of Corticobasal Syndrome.
Patient/doctor Relationship: a National Survey
on Current Clinical Practice for the Diagnosis
Disclosure
Fabio Izzicupo, Sabina Gainotti, Marco Massari,
Angela Giusti, Francesca Galeotti, Nicola Vanacore
and Roberto Raschetti
Istituto Superiore di Sanità, Rome, Italy
Background: In Italy there is little data available
on clinicians’ attitudes towards the disclosure of the
diagnosis of Alzheimer’s Disease (AD).
Aims and methods: The Istituto Superiore di Sanità
has conducted a survey on 448 AD units, with a reply of
212 AD units (48.2%), 46 (21.7%) of which are located
in Northern Italy, 25 (11/8%) in Central Italy and 141
(66.5%) in Southern Italy. Besides, a qualitative study
was conducted with 5 focus group.
Results: Quantitative data indicate that clinicians
often communicate the diagnosis to the patient’s rel-
atives (98.6%) and directly to the patient (70.5%).
However, they use expressions like “memory disturbs”
(79.7%) and “cognitive decline” (75%) more than
“Alzheimer” (45.3%). The main reasons to avoid full
disclosure are the fear that disclosure may worsen
a patient’s psychological condition (57.4%) and the
opposition of the family (45.1%). However, clinicians
believe that disclosure improves patient’s adherence
(60%) and helps understanding the causes of daily
difficulties (52.6%). In the majority of AD units the
problem has not been formally discussed (75.3%).
Many clinicians would find specific training useful
(95.7%).
Conclusions: Results of the qualitative research
describe “how” do clinicians communicate with
patients, which are the reasons for their choices and
which strategies they find more successful.
Cerebrospinal Fluid Levels of A 1-42 inﬂuence
cholinergic cortical activity in Alzheimer’s disease
patients
Giacomo Kocha,b, Zaira Espositoa, Viola Giacobbeb,
Francesco Di Lorenzob, Giulia Bucchib, Sonia Bonnìb,
Carlo Caltagironea,b and Alessandro Martoranaa,b
aTor Vergata University, Rome, Italy
bFondazione Santa Lucia IRCCS, Rome, Italy
Background: In Alzheimer’s disease (AD) the dys-
function of cholinergic neurons is considered a typical
hallmark. It is known that fragments of amyloid beta
protein (A) and Tau protein are supposed to inter-
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fere with synaptic transmission. In animal models of
AD, A interact with central acetylcholine transmis-
sion interfering with transmitter synthesis and release.
In AD patients, central cholinergic function can be
evaluated in vivo by using a neurophysiological tool
called Short Afferent Latency Inhibition (SLAI).
Aims and methods: We aimed to investigate whether
in AD patients (n = 26) the levels of cerebrospinal
(CSF) biological markers of AD such as A1-42 and
tau could influence the cortical cholinergic activity
assessed through SLAI.
Results: We found that SLAI was decreased in AD
patients in comparison to a group of healthy controls.
In AD patients, there was a positive correlation
between the individual amount of cholinergic activity
assessed by SLAI and A1-42 CSF levels, but not with t-
Tau CSF levels, suggesting that A1-42 CSF levels may
impact mechanisms of cortical cholinergic activity.
Conclusions: This correlation confirms previous
data obtained in experimental models, showing that
cholinergic dysfunction may be the result of direct
influence of A1-42 on neuronal function.
Posterior Cortical Atrophy Presentino as right
Parietal Syndrome: a Neuropsychological Single
Case Study
Federica Lucchelli, Alessia Monti and Roberto Cubelli
University of Trento, Rovereto, Italy
Case report: RI, a 63-year-old, left-handed male and
a former lawyer, presented with a 3-year-long history
of progressive visuo-spatial impairment and motor dis-
turbances. As his wife reported, he had difficulties to
correctly place and move his trunk and limbs (e.g.,
sitting on a chair or walking down stairs) and to use
objects. Reportedly, language, memory and navigation
abilities were spared. Brain MRI and 99mTc SPET
pointed to pathological changes in the right posterior
cortex. Behavioural observation confirmed a marked
impairment in moving, with hints of left-sided motor
neglect. RI’s memory was surprisingly good, as he
could remember most information from one session
to the other and he could keep track of appointments;
he always recognized the place, the examiners and
the personnel. Neuropsychological assessment demon-
strated a severe visuo-spatial impairment associated
with clear-cut signs of left-sided neglect. Limb apraxia
was also prominent in all standardized test, on imita-
tion, pantomime and real object use. In contrast, object
recognition and naming were fully preserved. All the
data fit with the diagnosis of posterior cortical atrophy.
Conclusions: We interpret RI’s neuropsychological
pattern as the result of disproportionate damage to
the right parietal cortex (with limb apraxia related to
his left handedness) with sparing of temporal cortical
areas.
Amnesia in Fronto-temporal Degeneration:
Encoding or Retriva Deﬁcits?
Federica Lucchellia, Susanna Venutaa,b, Giorgio
Rossib and Alessia Montia
aUniversity of Trento, Rovereto, Italy
bAPSS, Trento, Italy
Background: Early and severe amnesia in frontotem-
poral dementia (FTD) is more common than previously
thought. It has been suggested that in the case of
FTD the memory deficit could well be qualified as
“frontal” amnesia, namely characterized by encoding
and retrieval deficits in contrast with impaired consol-
idation typical of Alzheimer’s disease.
Case report: NM, a 59-year-old lady, presented with
a typical history of progressive behavioural and exec-
utive disturbances. An extensive neuropsychological
assessment confirmed markedly impaired executive
functions and social cognition. A distinctive neu-
roimaging pattern of frontal atrophy further supported
the diagnosis of behavioural variant FTD. However,
severe amnesia was reported as a prominent deficit
since onset and standard memory tests were also found
to be significantly impaired. To assess retrieval and
encoding deficits, NM’s amnesic profile was further
investigated by several recognition tests and different
versions of the Grober and Buschke test. Only recog-
nition procedures led to significant improvement up
to normal performance, while encoding manipulation
and provision of cues were not effective.
Conclusions: Our results point to the overwhelm-
ing role of retrieval deficits, which appear to be fully
compensated by the recognition procedure but are still
partially at play when only encoding is checked for.
When “frontal” Dysfunction Takes Over: The
Sense of Brain Imaging Asymmetry
Federica Lucchelli and Alessia Monti
University of Trento, Rovereto, Italy
Case report: MA, a 57-year-old man, was referred
for evaluation of behavioural and cognitive distur-
bances. At the age of 47 he had presented dramatic
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personality and behavioural changes, consisting of
hypomania, compulsiveness, loss of insight and im-
paired social interaction. This led to relevant financial
loss, bankruptcy and divorce. For some years he let
himself go, living on the streets until, about one year
before our assessment, his wife took care of him again.
At that time dementia was diagnosed. At the time of our
evaluation, he was deeply apathetic and emotionally
unconcerned, but not overtly depressed. His behaviour
was always adequate and when stimulated he was
well cooperative. An extensive neuropsychological
assessment demonstrated severe and pervasive impair-
ment of executive functions. His memory performance
showed a striking dissociation between spared ver-
bal and impaired visuo-spatial tasks. Language was
remarkably preserved, whereas visuo-spatial percep-
tual skills were mildly affected. MA’s cognitive profile,
primarily characterized by widespread impairment of
frontal abilities, yet suggests disproportionate involve-
ment of right hemisphere functions, in contrast with
sparing of left hemisphere ones.
Conclusions: This fits well with brain MRI findings,
that documented an unusual and marked asymmetry of
atrophy, whereby the right hemisphere is much more
severely affected than the left one.
ThaGAIAproject: a pilot program forAlzheimer’s
disease. A follow-up study
Tiziana Maci, Graziella Quattrocchi, Mario Cirmi,
Fabrizio Giammello, Francesco Le Pira, Santo Di
Nuovo, Vincenzo Perciavalle and Mario Zappia
University of Catania, Catania, Italy
Aims: To evaluate patients and caregivers three
months after the end of a pilot project, called GAIA
(“Gruppo Alzheimer In Attività”, i.e. “Alzheimer
Group In Activity”) assessing the effect of cognitive
stimulation, motor activity and social aggregation on
cognitive decline in AD.
Methods: We enrolled 14 AD patients, randomly
divided in two groups without significant clinical and
demographic differences: active treatment group and
control group. Treatment group underwent protocols
of both cognitive and motor stimulation as well as
encouraged to socialization.
Results: At the end of treatment we found a signif-
icant improvement of mood and QoL in the treatment
group, whereas we observed a significant worsening of
both parameters in the control group. Caregivers of the
treatment group exhibited a significant improvement
of their mood and of their perception of patients’ QoL.
A three months follow-up showed that while treatment
group maintains, although partially, the improvement
obtained during the treatment, the controls continued
their progressive worsening.
Conclusions: This investigation provides experi-
mental evidence that an integrated approach based on
cognitive stimulation, physical activity and socializa-
tion can improve QoL of AD patients and alleviate the
caregivers’ burden of care.
White Matter Integrity Assessment with Diffusion
Tensor Imaging in Mild Cognitive Impairment
Laura Maggiorea, Grazietta Gattellarob, Domenico
Aquinob, Anna R. Giovagnolib, Alessandra Erbettab,
Francesca Clericia, Maria Grazia Bruzzoneb and
Claudio Mariania
aUniversity of Milan, Sacco Hospital, Milan, Italy
bFondazione IRCCS Istitute “Carlo Besta”, Milan,
Italy
Aims and methods: In order to improve identifica-
tion of people at risk of developing Alzheimer’s disease
we employed Diffusion Tensor Imaging (DTI) analy-
sis to investigate the integrity of fiber tracts in Mild
Cognitive Impairment (MCI) patients and controls.
DTI is an advanced MR technique sensitive to white
matter microstructure integrity in vivo by measuring
directional changes in water diffusivity. Twenty-two
patients with MCI and seventeen controls underwent
conventional magnetic resonance imaging (MRI) 1.5-
Tesla and DTI examination Fractional anisotropy (FA)
and mean diffusivity (MD) were measured in region of
interest (ROI).
Results: In MCI patients FA values were signif-
icantly decreased in inferior longitudinal fasciculus,
anterior thalamus, anterior and posterior cingulum
and fornix compared to the controls. Conversely, MD
values were significantly increased in right inferior lon-
gitudinal fasciculus and anterior-posterior cingulum.
No difference in FA and MD was found between MCI
patients and controls in cortical spinal tract, corpus
callosum and in prefrontal dorsolateral region.
Conclusions: These results are in agreement with
those of previous studies DTI is a sensitive method
for detecting subtle microstructural changes of sev-
eral cortico-cortical and sub-cortical tracts that may be
predictors of AD progression.
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Progranulin plasma levels in patients with and
without TDP-43 pathology
Michela Magistrello, Silvia Grifoni, Andrea Calvo,
Cristina Moglia, Alessia Pellerino, Andrea Naldi,
Salvatore Gallone, Adriano Chiò and Maria Teresa
Giordana
University of Turin, ASO S. Giovanni Battista
Molinette, Turin, Italy
Background: PGRN gene mutations resulting in
haploinsufficiency are responsible of cases of familial
frontotemporal dementia (FTLD); plasma progranulin
levels are significantly reduced in subjects carrying
the mutations. FTLD due to PGRN gene mutations
is characterized by accumulation of TDP-43 protein
within neurons, a pathologic phenotype common to
other neurodegenerative conditions named TDP-43
proteinopathies, including amyotrophic lateral sclero-
sis. A possible mechanistic link between progranulin
expression and TDP-43 pathology was hypothesized.
Aims and methods: With the aim to investigate
whether plasma levels of progranulin reflect the
expected TDP-43 pathology, we measured the levels
of progranulin in 27 patients with ALS in comparison
to 25 age-matched patients diagnosed as Alzheimer’s
dementia or frontotemporal dementia (FTD), by an
ELISA method (Adipogen, Seul, Korea).
Results: None of patients carried PGRN gene
mutations. We found that plasma progranulin levels
were not significantly different in Alzheimer patients
(mean 153.20 ng/ml, range 121.6–202.0) in compar-
isons with ALS patients (mean 161.61 ng/ml, range
107.0–268.0). Mean value in FTD patients was 148.52
(139.9–141.4).
Conclusions: Plasma progranulin levels do not
reflect the expected TDP-43 pathology and do not clar-
ify any possible mechanistic link of progranulin and
TDP-43.
Clinical Phenotypic Variability in an Italian Family
Bearing an Intronic Mutation in PGRN Gene
Gabriella Marcona, Giacomina Rossia, Giorgio Gia-
cconea, Marina Grisolia, Anna R. Giovagnolia, Sergio
Zaninib, Onelio Geattic and Fabrizio Tagliavinia
aFondazione IRCCS Istituto Neurologico Besta,
Milano, Italy
bIstituto Scientiﬁco E. Medea, Pasian di Prato (UD),
Italy
cAzienda Ospedaliera-Universitaria, Udine, Italy
Background: Frontotemporal dementia (FTD) is
a complex presenile disorder characterized by be-
havioural changes and executive functions impairment,
expression of neurodegeneration of frontal and tempo-
ral lobes. Recently, mutations in the gene encoding
progranulin (PGRN) were reported and most of the 68
pathogenetic PGRN mutations described present a pre-
mature termination codon that induces the degradation
of mutant RNA by nonsense mediated decay. In these
mutations, prominent phenotypic variability within
and among affected kindreds has been described.
Aims and methods: We have studied a novel Italian
pedigree in which three affected members presented
clinical evidence of dementia. Their characteriza-
tion was documented with clinical records, imaging,
sequential neurological examinations and cogni-
tive assessments. Genetic analysis, performed after
informed written consensus, revealed the presence of
IVS6+5 8delGTGA PGRN mutation in all affected
members. The mutation is a deletion that leads to hap-
loinsufficiency.
Results: In the three patients the mutation is associ-
ated with different clinical phenotypes. In the proband
the FTD is associated with executive functions and lan-
guage impairment. Despite the clinical picture severity,
the MRI showed only mild asymmetrical atrophy with
enlargement of left silvian fissure and frontal sulci
associated with a minimal enlargement of the left
lateral ventricle. The second patient showed clinical
Alzheimer’s disease with deficits in all cortical func-
tions and normal temporo-mesial structures by MRI
scan. The third patient presented hallucinations with
rapid progressive cognitive impairment, mimicking
the onset of prion disorder.
Conclusions: The phenotypic variability and the sin-
gular MRI data, incompatible with the clinical picture,
confirm the clinical complexity of PGRN mutations.
Progression to Dementia of a Population with
aMCI: Clinical Variables Associated to Conversion
Marco Mauria, Elena Sinforiania, Simona Corbettab,
Chiara Zucchellaa, Valentina Giarraccab and Giorgio
Bonob
aIRCCS Neurologico C Mondino, Pavia, Italy
bInsubria University, Varese, Italy
Aims: To investigate clinical predictors and rate to
conversion to dementia syndrome in a case-series of
amnesic Mild Cognitive Impairment (aMCI).
Methods: Two hundred and eight aMCI subjects
(mean age 73.61 SD 6.9 years, M/F 84/124) were fol-
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lowed over a six-year period. The analysis considered
cognito-motor-behavioral status, vascular risk factors
and CT findings. Conversion to dementia was con-
sidered when current criteria were fitted (Alzheimer’s
Disease – AD: NINCDS-ADRDA; FrontoTemporal
Dementia: Work Group 2001; Lewy Body Dementia:
McKeith 2005; Vascular Dementia: NINDS-AIREN).
Results: After six years, 68.8% aMCI patiens had
converted to ouvert dementia: mean time for conver-
sion was 18.2 months (80.7% within three years, AD:
90.3%). Lower MMSE score (24 to 27) and an age
over 75 years were significant predictors for dementia
(p < 0.01); MCI patients with minor BPSDs showed a
faster conversion rate (p < 0.05).
Conclusions: Lower cognitive performance and the
association with minor BPSDs are relevant factors,
among the aMCI patients, for the development of
dementia and faster rate of conversion respectively.
Mild Cognitive Impairment: Spatial Abilities
and Imaging Predictors for Incipient Dementia
Micaela Mitoloa, Paolo Caffarrab and Francesca
Pazzagliaa
aUniversity od Padova, Padova, Italy
bUniversity of Parma, Parma, Italy
Aims and methods: This is a prospective study in
which clinical, cognitive and neuroimaging variables
was collected at baseline in newly diagnosed patients
with MCI and controls. These variables was used to
identify those more strongly associated to the devel-
opment of AD. All patients was assessed with the
following neuropsychological battery: MMSE, Rey
Auditory Verbal Learning Test, Digit Span, Rey-
Osterrieth Complex Figure, Wisconsin Card Test,
Tower of London test, RPM, Stroop Test, Clock Draw-
ing Test and Corsi Visuo-spatial supraspan. Spatial
and orientation abilities was assessed with new exper-
imental instruments: Objects’ Recognition Test, Map
Learning Test, Route Learning Test. To investigate the
relation between spatial impairment and metacogni-
tive sphere we also administer four specific self-rating
scales.
Results: A first phase was dedicated to the patients
and controls recruitment and to the administration of
a neuropsychological battery. Twenty-one MCI have
been assessed until now (10 males and 11 females;
mean age 74.67 + 6.67). A second phase will be ded-
icated to a cognitive follow-up at 12 month after the
initial evaluation, to validate the predictive diagnostic
value of early functional brain impairment in cognitive
processing detected with fMRI and to verify the speci-
ficity of the cognitive deficit for each MCI subtype.
Neuroscience and Law: Validation of new
Neuropsychological Tests for Forensic use
Daniela Ovadiaa, Anna Seddab and Gabriella Bottinia
aOspedale Niguarda, Milan, Italy
bUniversity of Pavia, Pavia, Italy
Background: Recent progress in neurosciences
made the cooperation between jurists, neuroscien-
tists and neuroethicists more an more complex. The
new European Association for Neuroscience and Law
(EANL) was launched to analyze the needs of jurists
and the role of neuroscientists as forensic experts. In
particular, neuroscience experts need new validated
tools to answer with good efficacy and reliability the
questions raised by the the judges and the courts.
Aims and methods: At the Cognitive and Neuro-
psychological Center of Niguarda Hospital we are
designing and validating a new questionnaire for
hypersexuality symptoms in patients with early stage
frontotemporal dementia (FTD) and in epileptic pa-
tients who underwent surgery for pharmacoresistant
epilepsy.
Results: Hypersexuality symptoms are frequent in
FTD and apparently also after surgery for epilepsy but,
in this case, their prevalence is unknown, although they
can have legal and personal consequences. Our ques-
tionnaire is based on the new criteria for hypersexuality
diagnosis proposed by the DSM-V and could be a use-
ful tool in criminal, civil and family law judgements.
Conclusions: Our research will provide more
information on the prevalence and incidence of hyper-
sexuality and will help us in rewriting the informed
consent forms for epileptic patients.
Prospective Memory in Mild Cognitive
Impairment. Comparison between
Self-evaluation Measures and Performance
on an Experimental Task
Cristina Pagni, Cecilia Carlesi, Leda Volpi, Irene
Falorni, Irene Ghicopulos, Cristina Frittelli and Gloria
Tognoni
University of Pisa, Pisa, Italy
Aims: The present study aimed to investigate pros-
pective memory (PM) in subjects with mild cognitive
impairment (MCI).
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Methods: Self administered questionnaire on mem-
ory functioning (The Memory Functioning Question-
naire and the Prospective Memory Questionnaire)
together with an event-based prospective memory task
were used to assess prospective memory dysfunction
in amnestic MCI (a-MCI; N = 12), non amnestic MCI
(na-MCI; N = 6) and multiple domain MCI (md-MCI;
N = 7). A control group of 22 subjects, matched for
age and education, complete the PM task. Separate
scores were computed for correct execution of intended
action (prospective component) and recall of intention
(retrospective component).
Results: MCI group showed poorer performance
with respect to controls in both prospective and retro-
spective component of the task (p < 0.001). A relative
sparing of retrospective component was particularly
evident in MCI participants presenting with na-MCI
with respect to those with md-MCI. Correlation anal-
yses revealed an association between Prospective
Memory Questionnaire and retrospective component
(rho = −0.51; p < 0.01).
Conclusions: These results suggest that PM impair-
ment is evident in MCI subjects. PM measures could
be used in routine evaluation also for that patients who
report only subjective memory disturbances. More-
over, although the small sample size, MCI patients tend
to correctly operate metamemory judgements.
Qualitative Differences in the Pattern of Memory
Deﬁcit of Patients with Alzheimer’s Disease,
Frontotemporal, Vascular and Lewy Body
Dementia
Roberta Perri, Carlo Caltagirone and Giovanni A.
Carlesimo
Tor Vergata University, Foundation Santa Lucia,
Rome, Italy
Background: Impaired consolidation mechanisms
due to mesio-temporal pathology in Alzheimer’s di-
sease (AD) make memory traces unavailable for
retrieval. In frontotemporal dementia (FTD) frontal-
lobe dysfunctions interfere with encoding/retrieval
strategies. In vascular (VD) and Lewy-body dementia
(LBD) both these mechanisms may operate.
Aims: To Assess qualitative memory differences in
AD, FTD, VD and LBD patients by tests with different
memoranda organization.
Methods: Subjects: 20 AD, 20 FTD, 20 VD and
20 LBD patients comparable for dementia severity,
34 matched controls (NCs). Tests: Delayed recall of
15-Word-list, Short prose passage.
Results: Dementia groups scored worse than NCs on
both tests (consistently p < 0.001). In Word-list test AD
performed slightly worse than FTD (p = 0.04) and sim-
ilarly to VD and LBD. On Prose recall AD achieved
the worst performance (p < 0.01). No differences were
recorded among FTD, VD, LBD. The Group × Test
interaction (F = 8.22, p < 0.001) confirmed the dispro-
portionate deficit of AD as compared to other groups
on Prose recall (consistently p < 0.05).
Conclusions: fv-FTD outperfomed AD patients
specifically on Prose recall, suggesting that the well-
organised memoranda enabled them to overcome their
encoding deficit. VD and LBD groups performed as
AD on Word-list and outperfomed them on Prose
recall, suggesting the existence of consolidation and
encoding problems in these pathologies.
Effects of Minimal Interference in aMCI and AD:
a Longitudinal Study
Martina Pesallacciaa, Michaela Dewarb, Nelson
Cowanc, Leandro Provincialia and Sergio Della Salab
aUniversità Politecnica delle Marche, Ancona, Italy
bUniversity of Edinburgh, Edinburgh, UK
cUniversity of Missouri-Columbia, USA
Background: Delayed recall is at floor in AD and
aMCI patients when learning is followed by further
cognitive activity. It can be improved when learn-
ing is followed by a reduced interference. A strong
association between delayed recall following ‘minimal
interference’ (minRI) and disease severity has been
showed, with aMCI performing better than AD and
the degree of benefit from minRI probably declines
with disease progression.
Methods: Twenty five aMCI, 24 AD and 25 controls
were tested on Phase 1 and Phase 2 (after 1 year). All
participants were presented with 15 words and asked
to recall as many of them as possible, after presentation
and after a 10 minute delay. In the interval participants
either named drawings or they rested alone in the dark-
ened testing room (minRI). Twenty aMCI was called
back for a Phase 3 (2 years following Phase 1).
Results: Retention in the minRI condition dropped
significantly over 1 year only in the AD. A significant
correlation was obtained for change in minRI reten-
tion and disease severity over 2 years in the aMCI.
Conclusions: MinRI retention decreases as AD pro-
gresses, and appears to do so at a more accelerated rate
in AD than in aMCI.
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Neuropsychological Proﬁle of CADASIL
and Age-related Leukoencephalopathy Patients
and Inﬂuence on Functional Performances:
Observations from the MIcrovascular
LEukoencephalopathy Study (MILES)
Francesca Pescinia, Laura Ciollia, Emilia Salvadoria,
Alessandra Del Benea, Cristina Sartia, Annamaria
Basileb, Federica Squarzantib, Lucia Nardettob, Enza
Zicaric, Silvia Bianchic, Maria T. Dottic, Enrico
Adrianod, Maurizio Balestrinod, Carlo Gandolfod,
Leonardo Pantonia and Domenico Inzitaria
aUniversity of Florence, Florence, Italy
bUniversity of Padova, Padova, Italy
cUniversity of Siena, Siena, Italy
dUniversity of Genoa, Genoa, Italy
Background: Microangiopathic leukoencephalopa-
thy is frequently seen in the elderly with vascular risk
factors (sporadic Age-Related Leukoencephalopathy-
ARL). Similar white matter changes are found in
CADASIL, a genetically-determined small vessel dis-
ease. Both conditions are characterized by progressive
cognitive impairment and disability.
Aims: To assess the neuropsychological profile of
70 ARL and 55 CADASIL patients and the possible
influence on functional performances.
Methods: Functional and neuropsychological per-
formances were evaluated using a comprehensive
battery. Z scores were calculated considering age and
education. Compound measures were obtained using
standard scores for the following domains: Memory,
Speed and Executive Functions. Differences in the
neuropsychological profile were explored using t-test.
The predictive value of neuropsychological indexes on
functional performances was valuated using correla-
tion and logistic regression analyses.
Results: No significant difference was found bet-
ween the neuropsychological indexes of the two
groups (Memory, t(121) = 1.3, p = 0.19; Speed, t(115)
= −1.1, p = 0.29; Executive Functions, t(82) = 0.2,
p = 0.85). In CADASIL, Memory index was a signif-
icant predictor of functional performance (B = 0.66,
p < 0.01), in ARL it was the Executive Functions index
(B = 2.24, p < 0.05).
Conclusions: Our study shows that the neuropsy-
chological profile is similar in CADASIL and ARL
patients, but there is a different relation with func-
tional tests: memory seems to have a greater impact on
functional performance in CADASIL, executive func-
tioning in ARL.
Implication of a Genetic Variant at PICALM
in Italian Alzheimer’s Disease Patients and
Centenarians
Irene Piaceria, Silvia Bagnolia, Ersilia Lucentefortea,
Michelangelo Mancusob, Andrea Teddea, Gabriele
Sicilianob, Silvia Piacentinia, Laura Braccoa, Sandro
Sorbia and Benedetta Nacmiasa
aUniversity of Florence, Florence, Italy
bUniversity of Pisa, Pisa, Italy
Background: A common polymorphism (rs38511
79) in the PICALM (phosphatidylinositol-binding
clathrin assembly protein) gene has been recently
associated with reduced risk of developing late-onset
Alzheimer’s disease (LOAD).
Aims and methods: We analyzed the genotype and
allele distributions of the PICALM polymorphism in
813 Italian subjects, including LOAD patients and
centenarians.
Results: The segregation of the PICALM rs3851179
showed no statistically significant difference between
LOAD cases and controls.
Conclusions: The implication of a genetic variant at
PICALM is confirmed for the first time, in centenari-
ans, thus suggesting a possible role in longevity.
Increased Levels of Tissue Factor Pathway
Inhibitor in Cerebrospinal Fluid are Related
to Neurodegeneration in Alzheimer’s Disease
Patients
Fabrizio Piazzaa, Daniela Galimbertib, Barbara
Borronic, Alessandro Padovanic, Elio Scarpinib and
Carlo Ferraresea
aSan Gerardo Hospital, University of Milano-Bicocca,
Monza, Italy
bUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
cUniversity of Brescia, Brescia, Italy
Background: Although Alzheimer’s Disease (AD)
is mainly considered a neuronal disease, much evi-
dence points to a vascular pathogenetic involvement in
its etiology. We recently demonstrated that an impair-
ment of endothelial function may occur in AD patients,
associated with an increase of Tissue Factor Pathway
Inhibitor (TFPI), the serine protease inhibitor induced
by endothelial injury, and higher Homocysteine or
lower Folate plasma levels.
Aims: To investigate central and plasmatic source of
TFPI.
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Methods: We evaluated the Cerebrospinal Fluid
(CSF) levels in a cohort of subjects affected by AD,
other neurodegenerative diseases and healthy controls,
where the presence of major vascular disorders was
ruled out with a thorough clinical, laboratory and
neuroimaging assessment, and acute or chronic cere-
brovascular disease patients. Moreover, to figure out
if the increased TFPI levels are related to neurode-
generation, Tau and p-Tau proteins levels were also
evaluated.
Results: Our study demonstrates for the first time
an abnormally high CSF levels of TFPI in AD, also
related to neurodegeneration, strengthening the
hypothesis that an impairment of endothelial function
may occurs despite the absence of manifest cerebrovas-
cular lesions.
Conclusions: TFPI may represent a candidate
marker of endothelial damage in AD and it might be
used to monitor therapeutic interventions on vascular
risk factors.
Phenotypic Heterogeneity of the GRN Asp22fs
Mutation in a Large Italian Kindred
Anna M. Pietrobonia, Giorgio G. Fumagallia, Laura
Ghezzia, Chiara Fenoglioa, Francesca Cortinia, Maria
Serpentea, Claudia Cantonia, Emanuela Rotondoa,
Priscilla Cortia, Miryam Carecchiob, Mariateresa
Bassic, Nereo Bresolina,c, Domenico Galbiatic,
Daniela Galimbertia and Elio Scarpinia
aUniversity of Milan, IRCCS Fondazione Cà Granda,
Ospedale Maggiore Policlinico, Milan, Italy
b
“Amedeo Avogadro” University, Novara, Italy
cIRCCS E. Medea, Associazione La Nostra Famiglia,
Bosisio Parini (LC), Italy
Background: The Asp22fs(g.63 64insC) mutation
in progranulin gene (GRN) has been reported in one
patient with Frontotemporal Dementia (FTD).
Aims: To describe the clinical heterogeneity associ-
ated with the GRN Asp22fs mutation in a large Italian
family.
Methods: Clinical and instrumental workup of two
symptomatic carriers in two generations has been car-
ried out, together with genetic analysis of probands and
of nine asymptomatic family members.
Results: The first proband was a 47-year old male
clinically diagnosed with FTD with a positive fam-
ily history. Evaluation of plasma GRN levels was
consistent with the presence of a mutation in its
encoding gene, that was demonstrated by sequencing
[Asp22fs(g.63 64insC)]. Brain MRI showed multiple
T2 and FLAIR hyperintense areas in the frontal lobe
white matter and right hemisphere cortical atrophy.
The second proband was his 79 years old uncle, pre-
senting with a mild cognitive impairment. Brain MRI
showed small T2 hyperintense lesions and widespread
cortical atrophy. Cerebrospinal fluid Amyloid beta, tau
and phosphotau protein levels were in both cases nor-
mal. Additional nine asymptomatic family members
were studied.
Conclusions: This family’s description expands the
spectrum of clinical presentations of Frontotemporal
Lobar degeneration caused by GRN mutations, sug-
gesting that the diagnosis could be missed in some
individuals with an atypical presentation.
PGRN and TARDBPMutations in Frontotemporal
Lobar Degeneration: Two Faces of TDP43
Proteinopathies
Andrea Pilottoa, Barbara Borronia, Antonella
Albericia, Silvana Archettib, Alice Papettia, Maura
Cosseddua, Cristian Bonvicinic, Roberto Del Bod,
Marinella Turlae, Emanuele Burattif , Giacomo P.
Comid, Massimo Gennarellic, Monica Di Lucad and
Alessandro Padovania
aUniversity of Brescia, Brescia, Italy
bSpedali Civili Brescia, Brescia, Italy
cIRCCS Fatebenefratelli, Brescia, Italy
dUniversity of Milan, Milan, Italy
eValleCamonica Hospital, Esine (BS), Italy
f International Centre for Genetic Engineering and
Biotechnology, Trieste, Italy
Background: Monogenic forms of Frontotemporal
Lobar Degeneration (FTLD) with TDP-43 positive
inclusions have been associated with Progranulin
(PGRN) or 43-kDa transactive response (TAR)-DNA-
binding protein (TARDPB) mutations.
Aims: Distinguish the two different genetic con-
ditions by defined clinical and neuropsychological
features.
Methods: Three hundred FTLD patients genetic
analysis revealed 13 PGRN and 6 TARDBP mutations
carriers. These 19 patients underwent an extensive
clinical and neuropsychological evaluation at disease
presentation and during its progression.
Results: PGRN subjects revealed to have a Pro-
gressive Non-Fluent Aphasia or behavioral variant
Frontotemporal Dementia (bvFTD), whilst TARDBP
cases had bvFTD with or without motoneuron dis-
ease (FTD-MND). PGRN patients’ disease mean
onset was a decade before TARDBP (p < 0.001). The
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two groups were comparable in all the investigated
cognitive domains except for a worse phonological
fluency in PGRN carriers (P = 0.003). Disease progres-
sion in both PGRN and TARDBP patients leaded to
progressive executive dysfunction and to behavioral
disturbances, however most of PGRN cases developed
mutacism, progressive limb apraxia and parkinson-
ism while TARDBP patients did only seldom develop
MND.
Conclusions: This preliminary report identifies dif-
ferent clinical phenotypes associated to PGRN and
TARDBP mutations carriers, suggesting how FTLD
TDP-43 may not be a single entity, but a complex
disease involving various genes and pathways.
CSF Biomarkers Signature in FTLD
Sara Pompanina, Gianluigi Zanussoa, Michele
Fiorinia, Nela Jelcica, Francesca Gnoatoa, Salvatore
Monacob and Annachiara Cagnina
aUniversity of Padova, Padova, Italy
bUniversity of Verona, Verona, Italy
Background: Frontotemporal lobar degeneration
(FTLD) present with behavioural (bvFTD) or lin-
guistic deficits (progressive non fluent aphasia-PNFA;
semantic dementia-SD), caused by heterogeneous
neuropathology.
Aims: To evaluate CSF biomarkers in the differential
diagnosis between FTLD and AD.
Methods: Twenty three FTLD (bvFTD = 15; PNFA–
SD = 3; CBD-PSP = 5) and 11 AD patients underwent
neuropsychological evaluation and lumbar puncture.
CSF analysis of total Tau and 181-p Tau, A40 and
A42 was performed by ELISA.
Results: CSF 181-p Tau and A42/181-p Tau values
are significantly different between bvFTLD (pTAU:
mean 32.8 ± 9.9 pg/ml; A42/pTau: 5.6 ± 3) and AD
(pTAU: 93.9 ± 59 pg/ml, p = 0.001; A42/pTau: 1.5 ±
1.2, p = 0.001). 181-p Tau cut-off level of 50 pg/ml
could discriminate between bvFTLD and AD with a
sensitivity of 70% and a specificity of 100% (accu-
racy 86%). Accuracy was increased to 90% by adding
the recall memory test scores. In the linguistic vari-
ant (PNFA–SD) we found a high heterogeneity of
CSF A42/181-p Tau ratio, mirroring different patho-
logical substrates including the frontal variant of
AD.
Conclusions: Low CSF 181-p Tau level (below the
threshold of 50 pg/ml) and high A42/181-p Tau ratio
are the biological signatures of FTLD and may be used
in the differential diagnosis with atypical AD (frontal
variant or corticobasal syndrome).
Late-onset OCD as Presenting Condition
of Semantic Dementia
Sara Pompanin, Giulia Perini, Francesca Gnoato,
Renzo Manara, Diego Checchin and Annachiara
Cagnin
University of Padova, Padova, Italy
Background: Semantic dementia (SD) is a variant of
frontotemporal lobar degeneration (FTLD) with pro-
gressive loss of words and objects knowledge and
behavioural disorders such as obsessive-compulsive
symptoms.
Aims: To describe a case of SD with late-onset
obsessive-compulsive disorder (OCD) that lasted for
ten years as isolated clinical condition before dementia
onset.
Case description: A 64-year-old right-handed men
who had OCD beginning at the age of 50 with
disabling aggressive/religious obsessions and control
compulsions (Y-BOCS = 21/40). At the age of 60 he
was admitted to our Memory Clinic with mild cogni-
tive impairment (MMSE = 26/30). Neuropsychologi-
cal tests revealed the presence of language impairment
and executive deficits. Routine blood and cerebrospinal
fluid (CSF) studies were unremarkable. He under-
went extensive workup with CSF biomarkers analysis
(A42/181p-TAU = 1.68), genetic test (negative for
MAPT, GRN mutations), MRI (left temporal pole
atrophy), 18FDG PET scan (left temporal and ante-
rior cingulate hypometabolism) and DaT-Scan (left
basal ganglia decreased uptake). Two years later
he developed left extrapyramidal syndrome; OCD
(Y-BOCS = 34/40) and anomic speech went worse.
Conclusions: Atypical onset OCD (idiopathic-OCD
onset before 25 years meanly) can be primary presenta-
tion of neurodegenerative disorders like FTLD, mainly
in SD variant.
Mid life Metabolic and Dietary Risk Factors
of Dementia. A 15 Year Cohort Study in the
Municipality of Bollate-Milan, Preliminary
Results
Federica Prinellia, Francesca Clericib, Carla Pettenatic,
Fulvio Adornia, Antonio Russod, Claudio Marianie
and Massimo Musiccoa
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Dementia HR
No Yes (95% CI)
1210 (96.0) 51 (4.0)
Age (yrs)
40–49 219 (18.1) 2 (3.9) 1
50–59 548 (45.3) 17 (33.3) 2.31 (0.79–6.74)
60–69 348 (28.8) 26 (51.0) 6.09 (2.15–17.27)
70+ 95 (7.9) 6 (11.8) 9.05 (2.83–28.87)
Gender
Men 659 (54.5) 30 (58.8) 1
Women 551 (45.5) 21 (41.2) 0.87 (0.54–1.41)
BMI 27.0 ± 4.0 27.8 ± 4.3 1.06 (1.00–1.12)
Waist circumference (cm) 92.5 ± 12.3 95.1 ± 12.9 1.02 (1.00–1.04)
Glucose (mg/dL) 97.9 ± 25.8 98.7 ± 17.3 1.00 (0.99–1.01)
HDL-Chol (mg/dL) 57.8 ± 15.7 54.9 ± 13.2 0.99 (0.97–1.01)
Triglycerides (mg/dL) 134.0 ± 90.5 148.2 ± 80.8 1.00 (1.00–1.00)
Blood pressure
Systolic (mm/Hg) 137.8 ± 18.5 142.8 ± 15.3 1.01 (1.00–1.02)
Diastolic (mm/Hg) 84.9 ± 8.9 84.7 ± 8.1 1.01 (0.98–1.03)
Metabolic syndrome
No 799 (66.0) 29 (56.9) 1
Yes 411 (34.0) 22 (43.1) 1.52 (0.87–2.64)
Follow-up (yrs) 16.5 ± 1.9 16.3 ± 2.2
aITB CNR Segrate Milano
bDipartimento Neurologia AO Ospedale Luigi Sacco
Milano
cCentro Alzheimer AO Ospedale G. Salvini Garbag-
nate Mi
dASL Milano 1 Magenta Mi
eCattedra di Neurologia Università di Milano
Background: There is growing evidence that mid
life dietary exposures and disturbances of glucose
metabolism might increase the risk of dementia in late
life. In particular the condition of metabolic syndrome
(glucose intolerance plus two of the following: high
triglycerides, low HDL cholesterol, hypertension and
high abdominal fat) has been reported as a risk factor
of dementia and in particular of Alzheimer disease.
Aims and methods: During 1994 we carried out an
investigation on a healthy population of residents in
Bollate a municipality of the province of Milan. The
investigation was centered on dietary habits and on
some routine laboratory evaluations. During 2010 we
retrieved the persons of the cohort who potentially had
a dementia from the two referral Alzheimer centers of
the geographical area of Bollate (Sacco Hospital and
Passirana Hospital) and from the health informative
system of the local health authority. We considered
as demented all the persons of the cohort who had a
diagnosis of dementia in at least one of the two refer-
ral Alzheimer centers and/or had an hospitalization
for dementia and/or were prescribed an antidementia
drug (donepezil, rivastigmine, galantamine or meman-
tine). The entire cohort was composed by 1261 subjects
(689 men and 572 women) with a mean age of about
55 years. From 1994 to June 2010 we could assign a
diagnosis of dementia to 51 subjects (30 men and 21
women). The risk of dementia was analyzed with sur-
vival analysis and the relative risk of dementia were
estimated as hazard ratios with Cox’s proportional
hazard method.
Results: A part from age that was the most important
predictor of the risk of dementia persons who devel-
oped dementia had higher body mass indexes, higher
glucose and triglycerides blood levels, lower HDL
cholesterol levels, higher systolic blood pressure and
larger waist circumference. The presence of metabolic
syndrome was associated with a 50% increase of the
risk of dementia.
Conclusions: The preliminary results of this cohort
study confirm the potential role of some metabolic dis-
turbances in determining an increase of the risk of
dementia.
Neuropsychological Staging of Alzheimer’s
Disease (AD)
Davide Quaranta, Camillo Marra, Maria G. Vita and
Guido Gainotti
Università Cattolica del Sacro Cuore, Rome, Italy
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Objectives: To define the steps of neuropsychologi-
cal progression in AD.
Methods: Four hundred and five AD subjects under-
went neuropsychological testing including: MMSE,
RAVLT, Multiple Features Targets Cancellation,
Raven’s Matrices (PM’47), phonological and seman-
tic fluency, copy of figures without/with landmarks,
digit span, Stroop test. Subjects were stratified
for severity into: Group A (MMSE > 23); Group
B (19 < MMSE < 22); Group C (15 < MMSE < 18);
Group D (MMSE < 15). The number of pathological
performances (PP) was computed after age/education
correction. Frequencies were compared by chi-square.
Tests displaying a significant difference of PP inci-
dence between contiguous groups were considered as
markers of progression.
Results: Group A subjects were impaired mainly on
RAVLT delayed recall. The following markers of pro-
gression were identified: – higher incidence of PP on
PM’47 (p < 0.001) and semantic fluency (p < 0.001) in
Group B; – higher incidence of PP on copy of figures
with landmarks (p < 0.001) and RAVLT-immediate
recall (p = 0.001) in Group C; – higher incidence of
PP on phonological fluency (p < 0.001) and digit span
backward (p < 0.001) in Group D.
Conclusions: Specific neuropsychological steps
could define the progression of AD. After defects of
episodic memory, deficits in semantic knowledge and
abstract reasoning, then deficits in constructive abili-
ties and finally deficits in working memory and verbal
initiation are sequentially observed.
Association Between Alzheimer’s Disease
and the Hypocretin Receptor 2 Gene
Innocenzo Raineroa, Elisa Rubinoa, Daniela Gali-
mbertib, Salvatore Gallonea, Pierpaola Fenoglioa,
Chiara Fenogliob, Elio Scarpinib and Lorenzo Pinessia
aUniversity of Turin, Turin, Italy
bUniversity of Milan, IRCCS Fondazione Cà Granda,
Ospedale Maggiore Policlinico, Milan, Italy
Background: A recent study in animals suggested
that hypocretins may play a role in Alzheimer’s dis-
ease (AD) promoting the deposition of beta-amyloid.
Hypocretins are hypothalamic neuropetides that reg-
ulate several physiological functions, like sleep-wake
cycle, attention, and feeding.
Aims: To investigate the association of polymor-
phisms in the hypocretin gene system and AD.
Methods: A group of 261 Italian AD patients was
selected for the study and compared with 261 controls.
Cases and controls were genotyped for several SNPs
of the HCRT, HCRTR1, and HCRTR2 genes.
Results: The genotype and allele distribution of the
HCRTR2 G1246A polymorphism varied significantly
between patients and controls. Homozygous carriers of
the A-allele had an approximately twofold increase in
AD risk (OR 1.75; 95% CI 1.25 to 2.46;p = 0.0006). No
significant difference between the examined character-
istics of the disease and different genotypes was found.
Conclusions: This is the first study that examined
the association between hypocretin system genes and
AD; so our data must be viewed cautiously. We found
a significant association between the HCRTR2 gene
and AD. Our data support the hypothesis that genetic
variations within the HCRTR2 gene are risk factors for
AD and may be involved in the disease pathogenesis.
Role of hnRNP-A1 and miR-590-3p in Neuronal
Death: Genetics and Expression Analysis
in Patients with Alzheimer’s Disease and
Frontotemporal Lobar Degeneration
Elisa Ridolfia, Chiara Villaa, Chiara Fenoglioa, Fran
cesca Clericib, Alessandra Marconec, Luisa Benussid,
Roberta Ghidonid, Salvatore Gallonee, Francesca
Cortinia, Maria Serpentea, Claudia Cantonia, Gior-
gio G. Fumagallia, Stefano Cappac, Giuliano Binettid,
Massimo Franceschif , Innocenzo Raineroe, Mari-
ateresa Giordanae, Claudio Marianib, Nereo Bresolina,
Elio Scarpinia and Daniela Galimbertia
aUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
bUniversity of Milan, Ospedale Sacco, Milan, Italy
cOspedale San Raffaele Turro, San Raffaele Scientiﬁc
Institute, Milan, Italy
dIRCCS Centro S. Giovanni di Dio-FBF, Brescia, Italy
eUniversity of Turin, Turin, Italy
fClinica Neurologica, Casa di cura Santa Maria di
Castellanza, Varese, Italy
Aims and methods: An association study of Hetero-
geneous nuclear ribonucleoprotein (hnRNP)-A1 was
carried out in a population of 274 patients with Fron-
totemporal Lobar Degeneration (FTLD) and 287 with
Alzheimer’s disease (AD) as compared with 344 age-
and gender-matched controls. We evaluated expres-
sion levels of hnRNP-A1 and its regulatory microRNA
(miR)-590-3p in blood cells from patients and controls.
Results: A statistically significant increased fre-
quency of the hnRNP-A1 rs7967622 C/C genotype
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was observed in FTLD, but not AD, patients versus
controls (23.0 versus 15.4%; p = 0.022, OR: 1.64, CI:
1.09–2.46). Stratifying according to gender, a statisti-
cally significant increased frequency of the hnRNP-A1
rs7967622 C/C genotype was observed in male patients
as compared with male controls (23.1 versus 11.3%;
p = 0.015, OR: 2.36, CI: 1.22–4.58), but not in females.
A significant increased hnRNP-A1 relative expression
levels in PBMC was observed in patients with AD, not
with FTLD, as compared with controls (2.724 ± 0.570
versus 1.076 ± 0.187, p = 0.021). Decreased relative
expression levels of the hsa-miR-590-3p was observed
in patients with AD versus controls (0.685 ± 0.080
versus 0.931 ± 0.111, p = 0.079), and correlated neg-
atively with hnRNP-A1 mRNA levels (r = −0.615,
p = 0.0237).
Conclusions: hnRNP-A1 and its miR-590-3p are
disregulated in patients with AD, and hnRNP-A1
rs7967622 C/C genotype is likely a risk factor for
FTLD in male populations.
Cognitive Neurosciences Contribution to Law
in Emotional Processing
Anna Seddaa, Daniela Ovadiab, Roberto Sterzib and
Gabriella Bottinia
aUniversity of Pavia, Pavia, Italy
bOspedale Niguarda, Milan, Italy
Background: Many legal issues are concerned with
the concept of mens rea. Recently, Law has turned to
Neuroscience in order to obtain more exhaustive infor-
mation. Several neurological diseases, in fact, may
alter the behavioral and cognitive profile of subjects,
impairing their decision making and emotional pro-
cesses. Cognitive neurosciences may provide sensitive
and effective instruments to distinguish between volun-
tary acts deviating from legality and atypical behaviors
due to focal or diffuse brain damage.
Aims and methods: At the Cognitive Neuropsy-
chology Center of Niguarda Ca´ Granda Hospital, we
are studying emotional processing impairments whose
consequences are strictly related to the law domain.
Results: On one hand, brain damaged subjects may
manifest impaired facial emotion recognition, ending
in compromised social interactions. On the other hand,
it has been demonstrated that brain atrophy may alter
the psychiatric profile, causing ex novo pathological
manifestation or worsening of already present psy-
chosis.
Conclusions: Protocols evaluating several compo-
nents of emotional processing must be taken into con-
sideration by Law when patients, affected for instance
by dementia, manifest illegal social behaviors.
Titolo abstract: OLR1 and its Regulatory
miR-369-3p: Genetics and Expression Analysis
Maria Serpentea, Chiara Fenoglioa, Francesca
Clericib, Roberta Ghidonic, Luisa Benussic, Salvatore
Galloned, Alessandra Marconee, Chiara Villaa, Fran-
cesca Cortinia, Claudia Cantonia, Elisa Ridolfia,
Massimo Franceschif , Giuliano Binettic, Innocenzo
Rainerod, Stefano Cappae, Claudio Marianib, Nereo
Bresolina, Elio Scarpinia and Daniela Galimbertia
aUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
bUniversity of Milan, Ospedale Sacco, Milan, Italy
cIRCCS Centro S. Giovanni di Dio-FBF, Brescia, Italy
dUniversity of Turin, Turin, Italy
eOspedale San Raffaele Turro, San Raffaele Scientiﬁc
Institute, Milan, Italy
fClinica Neurologica, Casa di cura Santa Maria di
Castellanza, Varese, Italy
Aims and methods: An association analysis of Oxi-
dised LDL Receptor 1 (OLR1) was carried out in
a population of 443 patients with Alzheimer’s dis-
ease (AD) compared with 391 age-matched controls.
In addition, we performed an expression analysis of
OLR1 and its regulatory hsa-miR-369-3p in Peripheral
Blood Mononuclear Cells (PBMC).
Results: An increased frequency of OLR1 rs10502
83C allele was observed in patients compared with con-
trols (43% versus 46%, p = 0.011, OR: 1.48, 95% CI:
1.10–2.00). Stratifying according to gender, a statisti-
cally increased frequency of OLR1 rs1050283C allele
was observed in female patients compared with female
controls (37% versus 51%, p < 0.001, OR: 2.8982,
95% CI: 1.97–4.24), but not in males. Significantly
decreased relative expression levels of OLR1 in PBMC
was observed in patients carrying the rs1050283C
allele as compared with non-carriers (0.23 ± 0.13 ver-
sus 0.92 ± 0.8, p = 0.04). A trend towards increased
relative expression levels of the hsa-miRNA-369-3p
were observed in patients carrying the rs1050283C
allele (2.23 ± 1.35 versus 1.16 ± 0.31, p > 0.05). A ten-
dency towards a negative correlation between OLR1
and hsa-miRNA-369-3p gene expression was found in
patients carrying the rs1050283C allele (r = −0.313,
p = 0.05).
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Conclusions: The OLR1 rs1050283C allele is a risk
factor for sporadic AD; OLR1 and its transcriptional
regulatory factor hsa-miR-369-3p are de-regulated in
patients carrying the rs1050283C allele.
Assessment of Peripheral Markers
of Macroautophagy in Patients with Alzheimer’s
Disease
Giovanni Stefanonia, Gessica Salaa, Chiara P. Zoiaa,
Eleonora Vergaa, Diletta Ceredaa,b, Valeria Isellaa,b
and Carlo Ferraresea,b
aUniversity of Milano-Bicocca, Monza, Italy
bSan Gerardo Hospital, Monza, Italy
Background: Emerging evidence supports the view
that defective autophagy promotes neuronal cell
death in most neurodegenerative diseases, includ-
ing Alzheimer’s disease (AD). Beclin-1 deficiency is
known to lead to beta-amyloid accumulation in trans-
genic AD mice; furthermore, a reduction of beclin-1
has also been demonstrated in postmortem AD brains.
Aims and methods: We evaluated beclin-1 expres-
sion in peripheral blood mononuclear cells (PBMC)
from 15 AD patients and 15 age-matched controls
to identify a putative peripheral marker of macroau-
tophagy dysfunction occurring in AD brains, useful as
diagnostic tool and as parameter to monitor in ex vivo
cells from patients the effect of possible therapeutic
interventions aimed at activating autophagy. To ver-
ify whether PBMC represent a suitable model to test
autophagy modulation, we exposed cultured PBMC to
autophagy enhancer rapamycin, resulting in a signifi-
cant 25% increase of beclin-1 immunoreactivity.
Results: Results obtained by Western blot analy-
sis in a limited number of collected PBMC did not
show significant difference in beclin-1 immunore-
activity between AD and controls, suggesting that
peripheral expression of this protein does not mirror
the alterations observed in the brain. We are concluding
beclin-1 protein evaluation and setting up experiments
of RTqPCR to quantify mRNA levels to verify the
existence of possible alterations at this level.
Restless Legs Syndrome and Alzheimer’s Disease
Giuseppina Talarico, Federica Letteri, Marco Prastaro,
Giuseppe Tosto, Marco Canevelli, Elisa Piacentini,
Marina Gasparini, Gianluigi Lenzi and Giuseppe
Bruno
“Sapienza” University, Rome, Italy
Introduction: Alzheimer’s disease (AD) is a neu-
rodegenerative disease characterized by progressive
neuronal loss in the central nervous system and, con-
sequently, biochemical changes in neurotransmitter
systems including the cholinergic and dopaminergic
systems. Restless legs syndrome (RLS) is a neurolog-
ical disorder characterized by an urge to move the legs
and peculiar unpleasant sensations deep in the legs
during period of rest and inactivity, such as at night,
that typically relieve by movement. Its prevalence is
about 8% of the population over 65. It is supposed that
RLS may be due to dysfunction of dopamine system.
Few studies were analyzed RLS in neurodegenerative
diseases such as Alzheimer’s Disease (AD).
Aims and methods: Three hundred and thirty-four
subjects with diagnosis of AD were recruited at the
“Memory Clinic” of the Department of Neurology
and Psychiatry, University “Sapienza” in Rome. Thir-
teen subjects met the RLS criteria, revised by Allen
et al. in 2003. To basal time, clinical assessments
included general physical and neurological examina-
tion, laboratory tests, morphological (MRI/CT) and/or
functional (SPECT/PET) neuroimaging, neuropsycho-
logical evaluation, Mini-Mental State Examination
(MMSE), Activities of Daily Living (ADL), Instru-
mental Activities of Daily Living (IADL) and Neuro-
Psychiatric Inventory (NPI).
Results: RLS subjects were frequently male (76,9%)
and younger than AD subject without RLS. Median
time of RLS appearance was two years after the AD
diagnosis (71.54 ± 7.24). MMSE, ADL and IADL at
diagnosis and at time of RLS onset were not more
different, while NPI total score showed a significant
worsening (t: −2.61, p: 0.023), notably in subitem apa-
thy (t: −3.95, p: 0.002). Moreover AD patients with
RLS were more apathetic (t: 3.59, p: 0.001) than AD
subjects without RLS and showed difference in short
and long term visual memory (t: 2.51, p: 0.0013 and
t: 2.61, p: 0.0010 respectively) and constructional abil-
ity (t: 2.38, p: 0.0021).
Conclusions: The RLS prevalence in our AD
patients is about 4%. RLS appears to be associated
with deficit in visual memory and neuropsychiatric
symptoms such as apathy.
Mutation Analysis in the Presenilin Genes Linked
to Italian Kindreds with Alzheimer’s Disease
Andrea Teddea, Benedetta Nacmiasa, Silvia
Bagnolia, Irene Piaceria, Silvia Piacentinia and Paolo
Nichellib
S76 Abstracts
aUniversity of Florence, Florence, Italy
bUniversity of Modena and Reggio Emlia, Reggio
Emilia, Italy
Background: Mutations in APP, PSEN1 and PSEN2
are the most common cause of autosomal dominant
familial Alzheimer’s disease (FAD).
Aims and methods: A genetic screening of DNA
samples belonging to FAD families present in the DNA
bank at the Department of Neurological and Psychi-
atric Sciences (University of Florence, Italy) was con-
ducted by PCR and HRM analysis in the APP, PSEN1
and PSEN2 genes. Genetic variants were sequenced
by ABI PRISM 310 sequencer. In silico prediction of
the functional consequence of the missense variant was
performed using SIFT (Sorting Intolerant From Toler-
ant), Polyphen and PMut bioinformatic softwares.
Results: We identified four Italian families with
the following missense variants: a pedigree linked to
Met139Thr mutation at the second transmembrane
domain of PSEN1. A Leu166His mutation at the third
transmembrane domain of PSEN1 was described in
a family with a severe cognitive decline with a very
early-onset (34 ys). Another pathogenetic mutation
was identified in PSEN2 gene at exon 4 (N-terminal)
resulting in a Arg71Trp substitution. Moreover, the
Arg62His variant at the exon 4 (N-terminal) in the
PSEN2 gene was found in a subject, but the nature
of this variant was not clear because, according to the
literature, it was present as common polymorphism in
African populations.
Presenilins Mutations in a Small Cohort of Italian
Patients with Alzheimer’s Disease
Silvia Testia, Tiziana Cavallaroa, Roberta Pantierib,
Giuseppe Gambinaa and Gianmaria Fabrizia
aAziendaOspedalieraUniversitaria Integrata, Verona,
Italy
bOspedale Bellaria, Bologna, Italy
Objective: To define mutational frequencies of Pre-
senilins genes in a small Italian series.
Background: Familial Alzheimer’s Disease (FAD) is
associated with mutations in Amyloid Precursor Pro-
tein (APP), Presenilin 1 (PSEN1) and Presenilin 2
(PSEN2) genes. PSEN1 and APP account for up to
70% and 15% of all cases whereas PSEN2 is the rarest
cause.
Methods: We analyzed 45 unrelated index patients
with AD (n = 26) or FAD (n = 19) and mean age of
onset 64.38 (±10.1). Mutational analysis was done
by Denaturing High Performance Liquid Chromatog-
raphy (DHPLC), automated direct sequencing and
Real-Time PCR.
Results: In four unrelated FAD cases we identi-
fied one PSEN1 and three PSEN2 missense mutations;
PSEN2 p.Arg71Trp (onset 59 years) and p.Met174Val
(onset 75 years) were already reported in AD whereas
PSEN2 p.Thr18Met (onset 72 years) and PSEN1
p.Ile437Asn (onset 70 years) were novel. Based upon
phylogenetical and in silico analysis, PSEN1 p.Ile
437Asn and PSEN2 p.Arg71Trp and p.Thr18Met are
likely pathogenic.
Conclusions: We identified two novel mutations of
PSEN1 and PSEN2 as possible candidate to FAD.
Mutational frequencies in our series diverged from
the literature likely reflecting the relatively late age
of onset in our series.
Somatoform Disorders in Parkinson’s Disease
Predicts the Appearance of Dementia
and is Frequently Observed in Dementia
with Lewy Bodies
Astrid Thomas, Laura Bonanni, Daniela Monaco,
Stefania Bifolchetti, Leopoldo Ricciardi, Francesca
Anzellotti, Iole Borrelli, Maria C. D’Amico, Fausta
Ciccocioppo and Marco Onofrj
Università Chieti-Pescara, Fondazione Università,
Cesi, Chieti, Italy
Aims and methods: Somatoform Disorders in Par-
kinson’s Disease (SFMD) were assessed by direct
observation of symptoms with definite diagnosis of
PD, DLB, AD, MSA, PSP, FTD and by interviews
with patients, caregivers, GPs, reviews of prior hospital
admissions, in a cohort of 942 patients with neu-
rodegenerative disorders and 1400 psychotic patients.
In followed-up over 4 years matched groups of PD
and DLB patients without and with SFMD were
compared.
Results: The frequency of SFMD was higher in DLB
(15 patients, 12%) and PD (29 patients, 7%) than
in other neurodegenerative diseases (0–3%). SFMD
consisted of conversion motor or sensory disorders,
often accompanied by delusional thought content;
in one patient catatonic symptoms were observed
concomitantly with PD diagnosis. SFMD symptoms
precede diagnosis by six months–10 years. Observa-
tion obtained in 28 PD and all DLB patients. SFMD
symptoms recurred during follow-up, 9 PD and 8 DLB
patients presented catatonic signs. Baseline demo-
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graphic and clinical features did not differ between
subjects with or without SFMD. Decline of cogni-
tive function was greater in PD-SFMD patients than
in those without SFMD (p < 0.01); it was comparable
to that observed in DLB.
Conclusions: The frequency of SFMD (with cata-
tonic signs) in PD and DLB suggests that SFMD should
be studied and used as predictor factor in appearance
of dementia.
Sentence Writing Component and Alzheimer’s
Disease Clinical Progression
Giuseppe Tosto, Giuseppina Talarico, Elisa Piacen-
tini, Marco Canevelli, Federica Letteri, M.C. Viselli,
F. Troili, Gianluigi Lenzi and Giuseppe Bruno
“Sapienza” University, Rome, Italy
Background: Written expressions of patients with
Alzheimer’s Disease (AD) have shown that agraphia
is an early manifestation of the disease, mainly in the
lexico-semantic area than in the syntactic aspects.
Aims and methods: The MMSE’s “sentence-writing
compound” of fifty mild-AD patients was evaluated at
baseline and after 1 year of AChIs treatment.
Results: Our data demonstrate that initial cognitive
performance does not correlate with sentence richness
in term of subjects, verbs, names etc. instead of educa-
tion identified as the most striking factor that accounts
for those items. Baseline numerosity of grammati-
cal/syntax errors, adverbs and conjunctions correlates
with their numerosity after 1 year of follow up; the
use of 1th person in the sentence is more likely to be
present after 1 year if it is present at baseline. An early
unmeaningful sentence seems to be the only risk for
“non response” to drugs treatment, regardless of educa-
tion; on the other side, only in highly educated patients
grammatical errors at baseline seem to relate with poor
response to AChIs.
Conclusions: Careful examination of written expres-
sions in early AD appears as a meaningful way to
follow up clinical evolution of the disease.
Titolo Abstract: Expanding the Phenotype
of PGRN Mutations: Progressive Supranuclear
Palsy?
Lucio Tremolizzo, Carlo Ferrarese and Ildebrando
Appollonio
University of Milano-Bicocca, Monza, Italy
Background: Both frontotemporal lobar degenera-
tion and corticobasal syndrome are clinical phenotypes
which can be the expression of heterogeneous neu-
ropathologies and progranulin (PGRN) mutations have
been recently described as major contributors. By con-
trast, progressive supranuclear palsy is still regarded as
one clinical syndrome with a unique neuropathological
basis, i.e., tauopathy.
Case report: Here we describe the case of a patient
affected by progressive supranuclear palsy (clinical
and neuroradiological evidence) that started out with
mild cognitive impairment in a familial history of
early-onset dementia. The patient eventually resulted
to be a carrier of a PGRN mutation.
Conclusions: To our knowledge this is the first report
of such an association: an exhaustive discussion of the
literature will be provided.
Apathy Evaluation Scale Efﬁcacy in Evaluating
Apathy Symptoms in Subjects Affected by Mild
Cognitive Impairment
Barbara Vicini Chilovi, Salvatore Caratozzolo,
Marina Zanetti, Giulia Mombelli, Luca Rozzini and
Alessandro Padovani
University of Brescia, Brescia, Italy
Background: Apathy has been demonstrated an
important symptom in the characterization of Mild
Cognitive Impairment (MCI) evolution, being asso-
ciated to an increased risk of progression towards
dementia.
Aims: To describe the correlation between different
psycho-behavioural symptoms evaluation instruments
and the cognitive profile of MCI subjects with and
without apathy.
Methods: Apathy and depression symptoms have
been evaluated in 107 outpatients using two specific
instruments: the Apathy Evaluation Scale (AES) and
the Beck Depression Inventory (BDI). The Neuropsy-
chiatry Inventory (NPI) has been administered to the
caregivers.
Results: Sixty-three (57.3%) subjects have been
classified as normal MCI (without apathy and depres-
sion), 15 (13.6%) as depressed MCI (with or without
apathy), 29 (26.4%) as apathetic MCI. Any signifi-
cant correlation has been found between the AES and
apathy from the NPI, but a significant correlation has
resulted between the BDI and apathy and between
apathy and depression from the NPI. Apathetic MCI
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showed a lower memory performance than the other
groups.
Conclusions: Apathy is hardly distinguishable from
depression, it is necessary to use a specific instrument
as the AES to evaluate it in clinical practice. Apathetic
MCI subjects identified through the AES seem to have
an higher risk to develop Alzheimer’s Disease.
Causal Frontotemporal Lobar Degeneration
Mutations: a Novel Mutation in MAPT Associated
with Non-ﬂuent Progressive Aphasia Phenotype
Chiara Villaa, Laura Ghezzia, Anna M. Pietrobonia,
Chiara Fenoglioa, Francesca Cortinia, Maria
Serpentea, Claudia Cantonia, Elisa Ridolfia, Alessan-
dra Marconeb, Luisa Benussic, Roberta Ghidonic,
Francesca Jacinia, Andrea Arighia, Giorgio G. Fum-
agallia, Alessandra Mandellia, Giuliano Binettic,
Stefano Cappab, Nereo Bresolina, Elio Scarpinia and
Daniela Galimbertia
aUniversity of Milan, Fondazione Cà Granda IRCCS
Ospedale Policlinico, Milan, Italy
bOspedale San Raffaele Turro, San Raffaele Scientiﬁc
Institute, Milan, Italy
cIRCCS Centro S. Giovanni di Dio-FBF, Brescia, Italy
Aims and methods: A mutation scanning of Micro-
tubule Associated Protein Tau gene (MAPT) was
carried out in 67 patients with Frontotemporal Lobar
Degeneration (FTLD) with an early onset and without
mutations in progranulin gene.
Results: A novel variant has been found in a pa-
tient diagnosed clinically with non-fluent Progressive
Aphasia (PA), with a positive familial history for
dementia. At 65 years she started developing pro-
gressive language disturbance, characterized by verbal
production defict and articulation impairment. She
came to our attention at 67 years. Her MMSE score
was 22/30. A Brain CT scan showed ventricles’ asym-
metry (L > R) and signs of chronic vasculopathy.
Cerebrospinal fluid analysis showed slightly decreased
Abeta, slightly increased total tau and normal Ptau lev-
els. She was diagnosed with PA according to current
criteria. A novel exon 10 MAPT variant was identi-
fied (g.123798G > A), which leads to an amino acidic
change (p.Gly304Ser) in the second microtubule bind-
ing domain. In silico analysis predicted that this variant
is damaging on protein structure and function. Addi-
tional 168 FTLD patients and 503 controls screened did
not carry the variant, suggesting that it is a mutation
rather than a polymorphism.
Conclusions: The aminoacid change could compro-
mise the ability of tau to properly regulate the dynamic
behaviour of microtubules.
Cognitive Proﬁle at Presentation and Rate of
Progression of Alzheimer’s Disease with Early
(EOAD) and Late Onset (LOAD)
Maria Gabriella Vita, Camillo Marra, Davide Quar-
anta, Eugenia Scaricamazza, Giordano Lacidogna and
Guido Gainotti
Università Cattolica del Sacro Cuore, Policlinico A.
Gemelli, Rome, Italy
Aims: To study if EOAD and LOAD are char-
acterized by different pattern of neuropsychological
presentation and evolution.
Methods: Four hundred and seventy
seven AD were divided according to age
at onset (EOAD < 66 and LOAD > 74). Patients
underwent: MMSE, RAVLT immediate/delayed
recall, Forward and Backward Digit Span (FS, BS),
Phonological and Semantic Fluency (FVF, SVF),
Stroop’s Test (ST), Multiple Features Targets Cancel-
lation (MFTC), Raven’s Matrices (PM’47), Copy of
figures without and with landmarks (CF, CFL). A two
years follow-up evaluation was completed for 208
subjects.
Results: At baseline, EOAD patients showed signif-
icantly more pathological performances in RAVLTir,
FVF, CF, BS, PM’47, ST. At follow-up the pattern of
worsening did not differ in the two groups but EOAD
progressed more severely on MMSE, RAVLT, CFL,
FS, BS, MFTC, ST. Irrespectively of the group, global
worsening was not influenced by early treatment with
cholinesterase inhibitors, but subjects earlier treated
showed a significantly slighter decline in PM’47 and
SVF.
Conclusions: At presentation, EOAD showed more
severe impairment in several cognitive domains. Both
EOAD and LOAD evolved towards a diffuse cognitive
decline, slower for LOAD in several domains, with
comparable effects of therapy. These results suggest an
unitary nosology for EOAD and LOAD; age at onset
influences only disease severity.
CarotidAtherosclerosis as aMarker ofAlzheimer’s
Disease Progression
Giovanna Viticchia, Mauro Silvestrinia, Lorenzo
Falsettib, Clotilde Balucanic, Fabrizio Vernierid,
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Raffaella Cerquaa, Simona Luzzia, Marco Bartolinia
and Leandro Provincialia
aUniversità Politecnica delle Marche, Ancona, Italy
bOspedali Riuniti, Ancona, Italy
cUniversity of Perugia, Perugia, Italy
dUniversità Campus Biomedico, Rome, Italy
Background: There are not definite modifiable risk
factors for Alzheimer’s disease (AD), but in the last
years several authors highlighted a vascular cerebral
compromission in AD patients.
Objective: To assess whether cerebrovascular
impairment, caused by internal carotid stenosis, influ-
ences a progression of cognitive decline in AD.
Methods: We enrolled 411 AD patients: each sub-
ject underwent a neuropsychological battery and a
B-Mode ultrasound and Doppler velocity evaluation of
neck vessels at the study beginning; in severe carotid
stenosis, we evaluated the cerebrovascular reactivity
to hypercapnia with transcranial Doppler ultrasono-
graphy using the breath-holding-index (BHI). After
12 months we repeated the same neuropsychological
evaluation to each patient.
Results: Ninety eight patients had a severe carotid
stenosis, 41 in the right side and 57 in the left side.
Comparing MMSE score at beginning and at the end
of the study, we found that patients with left steno-
sis showed a significant worse results respect to right
stenosis or no stenosis subjects. In patients with carotid
stenosis, an ipsilateral BHI values <0.69 predicts a
worse MMSE score at 12 months.
Conclusions: Severe internal carotid artery stenosis
and a deficit in cerebrovascular reactivity could play
a significant role in cognitive impairment progression
of AD.
Anosognosia and Behavioural Changes in Mild
Cognitive Impairment
Leda Volpi, Cristina Pagni, Irene Falorni, Cecilia
Carlesi, Irene Ghicopolus and Gloria Tognoni
University of Pisa, Pisa, Italy
Background: Anosognosia and Neuropsychiatric
symptoms may variably associate in patients with Mild
Cognitive Impairment (MCI), even thought little is
known about their prevalence in this condition.
Aims and methods: Anosognosia Questionnaire for
Dementia (AQ-D) was used to assess anosognosia in
amnesic mild cognitive impairment (a-MCI; N = 23),
non amnesic MCI (na-MCI; N = 6) and multiple
domain MCI (md-MCI; N = 12). Caregivers com-
pleted the AQ-D and the ADCS-ADL-MCI to evaluate
functional abilities. Neuropsychiatric symptoms were
assessed using the Neuropsychiatric Inventory (NPI).
Results: Our findings indicate that only four indi-
viduals (3 a-MCI and 1 md-MCI) result anosognosic,
while other four subjects over-estimated their defects,
on the basis of AQ-D. Moreover, 32 patients exhibited
behavioural abnormalities, irritability (N = 13), apathy
and anxiety (N = 11) being the most frequent. Irritabil-
ity and apathy were also the items causing the higher
burden for care-givers. Apathy was more frequent
in na-MCI patients, if comparing the three groups.
No correlations were found between anosognosia and
NPI scores.
Conclusions: These results suggest that the diagno-
sis of anosognosia is infrequent and that the awareness
of cognitive functions is extremely variable in patients
with MCI, ranging from low knowledge to exag-
geration of symptoms. Furthermore, neuropsychiatric
symptoms are common features of MCI.
Cerebrospinal FluidMarkers in Creutzfeldt-Jakob
Disease
Gianluigi Zanusso, Michele Fiorini and Salvatore
Monaco
University of Verona, Verona, Italy
Background: Sporadic Creutzfeklt-Jakob disease
(sCJD) represents the most common human form of
prion disorder accounting for about 90% of all cases.
Intra vitam diagnostic criteria have been recently
revised and include specific clinical signs, a typical
EEG with periodic sharp and wave complexes and/or
a high signal in basal ganglia at MRI and a positive
14-3-3 protein in the cerebrospinal fluid (CSF). At
present, the distinct sCJD diseases phenotypes have
been included in molecular groups, based on the geno-
type at codon 129 of the PRNP of the host and on
the biochemical type of pathological prion protein
detected in the brain.
Aims and methods: In the present study, we ana-
lyzed CSF samples from 60 subjects with definite sCJD
diagnosis belonging to distinct molecular groups.
Results: All CSF samples resulted positive to
14-3-3 protein, except those cases with a dementing
illness with a relatively long duration. In addition, the
level of CSF Tau protein showed a consistent varia-
tion among groups depending on the clinical phenotype
and the disease course. To further increase the sensibil-
ity and the specificity of CSF markers to differentiate
S80 Abstracts
sCJD from other neurodegenerative disorders we also
evaluated the levels of phosphotau181 as well as of
A-beta 42.
Conclusions: The combination of these markers
on the whole, definitely distinguish sCJD from other
dementias.
Modulation of MAPK Pathway in Fibroblasts
from Alzheimer’s Disease Patients: A Possible
Interaction between ERK and EAAT1 mRNA
Chiara P. Zoia, Eleonora Verga, Diletta Cereda, Valeria
Isella, Lucio Tremolizzo and Carlo Ferrarese
University of Milano-Bicocca, S. Gerardo Hospital,
Monza (Milan), Italy
Background: JNK, p38 and ERK1/2 activation has
been demonstrated in the CNS of AD patients, since the
early stages of disease, leading to neurodegeneration.
Methods: Fibroblasts from 15 patients, 7 MCI and
15 age-related controls were tested to investigate of
MAPK-pathway alterations associated to the different
stages of disease.
Results: p38- and JNK-phosphorylation were in-
creased in AD fibroblasts without any correlation with
disease-severity. In MCI subjects, a trend to phospho-
p38/JNK increase was observed, too. Instead, ERK1/2
phosphorylation was reduced in fibroblasts from
MCI and mild-to-moderate AD, compared to severe
patients. An inverse correlation was observed between
ERK1/2 phosphorylation and disease-severity. ERK-
pathway is involved in non-amyloidogenic APP
metabolism and anti-inflammatory processes and, by
specific transcriptional factors, seems to modulate the
expression of glutamate transporter (EAAT1) mRNA.
By EZ-ChIP assay, we are testing CREB association
with EAAT1-promoter to explain the mRNA EAAT1
increase, previously demonstrated correlating with
disease-severity in AD fibroblasts.
Conclusions: Since recent evidence suggests that
microRNAs may be a contributing factor in neurode-
generation, playing a dynamic role in neuroplasticity
and stress responses, miRNAs involvement in EAAT1-
mRNA up-regulation will be verified. Clarifying these
pathways might help to develop new therapeutic strate-
gies for AD.
Still Driving? An Observational Study in Dementia
Marta Zuffi, Stefania Castiglioni, Silvia De Battisti
and Massimo Franceschi
Clinica Neurologica, Casa di cura Santa Maria di
Castellanza, Varese, Italy
Background: Many people with dementia continue
to drive despite cognitive deficits impair their ability to
drive safely. In some countries this problem has been
considered and specific guidelines have been proposed
to determine the efficacy of driving risk reduction
strategies. In Italy no systematic study has been con-
ducted in order to clarify the characteristics of this
problem.
Aims and methods: In the period 2008–2009 in our
Clinic Memory we clinically assessed 490 patients
for possible dementia, dividing them into 4 groups:
Cortical Dementia (CD; 357 patients); Subcortical
Dementia (SD; 44 patients); Mild Cognitive Impair-
ment (MCI; 34 patients); people without cognitive
impairment or with other medical conditions (55
patients).
Results: More than a third of 51% patients who
got driving license continue to drive car, despite the
perceived risk frequently referred by caregivers on
Clinical Dementia Rating (CDR). The comparison of
patients currently driving car with those who don’t
drive anymore shows statistically significant differ-
ences in the CD group. Patients who continue to drive
are younger, cognitively less compromised (MMSE,
MODA, CDR), have less severe psychiatric symptoms
(NPI) and obtain better scores on neuropsychological
tests of logic memory (short story), attention (attentive
matrices) and abstract reasoning (Raven matrices).
Convergent Validity of the Italian Version
of MOUSEPAD: Preliminary Analyses on
Neuropsychiatric Symptoms in 240 Italian
Alzheimer’s Disease Patients Enrolled in the
EVOLUTION Switch Study
Gianfranco Spallettaa, Carlo Caltagironea,e, Alessan-
dro Padovanib, Sandro Sorbic, Mahmood Attard and
Delia Colombod on behalf of the EVOLUTION Study
Group
aIRCCS Santa Lucia Foundation, Rome, Italy
bUniversity of Brescia, Brescia, Italy
cUniversity of Florence, Florence, Italy
dNovartis Farma Italia, Origgio (Varese), Italy
eUniversity of Rome “Tor Vergata”, Rome, Italy
Background: Neuropsychiatric symptom improve-
ment is an outcome of Alzheimer’s disease (AD) treat-
ment. Switching from one CheI to another CheI may
potentially affect neuropsychiatric symptom severity.
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Thus, it is important to validate new instruments,
such as the MOUSEPAD, and we are doing it in the
EVOLUTION, a 9-month switch (from one CheI to
another CheI) study that aims to enroll 800 Italian AD
patients from 40 sites throughout Italy.
Objective: Describing the convergent validity of
MOUSEPAD Italian version in patients with Alzhei-
mer’s disease (AD) enrolled in a switch cholinesterase
inhibitor (CheI) study.
Methods: MOUSEPAD was translated in Italian,
corrected for semantic congruence, and back-trans-
lated in English for language congruence. Neuropsy-
chiatric Inventory (NPI), MOUSEPAD, ADL, and
MMSE were administered at 240 patients at the base-
line and after 3, 6 and 9 month follow-up. Prelimi-
nary analyses here reported regard convergent validity
which was assessed by comparing MOUSEPAD with
NPI scores at the baseline using Kruskal-Wallis test.
Results: At baseline, MOUSEPAD hallucinations,
delusions, aggression, sleep, and eating domain scores
increased as NPI severity increased (Kruskal-Wallis’
p < 0.0001; DF = 3; Chi-square > 43.1 for all analyses).
Conclusions: MOUSEPAD has a convergent rela-
tionship with the NPI. Sensitivity to change and
inter-rater reliability during 9-month follow-up will be
validated in further analyses.
Support: Study supported by an unrestricted grant
by Novartis, Italy.
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